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The widespread use of islet transplantation as a treatment for type 1 diabetes is limited in part 
by the necessity for long term immunosuppression. The principle of immunoisolation is to 
create a physical barrier surrounding the islets to prevent immune destruction after 
implantation, therefore removing the requirement for immunosuppression. Alginate 
microcapsules are the most commonly used immunoisolation device which are typically 
implanted intraperitoneally. Intraperitoneal microencapsulated islet grafts are suboptimal, 
requiring at least double the number of islets to reverse hyperglycaemia compared to non-
encapsulated islet grafts. The large size of microencapsulated islet grafts also restricts the 
selection of implantation site. We aimed to determine if the subcutaneous site is a suitable 
alternative site to the intraperitoneal site for microencapsulated islet grafts. It was discovered 
that equivalent microencapsulated islet grafts that were efficacious at the intraperitoneal site 
were ineffective at the subcutaneous site. Helper cells can be used to improve islet 
transplantation by secreting beneficial factors. L cells produce glucagon-like peptide-1 which is 
known to have several positive effects on islets. Co-encapsulation of islets with L cells 
increased islet insulin secretion but did not improve graft outcome. Mesenchymal stem cells 
(MSCs) can be co-transplanted to improve the graft outcome of non-encapsulated grafts. Islets 
co-encapsulated with MSCs had improved insulin secretion and also improved graft outcome. 
Immunoisolation of islets by conformal coating has the potential to maximise the diffusion of 
vital molecules and minimise the graft volume, enabling transplantation to preferred sites. 
Using allogeneic islets implanted at the kidney subcapsular site it was found that non-
encapsulated grafts rejected whereas a novel conformal coating protected grafts from 
rejection in 5/7 of recipients. In summary, immunoisolated graft efficacy can be optimised by 
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1 General Introduction 
 
1.1 Diabetes and the Islets of Langerhans 
 
1.1.1 Diabetes Mellitus 
Insulin is the central regulator of blood glucose in the body, causing cells in the liver, muscle, 
and fat tissues to take up glucose from the blood and thereby reduce the blood glucose level. 
Diabetes mellitus (DM) is characterised by elevated blood glucose levels (hyperglycaemia) 
caused by a lack of insulin production by the β cells in the pancreas or a deficiency in the 
utilisation of insulin in the body. The condition is estimated to affect 5% of the population 
worldwide (346 million) and the related mortality is predicted to double between 2004 and 
2030 (WHO, 2012). DM is classified into three main types; type 1 diabetes mellitus (T1DM), 
formally known as insulin-dependent diabetes mellitus or juvenile-onset diabetes, type 2 
diabetes mellitus (T2DM), formally known as insulin-independent diabetes mellitus or adult-
onset diabetes, and finally gestational diabetes. T1DM and T2DM can both occur at any age, 
however onset for T1DM is typically in children and young people and onset for T2DM is 
typically in older people. T1DM is caused by the autoimmune destruction of the insulin 
producing β cells in the islets of Langerhans in the pancreas resulting in an absolute lack of 
insulin. It is not fully known what causes the autoimmune response, and preventing T1DM is 
not currently achievable. Insulin replacement therapy is essential to keep T1DM patients alive. 
T2DM is caused by a combination of insufficient insulin production and peripheral insulin 
resistance in the tissues of the body which prevents the utilisation of insulin, thereby inhibiting 
the uptake of glucose from the blood. The major risk factors of T2DM are excessive body 
weight and physical inactivity, and disease progression can, in some cases, be prevented or 
reversed by lifestyle changes. Gestational diabetes is typically a transient form of diabetes 
which onsets during pregnancy and reverts after child birth. The causes are related both to 
insufficient insulin production and insulin resistance.  
 
The symptoms of hyperglycaemia include excessive excretion of urine (polyuria), thirst 
(polydipsia), weight loss, hunger, distortion of vision, and fatigue. These symptoms are severe 
and may occur suddenly in T1DM patients whereas they are subtle and gradual in T2DM and 
gestational diabetes patients. Following diagnosis, the management of DM involves medical 
treatments and changes in lifestyle to keep the patient’s blood glucose in the normal range 
(normoglycaemic, 4-7 mM). Achieving consistent normoglycaemia with disease management is 




to secondary complications in the long term.  As gestational diabetes is typically transient and 
usually well managed due to prenatal screening, minimal impact from hyperglycaemia is 
predicted in the long term, although the condition does complicate pregnancy. Due to the 
gradual presentation of symptoms with T2DM, diagnosis may be several years after initiation 
of hyperglycaemia when secondary complications may have already occurred. Secondary 
complications of DM include cardiovascular disease, nephropathy, retinopathy, neuropathy, 
poor wound healing, and pregnancy complications. Recently T2DM has been described as 
pandemic and aside from the human suffering caused by T2DM and its related secondary 
complications they are a major economic burden to individuals and governments.  
 
1.1.2 Type 1 Diabetes  
T1DM accounts for 5-10% of DM cases worldwide (ADA, 2004) and is increasing in incidence at 
a rate of 3-5% per year (Forlenza and Rewers, 2011). More than 85% of all DM cases in people 
<20 years of age are T1DM, with a peak incidence occurring at 10-14 years of age (Maahs et 
al., 2010). The increase in incidence of T1DM is particularly evident in young children and it is 
predicted that incidence of T1DM will double in children under 5 years old by 2020 (Patterson 
et al., 2009). The rate of change cannot be attributable to genetics alone and is likely to be 
related to the interaction between genes and the environment. The proportion of children 
with the highest risk human leukocyte antigen (HLA) haplotype has not increased concordantly 
(Gillespie et al., 2004) suggesting that changes in lifestyle and environmental factors such as 
diet, physical activity levels, infections, vaccinations, and pharmaceuticals may be contributing 
to the increased incidence.    
 
T1DM is classified into two main forms according to aetiology. Type 1a constitutes 90% of 
cases and is caused by T-cell mediated autoimmune destruction of the β-cells. Type 1b makes 
up the remaining 10% of cases and is characterised by β-cell destruction in the absence of 
evidence of autoimmunity. T1DM is thought to be initiated by environmental triggers in 
genetically predisposed individuals, resulting in the destruction of the insulin producing β cells 
of the islet of Langerhans of the pancreas (Eisenbarth, 1986). In the absence of insulin, glucose 
cannot be transported into the liver, muscle and fat tissue which results in ketosis and 
abnormal elevation of blood glucose levels resulting in osmotic dieresis. Together these cause 
ketoacidosis, dehydration, and unbalanced plasma solutes, which results in a progressive 
homeostatic imbalance which can ultimately lead to cerebral oedema, coma, and death.   
 
Genetic predisposition to T1DM is largely inherited and resides predominantly in the HLA class 




thought to account for 50% of the genetic predisposition to T1DM (Redondo et al., 2001), and 
two specific haplotypes are present in 90% of children with T1DM (Devendra and Eisenbarth, 
2003). These regions affect the ability of antigen-presenting cells to present β cell autoantigens 
to T lymphocytes to confer self-tolerance to β cells. The second most important genetic 
susceptibility factor is the insulin gene which contributes to 10% of the genetic predisposition 
(Bell et al., 1984). Two other genes associated with inhibition of T cell activation, cytotoxic T-
lymphocyte antigen-4 (CTLA-4) and lymphoid tyrosine phosphatase (LTP) are considered the 
third and fourth most important susceptibility genes. All of these genes can have susceptibility 
and protective alleles. For example, a variable number tandem repeat in the insulin promoter 
is associated with susceptibility with fewer repeats, and protection with a greater number of 
repeats (Bennett et al., 1995).  
 
The genetic predisposition to T1DM couples with exposure to one or more environmental 
triggers that alter immune function to initiate β cell destruction. Putative triggers include 
viruses (enteroviruses, coxsackie, and congenital rubella), bacteria, cow’s milk, wheat proteins, 
and vitamin D deficiency (van Belle et al., 2011). Viruses are hypothesised to act in a number of 
ways to initiate an autoimmune response. For example, β cell death from viral infection may 
cause β cell antigen shedding, or viral antigens with sequence homology with β cell antigens 
may cross-react with β cell auto-antigens, re-stimulating resting β cell autoreactive T cells. 
Antigen cross-reactivity is also proposed to be the mechanism by which bacteria, cow’s milk, 
and wheat proteins may initiate the autoimmune response. Vitamin D inhibits immune 
activation and is thought to be protective.  An alternative theory to environmental triggering is 
the hygiene hypothesis which suggests that modern living conditions create a lack of exposure 
to antigens and infectious organisms which causes a hyperactive and deregulated immune 
system which leads to autoimmunity (Gale, 2002). Tolerance to self antigens is normally 
achieved by a combination of deletion of autoreactive T cells in the thymus during T cell 
maturation and peripheral control by regulatory T cell populations such as cluster of 
differentiation 25 positive (CD25+) CD62L+ CD4+ T cells and natural killer (NK) T cells. If self 
antigens are not presented correctly in the thymic cortex tolerance may not be established 
during T cell maturation. The failure of peripheral tolerance is likely to be significant as islet 
antigen reactive T cells can be detected without the development of diabetes (Roep et al., 
1999).  
 
Activation of the autoimmune response directed at β cells leads to inflammation in the islets 
(insulitis) and humoral production of β cell antibodies. Presentation of β cell antigens activates 




cells. Antibodies produced by B lymphocytes flag β cells for destruction by complement. The 
autoimmune destruction of the β cells is carried out by CD4+ and CD8+ T cells and 
macrophages. Activation of NK cells and cytotoxic (CD8+) T lymphocytes stimulate cell-
mediated destruction of β cells. β cell destruction occurs predominantly through apoptotic 
mechanisms (Kurrer et al., 1997) such as interaction of cell surface Fas with Fas ligand on 
infiltrating cells, perforin and granzyme B mediated membrane destruction by cytotoxic T cells, 
and macrophage-derived nitric oxide (NO) and toxic free radicals. T cell cytokines such as 
interleukin-1 beta (IL1β), tumour necrosis factor alpha (TNF-α), and Interferon gamma (IFN-γ) 
upregulate both Fas and Fas ligand, and also induce NO and toxic free radical production. 
Rodent models have demonstrated that it is possible to transfer the autoimmune response by 
grafting islet reactive T cells from a diabetic animal to a healthy animal (Matsumoto et al., 
1993). It is not possible to transfer the autoimmune response using only antibodies, which 
suggests that T1DM is a predominantly T cell mediated disease. The β cell specific destruction 
in T1DM is demonstrated by the presence of T lymphocytes and macrophages associated with 
residual β cells and the persistence of other islet cell types in the islets of patients. Major 
markers of insulitis are islet cell autoantibodies (ICAs), insulin autoantibodies (IAA), protein 
tyrosine phosphatase (IA2) antibodies and glutamic acid decarboxylase (GAD) antibodies. The 
presence of the antibodies does not necessarily indicate insulitis and an antibody positive 
prodromal period of months or years can occur.  
 
1.1.3  Architecture of the Islets of Langerhans  
The pancreas is composed mostly of exocrine tissue which produces the digestive enzymes 
that facilitate the breakdown of food in the gastrointestinal tract. The endocrine component of 
the pancreas is composed of approximately 1 million islets of Langerhans which constitute 
approximately 2-3% of the total gland mass. Islets vary in size from 50-400 µm with 
approximately 1,000-3,000 cells per islet. Islets are distributed throughout the exocrine tissue 
of the pancreas but at a higher density in the tail region. Islets are partially separated from an 
acinar cell parenchyma by an incomplete capsule infiltrated by connective tissue originating 
from the interstitial septa of the exocrine tissue. Islets consist of insulin producing β cells, 
glucagon producing α cells, somatostatin producing δ cells, and pancreatic polypeptide 
producing PP cells. In rodents the islet core is a uniform homocellular medulla of β cells, with 
α, δ, and PP cells located around the periphery. In human islets the different cell types are 
more heterogeneously distributed. The ratio of β:δ:α:PP cells is 68:10:20:2 in human adults. 
The function of the islets is mediated by a multitude of stimuli which regulate the secretions of 
the various cell types. The tissue is rich in vascular supply and nervous inputs which allow it to 





Islets contain a capillary network which is approximately 10 times denser than that of the 
surrounding exocrine tissue (Henderson and Moss, 1985, Kuroda et al., 1995). Accordingly the 
islets receive 20% of the total pancreatic blood flow yet constitute only 2-3% of the total gland 
mass (Lifson et al., 1985). Consequently the blood perfusion of the islets is approximately 10 
fold higher than that of the exocrine pancreatic tissue. The efficient blood perfusion in the 
islets provides a rich supply of oxygen and nutrients and allows for rapid response to blood 
glucose dynamics and dispersion of secreted hormones. Dense glomerulus-like anastomosing 
capillaries with fenestrated endothelium for rapid peptide release infiltrate the islet. The blood 
flow within islets is organised centrifugally which results in blood supplying β, then α, then δ 
cells (Samols et al., 1988). This would indicate that metabolic and hormonal signals are carried 
in this orientation. This also suggests that glucagon and somatostatin act on β cells through the 
systemic circulation. However gap junctions connecting islet cells are thought to provide a 
more direct communication. Blood flow to the islets can be altered in response to changes in 
blood glucose concentration by innervation of sympathetic adrenergic neurons supplying the 
blood vessels of the islets (Jansson, 1994). The nervous network in islets consists of cholinergic 
parasympathetic, adrenergic sympathetic and peptidergic neurons. Parasympathetic 
innervation from the vagus stimulates insulin release whereas adrenergic sympathetic 
innervation inhibits insulin and stimulates glucagon secretion. Nerves extending from outside 
the pancreas into the pancreatic tissue also secrete peptides such as enkephalin, substance P, 
cholecystokinin (CCK), calcitonin gene related peptide (CGRP), and neuropeptide Y (NPY). 
Vasoactive intestinal polypeptide (VIP) containing nerves are the most abundant of this type 
and are known to stimulate all islet hormones by paracrine mechanisms.   
 
1.1.4 Physiological Insulin Secretion  
In order to meet the metabolic needs of the body the β cell has complex and sensitive 
mechanisms for detecting the metabolic demands of the body and secreting insulin 
appropriately. Blood glucose levels are maintained at 4-7 mM by the balance between glucose 
entry into the circulation from the liver, intestinal absorption, and insulin-mediated glucose 
uptake into peripheral tissues such as muscle and adipose tissue. Glucose is the principle 
regulator of insulin secretion either directly through glucose transporter 2 (GLUT-2) 
transporters on the β cell or by amplifying the release of other insulin secretagogues.  
 
Insulin is synthesised in the β cells firstly by the expression of the preproinsulin gene product 
comprising an N-terminal sequence attached to proinsulin. Preproinsulin is cleaved by signal 




peptide chain (C-peptide). Proinsulin is packaged at the Golgi apparatus into secretory granules 
within which prohormone convertase 2 and 3 (PC2/3), and carboxyl peptidase H break down 
proinsulin to insulin and C peptide to from mature granules consisting of insulin and C-peptide. 
The mature insulin molecule consists of the 21 amino acid A chain and the 30 amino acid B 
chain linked by two disulphide bonds to give monomeric protein of 6 kDa. The cleavage of 
proinsulin is accompanied by a fall in pH suggesting that maturation of the granules requires a 
critical pH level. Insulin biosynthesis is regulated to meet the metabolic demands of the body. 
An acute rise in blood glucose concentration stimulates rapid upregulation and processing of 
preproinsulin, but does not affect the rate of conversion from proinsulin to insulin in the 
granules. Secreted insulin can be reabsorbed back into β cells in an autocrine manner which 
suggests a negative feedback mechanisms exists to self-regulate insulin secretion (Persaud et 
al., 2002). 
 
Insulin is secreted in a biphasic manner with the first phase lasting a few minutes followed by a 
sustained second phase. Glucose enters the β cell via the GLUT-2 transporter and becomes 
phosphorylated by glucokinase. GLUT-2 which is also found on liver, intestine, and kidney cells 
forms the glucose sensor together with glucokinase. Due to its high Km the rate of glucose 
entry into the β cell is proportional to the extra cellular glucose concentration. Glycolysis and 
mitochondrial metabolism produce adenosine triphosphate (ATP) from the glucose which 
closes ATP-sensitive potassium channels (KATP). This results in depolarisation and consequent 
opening of voltage-dependent calcium channels which triggers insulin granule translocation 
and exocytosis. Secretory granules are translocated on a network of tubulin microtubules by a 
combination of contractile proteins including actin microfilaments and myosin. Exocytosis of 
the granules occurs by a soluble N-ethylmaleimide-sensitive factor attachment protein 
receptor (SNARE) complex mediation. Vesicle-SNARE proteins on the granule dock with target-
SNARE proteins on the plasma membrane in conjunction with elevated intracellular Ca2+ and 
calcium-binding granule proteins such as synaptotagmin to permit fusion of the granule and 
plasma membranes. Released insulin stimulates the uptake of glucose from the circulation via 
GLUT-4 transporters expressed in adipose and skeletal muscle tissues, and GLUT-2 
transporters expressed in the liver tissue, thereby reducing the blood glucose concentration. 
Insulin also activates glycolysis, glycogen and fat synthesis, and inhibits glycogenolysis.  
Glucagon acts to counter-balance the effects of insulin by increasing blood glucose 
concentration by promoting glycogenolysis and gluconeogenesis predominantly in the liver. 
Somatostatin has an inhibitory effect on α and β cells and pancreatic polypeptide has systemic 





1.1.5 Modulation of Insulin Secretion  
The translocation and exocytosis of insulin secretory granules is a Ca2+ dependent process. An 
increase in intracellular Ca2+ can therefore stimulate the release of insulin. Glucose and amino 
acids cause an increase in intracellular Ca2+ by depolarising the membrane either directly by 
carrying positive charge into the cell or indirectly by generating ATP from metabolism which 
closes KATP channels. Insulin secretion can be modulated by hormones, peptides, and 
neurotransmitters. These molecules have an effect on either ion channels that regulate 
membrane potential, mobilization of intracellular Ca2+ stores, or modification of contractile 
protein interactions which sensitize translocation and exocytosis. Glucagon can potentiate 
insulin secretion by generating cyclic adenosine monophosphate (cAMP) in the β cell which 
ultimately leads to sensitization of the secretory machinery to Ca2+ (Samols et al., 1965). 
Somatostatin is associated with a decreased production of cAMP in β cells and as such acts as a 
paracrine inhibitor of insulin secretion (Samols and Stagner, 1990, Hauge-Evans et al., 2009). 
Preptin is derived from pro-insulin-like growth factor II and has been located to β cells where it 
can amplify glucose mediated insulin secretion (Buchanan et al., 2001). Parasympathetic nerve 
neurotransmitters acetylcholine (Ach), VIP, and gastrin-releasing peptide (GRP) along with 
pituitary adenylate cyclase-activating polypeptide (PACAP) all induce insulin secretion. 
Sympathetic nerve neurotransmitters norepinephrine, NPY, and galanin all inhibit insulin 
secretion. Putative sympathetic nerve neurotransmitters include CCK and neurotensin which 
have both been shown to stimulate insulin release. Other peptides such as bradykinin and 
oxytocin and various hormones such as growth hormone, parathyroid hormone and cortisol 
have also been shown to stimulate insulin secretion (Nielsen et al., 2001). Finally, incretin 
hormones secreted from intestinal endocrine cells play a major role in stimulating insulin 
secretion. These will be described in detail elsewhere in the general introduction (1.5.1). The 
organisation and physiology of the islet provides a multifaceted and complex regulation 
system for insulin secretion. Therapeutic approaches should aim to accurately mimic or 
directly provide physiological insulin secretion in order to provide an accurate and dynamic 
treatment for insulin deficiency.  
 
1.2 Therapeutic Approaches for Type 1 Diabetes 
 
1.2.1 Insulin Replacement Therapy  
Since the discovery of insulin in the 1920’s insulin therapy has been developed to treat T1DM. 
Insulin replacement therapy is effective in controlling hyperglycaemia by administration of 
exogenous insulin by subcutaneous injections. Patients using insulin therapy are expected to 




assistance of a medical team to educate the patient in self management. This involves 
attention to eating and exercise, and appropriate blood glucose monitoring and insulin 
administration. The treatment regimen attempts to mimic normal physiological insulin 
secretion patterns. Administration of intermediate or long-acting insulin simulates basal 
secretion throughout the entire day, and rapid-acting insulin administered before meals 
simulates prandial insulin secretion. However it is not possible to achieve constant 
normoglycaemia as exogenous insulin administration can not accurately and continuously 
mimic the pulsatile and ultradian oscillatory nature of physiological insulin secretion. Rapid-
acting insulin is absorbed too slowly and lasts too long to mimic normal prandial peaks, while 
long-acting insulin does not provide the steady low concentrations required between meals. 
To further the complexity, insulin must be administered to compensate for subjectively 
predicted variables such as food intake, exercise, and stress. Subcutaneous injections of 
identical doses of insulin can result in variable metabolic effects from day to day. This 
variability of insulin action can prevent optimal glycaemic control from being achieved and is a 
source of uncertainty and frustration for patients. Absorption rate is not the only factor as 
identical plasma concentrations can even cause variable glycaemic control (Heinemann et al., 
1998). Over the lifetime of a patient there is therefore a significant accumulation of time in 
hyper- and hypo-glycaemic states. Persistently aberrant blood glucose levels are associated 
with secondary complications in the long term such as microvascular (retinopathy, 
nephropathy, and neuropathy) and macrovascular (cardiovascular, cerebrovascular, and 
peripheral vascular disease) disorders. The major cause of mortality for patients with disease 
duration under 20 years is renal pathology and over 30 years is cardiovascular pathology 
(Orchard, 1994). Despite the efficacy of insulin therapy it has been estimated that a 10-year-
old boy or girl developing diabetes in the year 2000 would lose 18.7 and 19.0 life years on 
average, respectively, compared with non-diabetic peers (Narayan et al., 2003). 
 
An influential study by the diabetes control and complications trial (DCCT) reported that the 
use of intensive insulin therapy to achieve consistent blood glucose control was effective in 
preventing secondary complications (DCCT, 2003). However the DCCT reported that 
hypoglycaemic episodes were three times as likely using intensive insulin treatment verses 
conventional treatment. Some patients suffer from episodes of hypoglycaemia as a result of 
incorrect dosing of insulin or other factors. Such episodes can be unpredictable and highly 
disruptive to day-to-day quality of life. Severe hypoglycaemic episodes present with confusion, 
convulsion or unconsciousness and frequent episodes can lead to cognitive impairment. Fear 
of hypoglycaemic episodes can also interfere with the patients’ ability to correctly administer 




time (Boland et al., 2001) suffering an average of two symptomatic episodes per week and one 
occurrence of severe disabling hypoglycaemia per year (MacLeod et al., 1993). Additionally it is 
estimated that 2-4% of deaths of people with T1DM are due to hypoglycaemia (Laing et al., 
1999). Hypoglycaemia usually induces a stress response by epinephrine release which the 
patient can recognise and act upon. However for some patients with hypoglycaemia 
unawareness the stress response is attenuated, resulting in patient inaction and therefore an 
increased chance of progression to a severe hypoglycaemic episode. Brittle diabetes patients 
are described as having erratic glucose levels that are unpredictable and interfere with patient 
lifestyle. Labile diabetes is characterised by a gradual decline in glucose levels over the day 
even if they are not extremely erratic. For a subset of around 10% of diabetic patients with 
brittle or  labile diabetes, frequent hypoglycaemic episodes, hypoglycaemic unawareness, or a 
consistent failure of insulin based management due to clinical or emotional problems, the 
application of islet transplantation has shown to be beneficial compared to insulin therapy 
(Ryan et al., 2004a).  
 
Islet transplantation is the focus of this thesis, however other approaches are also being 
developed as alternatives to conventional insulin therapy. Insulin pumps can be used alone or 
coupled with continuous glucose monitoring to direct the infusion of insulin in what is referred 
to as a closed loop system or artificial pancreas. Continuous glucose monitoring has been 
achieved although it does not have the accuracy of conventional blood glucose meters (De 
Block et al., 2008). Insulin pumps alone offer continuous insulin infusion which can be adjusted 
for optimal basal insulin replacement. Adequate algorithms are yet to be developed to link 
continuous glucose monitoring with insulin pump action to fulfil the dynamic specific insulin 
requirements of individual patients. Whole pancreas transplantation is another alternative 
approach to insulin therapy. Pancreas transplantation is usually performed as a multi-organ 
transplantation in conjunction with kidney transplantation. As diabetic patients in need of 
kidney transplantations will undergo invasive surgery and lifetime immunosuppression, 
pancreas transplantation can be performed simultaneously without greatly increasing the 
existing risk. Previously pancreas transplantation resulted in better outcome compared to 
allogeneic islet transplantation as measured by insulin independence. However there is now 
evidence that islet transplantation provides comparable transplantation outcome to pancreas 
transplantation (Maffi et al., 2011). However islet transplantation has the advantages of being 







1.2.2 Islet Transplantation  
Islet transplantation for T1DM aims to replace the islet tissue in order to restore normal 
physiological glycaemic control to patients. It is hoped that restoring physiological glycaemic 
control would eliminate hypoglycaemic episodes, reduce the risk of progression of secondary 
complications, and also free patients from the burdens of injections, glucose testing, and 
dietary restrictions. The clinical procedure for islet transplantation involves the infusion of 
islets from cadaveric donors through a percutaneous cannulation of the portal vein and 
engraftment of the islets in the venules of the liver. Before the turn of the century less than 
10% of islet graft recipients achieved insulin independence. The first major breakthrough in 
clinical islet transplantation was the Edmonton protocol which was reported to achieve insulin 
independence in 7/7 patients at 1 year post-transplantation (Shapiro et al., 2000). The success 
of the study was due to using large islet grafts involving multiple infusions from multiple 
donors. The approach used a glucocorticoid-free immunosuppressive regimen, fresh rather 
than cultured islets, and reduced cold ischemia time.  Although this result was a major 
improvement on previous clinical islet transplantation outcomes the longevity of graft function 
was limited with only 10% remaining insulin independent after 5 years. The Edmonton 
protocol has since provided the basis of clinical islet transplantation at centres worldwide. The 
most recent report from the clinical islet transplantation registry analysed the outcome of 677 
islet grafts. The success of islet transplantation has gradually improved with 3 year insulin 
independence rates of 27%, 37%, and 44% in the early, middle, and late 00’s (Barton et al., 
2012). Recently there has been a drive towards achieving insulin independence with grafts 
derived from single donors (Shapiro, 2011). If graft success can be achieved with a single 
donor, islet transplantation will be comparable with pancreas transplantation which requires a 
single pancreas. In islet graft recipients without insulin independence some degree of 
physiological insulin production and hypoglycaemic awareness seems to persist. Consequently 
the risk of hypoglycaemia can be greatly reduced over the long term for islet transplantation 
recipients (Ryan et al., 2004b). Although islet transplantation does not assure complete insulin 
independence in the long term, patients report the reduction in hypoglycaemic episodes to be 
a major benefit. With some degree of physiological insulin control restored the necessity for 
larger and potentially inaccurate doses of exogenous insulin is obviated. In addition to the 
physiological benefits of a reduced frequency of hypoglycaemia, patients have also reported 
an increase in their quality of life due to a reduction in anxiety associated with hypoglycaemia. 
There is also evidence that islet transplantation can reduce the progression of secondary 





There is a donor shortage for islet transplantation such that with the current protocol and 
source of islets from heart-beating brain-dead donors it is estimated that only 0.1% of T1DM 
patients could be treated (Shapiro et al., 2001). This is exacerbated as donor pancreases are 
also considered for whole pancreas transplantation and multiple donors are required for islet 
transplantation. Isolation of islets causes vascular connections to be severed leaving the islet 
reliant on diffusion to obtain sufficient oxygen and nutrients until revascularisation has taken 
place after transplantation. Islets may also be damaged from collagenase digestion, 
mechanical force, and oxygen and nutrient deficiency during islet isolation. Isolation disrupts 
the complex architecture of the islet and causes loss of support from surrounding ductal cells 
(Ilieva et al., 1999) extracellular matrix (ECM) proteins (Wang and Rosenberg, 1999) and 
endothelial cells (Johansson et al., 2009), which all provide trophic factors for islet viability and 
function. Culture of islets has also been reported to cause hypoxic stress (Lau et al., 2009). 
Transplantation of islets rapidly after isolation was thought to be optimal, however current 
islet transplantation strategies emphasise the importance of a short culture period pre-
transplantation. Short term culture removes nonviable islets and decreases tissue factor 
expression which can cause inflammation and consequent islet loss (Johansson et al., 2005a). 
The culture period also allows time to perform microbiological screening and initiate 
immunosuppression in the recipient.   
 
Optimal engraftment of islets should prevent further islet damage and stress to that endured 
during islet isolation, culture, and transplantation. Ideally, islet morphology should be 
maintained and the islet architecture should be reconstituted with revascularisation and 
reinnervation, and the restoration of paracrine and ECM interactions. As clinical islet 
transplantation is at the intraportal site the restoration of neuronal innervation and paracrine 
interaction similar to that of the native pancreatic site are not possible. Islets entrapped in 
ECM scaffolds have demonstrated improved islet viability and glucose-stimulated insulin 
secretion (GSIS) (Zhang et al., 2012), and improved graft outcome in transplantation models 
(Salvay et al., 2008). However revascularisation is considered to be the most important factor 
in islet engraftment (Davalli et al., 1996). Following transplantation revascularisation is 
generated by both donor and recipient endothelial cells (Brissova et al., 2004). 
Revascularisation progresses with observable sprouting at 2 days post transplantation and 
takes up to 10-14 days to complete revascularisation (Menger et al., 2001). Delayed and 
insufficient vascularisation results in deprivation of oxygen and nutrients resulting in cell death 
which can lead to graft failure (Linn et al., 2006). Indeed hypoxia has been suggested to be a 





Upon transplantation, loss of graft function over time is due to both acute and chronic host 
challenges. The acute loss of cells in the first week is due to damage from the transplantation 
procedure and the instant blood-mediated inflammatory reaction (IBMIR). The IBMIR involves 
platelet deposition, coagulation, secretion of harmful cytokines such as IL-1β, TNF-α, and IFN-γ 
and leukocyte infiltration resulting in the immediate loss of up to half the islet mass (Eich et al., 
2007). The gradual loss of surviving islets over time is thought to be due to the host immune 
rejection and the toxic effect of the immunosuppressive agents. The immune response to islet 
grafts is similar in mechanism to the autoimmune response (1.1.2) except it is initiated 
predominantly by MHC alloantigens as opposed to autoantigens. In addition to the 
alloimmune response which is present in any type of allograft, the autoimmune challenge to β 
cell antigens which is particular to T1DM patients may also contribute to the continued 
destruction of the implanted islets. Immunosuppressants are able to inhibit the acute rejection 
to some degree but chronic rejection continues resulting in fibrosis, tissue damage, and graft 
failure, despite the immunosuppressive regimen. Indeed it has been demonstrated that under 
immunosuppressive regimens immunological parameters such as T cell alloreactivity correlates 
with clinical outcome (Roelen et al., 2009)   
 
The transplantation of allogeneic islets necessitates the use of immunosuppression in order to 
prevent graft rejection. Immunosuppression naturally results in an increased risk of infection, 
and also malignancy (Riminton et al., 2011).  Long-term follow-up studies from islet 
transplantation are forthcoming but indications from renal transplant patients under similar 
immunosuppressive regimes suggest a 42-fold increase in risk of infection (Abbott et al., 2002) 
and a 10-15% risk of cancer over a 10 year period post transplantation (Euvrard et al., 2003). 
Nephrotoxicity also occurs with an estimated 16.5% of patients developing chronic renal 
impairment. This is particularly unfavourable as recipients are already at risk of kidney disease 
as a secondary complication of diabetes. Other complications for immunosuppressed islet 
transplant patients include mouth ulcers (96%), diarrhoea (67%), acne (35%) and some 
individuals require granulocyte colony-stimulating factor (GCSF) due to severely low mean 
white cell counts. Immunosuppressive agents are also known to be harmful to islet viability 
and function (Kaestner, 2007). The advances in islet transplantation in the last decade have 
mainly been due to improvements in strategies to prevent islet rejection. The Edmonton 
protocol established the use of IL-2 receptor antagonist for induction and mammalian target of 
rapamycin (mTOR) inhibitor and calcineurin inhibitor for maintenance of immunosuppression. 
Current protocols include induction with a T cell deleting antibody, with or without a TNF-α 
inhibitor, and maintenance with an mTOR inhibitor or an inosine monophosphate 





Several approaches aiming to improve islet transplantation outcome are in development. The 
process can be optimised at every stage including optimisation of islet isolation for greater 
yields and islet viability, maintenance of islet viability and function during culture, and 
enhancing islet engraftment and revascularisation. However, arguably the most important 
factor in the outcome of islet transplantation is the host immune response. Islet 
transplantation presents a challenge whereby it is not only necessary to provide for the islets 
to maintain islet viability and function but also to protect the islets from a dynamic and 
complex system which seeks to destroy the islets. For T1DM patients able to achieve relatively 
good normoglycaemia through insulin therapy and in the absence of renal disease, it is difficult 
to justify islet transplantation given the risks of immunosuppression. Overall islet 
transplantation results in stabilization of glucose control, better quality of life and may 
improve secondary diabetic complications. The risks are acute morbidity from the procedure, 
chronic morbidity from immunosuppression, and increased relative risk of mortality. In effect 
the patient is exchanging insulin therapy for immunosuppressive therapy. Induction of graft 
tolerance would provide a solution to the problem of chronic graft rejection. There are several 
strategies to confer immune tolerance including donor-reactive T cell depletion, co-stimulatory 
blockade, immune deviation, and generation of regulatory T cells (Bhatt et al., 2012). T cell 
depletion (Silveira et al., 2006) and co-stimulatory blockade (Posselt et al., 2010) have been 
used in clinical islet transplantation however they do not induce complete tolerance. Co-
transplantation of cells can confer immune deviation and will be discussed in this thesis (1.6.3). 
Finally regulatory T cell therapy is problematic due to the necessity to produce large numbers 
of antigen specific T cells and simultaneously restrain them to a regulatory T cell lineage. It 
would therefore be desirable to be able to implant islets in an allogeneic setting without any 
manipulation of the host immune system.    
 
1.2.3 Immunoisolation  
The aim of immunoisolation is to encapsulate the islets in a permselective biomaterial which 
allows the passage of small vital molecules such as oxygen and insulin but prevents the entry 
of large molecules and cells. This physical barrier should prevent cellular contact and 
recognition of MHC by host lymphocytes and therefore abolish cell mediated cytotoxicity. In 
addition antibodies should ideally be excluded by the barrier in order to prevent antibody-
mediated cytotoxicity and complement activation. The islets can therefore function effectively 
whilst preventing the destruction caused by host immunity and hence obviate the need for an 
immunosuppressive regimen. Encapsulation devices can broadly be categorised into three 




vessels. Extravascular macrocapsules which are diffusion chambers in the shape of a tube or 
disk which are implanted in body cavities such as the peritoneal cavity. And finally 
microcapsules which attempt to encapsulate islets singularly in spherical capsules. Both forms 
of macrocapsule have been largely unsuccessful due to the large size of the devices resulting in 
large diffusion distances for vital molecules. In addition large intravascular devices are difficult 
to surgically implant and promote blood clotting which increases the risk of thrombosis. 
Microcapsules have been the most widely used immunoisolation device for islet 
transplantation. The small size and spherical shape of microcapsules is designed to provide 
adequate cover of the islet without having unnecessary biomaterial, therefore minimising the 
diffusion distance and also limiting the interaction with surrounding tissues.  
 
1.2.4 Alginate Microencapsulation 
Microencapsulation of islets was first described in 1980 by Lim and Sun using alginate as the 
encapsulation material (Lim and Sun, 1980). Alginate is a component of the ECM of brown 
algae consisting of the polysaccharides β-D-mannuronic acid (M) and 1,4-linked α-L-guluronic 
acid (G). Raw alginate from seaweed is purified to remove polyphenols, proteins, and 
endotoxins to improve the biocompatibility (Dusseault et al., 2006). Islets are suspended in 
dissolved alginate and using air, mechanical or electrostatic force, or a combination of these, 
droplets are drawn into a divalent cationic solution containing Ca2+ and/or Ba2+ which causes 
gelification by cross-linking the alginate molecules to form a hydrogel. Hydrogels are 
hydrophilic and negatively charged, resulting in minimised protein and cell adhesion. 
Additionally the pliable gel formed from alginate hydrogels minimises mechanical or frictional 
forces to the surrounding tissue. Materials other than alginate have been used for 
microencapsulation, however alginate has several advantages. Alginate does not interfere with 
islet function, and can be cross-linked at physiological temperature, pH, and osmotic potential. 
Indeed insulin secretion from alginate microencapsulated islets is proportionally responsive to 
variable concentrations of glucose and insulinotropic agents (Figure 1). Alginate encapsulation 
of islets has also been shown to improve the survival of islets in culture (Sandler et al., 1997, 
Lopez-Avalos et al., 2001), and is stable in vivo. Alginate molecules are linear block co-polymers 
of M and/or G which vary in composition depending on the source. Blocks of G and blocks of M 
and G are able to cross-link with divalent cations (Donati et al., 2005). Alginates with specific 
M:G ratios can be selected to optimise the stability and binding efficiency to form 
microcapsules with specific properties. Due to the cross-linking ability of G blocks, high-G 
alginate is more stable and resistant to mechanical stress although it is also more permeable 
than high-M alginate (Martinsen et al., 1989). The most commonly used microcapsules were 




(PLL) and an alginate covering to mask immunoreactive unbound polycation groups (APA). 
Polycation is used to provide stability which is essential for Ca2+ gelified alginate and also 
decreases the permeability of the capsules. M rich alginate is able to bind PLL better which 
results in greater control over permeability and better coverage of PLL. Barium-alginate 
hydrogel has a stronger gel than calcium-alginate hydrogel and consequently is often used 
without a polycation coating (Thu et al., 1996). Barium is toxic, however using low 
concentrations and adequate microcapsule washing and culture, barium leakage from capsules 
is lower than established clinically tolerable levels (Morch et al., 2012). The benefit of cross-
linking with Ba2+ is only observed in alginates with high-G content (>60%).   
 
Figure 1. Perifusion of 
alginate 
microencapsulated islets. 
The insulin secretion of 
Institute for Cancer 
Research (ICR) mouse 
islets was assessed in 
response to 
glucose/glucose and 
carbachol challenge in a 
temperature-controlled 
islet perifusion system. 
Islets were exposed to 
concentrations of 
glucose/glucose and 
carbachol as indicated 
over 90 min (n=4(1)). 
 
It is challenging to assess the microencapsulated islet transplantation field as capsule 
composition is highly varied between groups and within groups over time. There is often a lack 
of “head to head” data comparing different capsule compositions in vivo. Additionally the 
source of alginate and purification is often variable which further complicates analysis. There 
are many reports of long term blood glucose correction by transplanting microencapsulated 
islets into rodent models of diabetes. Transplantation of high-M barium-alginate 
microencapsulated allogeneic islets have been shown to maintain normoglycaemia for >350 
days in non-obese diabetic (NOD) mice (Duvivier-Kali et al., 2001). In a follow up study it was 
found that capsule stability leading to capsule breakage was problematic when high-M barium-
alginate capsules were transplanted into rats. Consequently blood glucose was maintained for 
only 53±6 days (Omer et al., 2005). High-G barium-alginate capsules offer similar 
biocompatibility to high-M barium-alginate capsules (Zimmermann et al., 1992), have higher 
capsule stability, and have demonstrated efficacy in long-term allogeneic transplantation 































studies in NOD diabetic mice (Bohman and King, 2008). High-G barium-alginate capsules offer 
an attractive capsule composition and have been used for the studies in this thesis. 
Microencapsulated islet transplantation has also been reported in large animals although with 
less success. Transplantation of syngenic islets in APA capsules into diabetic dogs resulted in 
maintenance of normoglycaemia for 6 months (Soon-Shiong et al., 1993). The insulin 
requirements of diabetic cynomolgus monkeys were reduced for 6 months by transplantation 
of microencapsulated neonatal porcine islet cell clusters (Elliott et al., 2005). An ongoing 
clinical trial is investigating the use of barium-alginate microencapsulated islets transplanted 
into the peritoneal cavity of non-immunosuppressed diabetic patients (Tuch et al., 2009). 
Preliminary results of two patients indicate only a transient reduction in insulin requirements 
and undetectable C-peptide by 1-4 weeks. Capsules recovered at 16 months contained 
necrotic islet cells and were surrounded by fibrous tissue indicating poor biocompatibility. 
Another study using alginate-poly-L-ornithine (PLO)-alginate microencapsulated allogeneic 
islets in 4 human patients resulted in a reduction in insulin requirements and abolishment of 
hypoglycaemic episodes for at least 3 years and minimal biocompatibility issues (Basta et al., 
2011). The frequency of hypoglycaemic episodes is a major factor in determining if non-
encapsulated islet transplantation should be administered. If microencapsulated islet 
transplantation can be shown to abolish hypoglycaemic episodes it may stimulate rapid 
development of microencapsulated islet transplantation protocols in the clinic. However it is 
clear that in large animals and humans, biocompatibility of the capsules remains a critical issue 
determining graft outcome.  
 
1.2.5 Biocompatibility 
Pericapsular overgrowth of microcapsules is generated by non-specific absorption of proteins 
onto the material surface and chemotactic signals from the islets allowing adhesion and 
recruitment of macrophages and fibroblasts to the capsule surface. This process takes place 
for the most part in the first few weeks following transplantation and does not increase 
thereafter (De Vos et al., 1999). Overgrowth has been found to directly correlate with graft 
failure in part due to the overgrowth inhibiting adequate diffusion of oxygen and nutrients to 
the islet (de Groot et al., 2004). Indeed it has been shown that cells overgrowing capsules are 
metabolically very active with high glucose oxidation rates (King et al, 2003). Overgrowth 
occurs in approximately 10% of capsules, however it has an impact on neighbouring capsules 
(de Groot et al., 2003) and has been estimated to cause approximately 40% of the loss of 
microencapsulated islets (De Vos et al., 1999). The composition, purity, and integrity of the 
biomaterial including imperfections in the capsule surface have an effect on overgrowth. PLL is 




overgrowth if the PLL is inadequately bound with the alginate (Clayton et al., 1991). The use of 
Ba2+ solution for gelification has addressed this problem as Ba2+ cross-linked capsules have high 
enough stability without the use of PLL (Zimmermann et al., 2000). However, microcapsules 
with PLL have been shown to exclude cytokines more effectively (de Groot et al., 2001).  
 
The islet inside a microcapsule also has an impact on the biocompatibility of 
microencapsulated islet grafts. Studies have reported that islets can protrude outside of the 
capsule, particularly if small sized capsules are used (Halle et al., 1994, De Vos et al., 1996b, De 
Vos et al., 1996a). However there is evidence suggesting that this may be avoidable using 
specific capsule compositions (Strand et al., 2002). Adequately encapsulated islets also play a 
role in recruitment of host immune cells by mechanisms which can be described as 
chemotaxis. Passive shedding of islet antigens can potentially generate either an auto- or 
alloimmune reaction resulting in activation of macrophages and resultant release of cytokines 
such as IL-1β, TNF-α, and IFN-γ, NO and oxygen free radicals (Gill, 1999). These agents are 
small enough to penetrate the semipermeable membrane of some microcapsules and affect 
the function and vitality of islet cells (Eizirik and Mandrup-Poulsen, 2001). Islets under stress 
are known to secrete monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory 
protein (MIP), NO and IL-6. All these factors are known to contribute to the recruitment and 
activation of inflammatory cells (de Vos et al., 2004). For example, MCP-1 is produced in 
response to hypoxic conditions in order to stimulate angiogenesis. MCP-1 also recruits 
macrophages and consequently may be involved in graft failure (Paule et al., 2000). In addition 
to microencapsulated islet biocompatibility an inflammatory response is generated 
immediately post-transplantation to facilitate normal wound healing after surgery (Mikos et 
al., 1998). The surgical procedure causes minor tissue damage however the release of 
inflammatory chemotactic factors in the intraperitoneal cavity after surgery such as fibrinogen, 
thrombin, histamine, and fibronectin has been reported (de Vos et al., 2002).  
 
1.2.6 Diffusion  
It has been shown that microencapsulated grafts fail in the absence of overgrowth which 
suggests that biocompatibility is not the only factor concerning graft outcome (De Vos et al., 
1999). Microencapsulation offers better diffusion than macroencapsulation due to the 
increased surface:volume ratio, although it may still be suboptimal to support islet viability and 
function. In the majority of tissues the maximum diffusion distance for vital molecules such as 
oxygen and nutrients from capillaries is around 200 µm (Orive et al., 2006). Microencapsulated 
islets free-floating in the peritoneal cavity lack any vascular connection and must rely 




capsule creating a relatively large diffusional distance through the alginate to and from the 
islet. The absence of convection movement surrounding the capsule and within a capsule can 
create a gradient of vital molecules from the surface of the capsule to the core (Schrezenmeir 
et al., 1994). Consequently diffusion of vital molecules to and from the islet is inhibited which 
is detrimental to islet viability and function. It has been demonstrated that the oxygen tension 
of islets in small 180 µm diameter capsules is reduced by 55-73% compared to the oxygen 
tension outside of the capsule (Chen et al., 2012). In addition, mathematical modelling studies 
have suggested the oxygen tension in the core of islets in 500 µm alginate microcapsules in a  
40 mmHg environment such as the intraperitoneal cavity may be as low as <2 mmHg 
(Avgoustiniatos and Colton, 1997, Johnson et al., 2009). It has been suggested that the most 
likely limiting factor for islets implanted in bioartificial devices is the diffusion distance to and 
from blood capillaries (Cotton, 1996). Even partial hypoxia can inhibit ATP-dependent cell 
functions such as insulin secretion and may induce inflammatory mediators (Dionne et al., 
1993). Autologous microencapsulated islets grafted in the peritoneal cavity often have a 
necrotic core. The cells at the core are furthest away from the source of oxygen and nutrients 
outside of the capsule which suggests that poor diffusion is responsible. Microencapsulated 
islets receive glucose by passive diffusion, and secreted insulin enters systemic circulation by 
passive diffusion through the peritoneal fluid. Consequently insulin secretion is delayed due to 
poor diffusion (Trivedi et al., 2001) although a reduction in capsule size has been shown to 
minimize the lag in insulin secretion. Even so, it remains uncertain if the suboptimal metabolic 
control from insulin secretion into the peritoneal cavity will be sufficiently robust to minimise 
secondary complications. Due to the challenges presented to microencapsulated islet grafts 
the efficacy of the graft is limited, and consequently a >2 fold higher islet mass is necessary 
achieve stable normoglycaemia when compared with non-encapsulated grafts under the 
kidney capsule (Siebers et al., 1993). 
 
1.3 The Subcutaneous Site for Islet Transplantation 
 
Biocompatibility and adequate diffusion of vital molecules are both multifaceted challenges to 
the success of microencapsulated islet grafts. The site of implantation can have an effect on 
both of these factors. The optimal transplantation site for islet grafts will permit maximum 
survival and function of islets, maximum effectiveness of secreted hormones, and safety to the 
patient (Kemp et al., 1973). For microencapsulated grafts the intraperitoneal site has been 
used for the majority of studies predominantly due to the large capacity of the site and also as 




close contact with capillaries to supply vital molecules for islet survival. It has also been 
suggested that the peritoneum is a preferential site for inflammation and immunological 
reaction (Hall et al., 1998). Additionally removal of microencapsulated grafts from the 
intraperitoneal site is difficult and highly invasive. The accumulation of capsules on the pelvic 
floor may also be an issue in humans. Consequently the investigation of alternative sites which 
have a large enough capacity for microencapsulated grafts is valid. The subcutaneous site 
provides a large and easily accessible site which requires minimally invasive surgery to 
transplant islet grafts. Islet grafts from the subcutaneous site can be biopsied, easily removed, 
and can be easily re-implanted. Secreted insulin from subcutaneous islet grafts can only reach 
the liver and fat tissues through adsorption into the systemic circulation which causes a lag in 
response to blood glucose changes. However, injected exogenous insulin reaches the 
circulation through the subcutaneous site. As an alternative therapy to insulin therapy a 
subcutaneous islet graft would potentially be superior as insulin would be delivered to the 
same site but in a physiologically responsive manner. Taken together the subcutaneous site is 
an attractive option for islet transplantation. However there are challenges to implanting islet 
grafts subcutaneously and research is ongoing to optimise islet transplantation at the site.    
 
1.3.1 Transplantation of Non-Encapsulated Islets at the Subcutaneous Site 
Transplantation of islets at the subcutaneous site was first reported by Paul Lacy’s group in the 
early 1970’s (Kemp et al., 1973). The study compared the subcutaneous, intraperitoneal, and 
intraportal sites for syngeneic islet transplantation into diabetic rats. At the time 
intraperitoneal and intramuscular implantation of islets had already been reported. The 
authors reasoned that as islets in their native site secrete insulin into the portal venous system 
the intraportal site may be appropriate. They also suggested that in terms of safety the least 
hazardous implantation site may be the subcutaneous site. Transplantation of 890 islets 
subcutaneously had no impact on blood glucose. Transplantation of 770 islets intraperitoneally 
reduced the blood glucose to between 11.1-22.2 mM. Finally, transplantation of 550 islets 
intraportally resulted in reversal of the diabetic state and maintenance of normoglycaemia for 
50 days. This landmark study stimulated research into the intraportal site for islet 
transplantation which eventually lead to the adoption of the site for clinical islet 
transplantation. The failure of the graft at the subcutaneous site was suggested to be due to 
poor perfusion of the islet graft.  
 
There are reports of graft success after transplantation of non-encapsulated islets without any 
matrix or device to the unmodified subcutaneous site. Transplantation of 1,200 rat islets into 




et al., 1999), and transplantation of 600 mouse islets into syngeneic mice resulting in 
maintenance of normoglycaemia for 91 days have been reported (Juang et al., 2005). 
Conversely, the vast majority of studies with use of up to 3000 rodent islets implanted into 
mice (Perez-Basterrechea et al., 2009) and 5000 rodent islets implanted into rats (Kawakami et 
al., 2000) report graft failure of non-encapsulated islets at the unmodified subcutaneous site 
(Yang et al., 2002b, Fumimoto et al., 2009, Kawakami et al., 2001, Kemp et al., 1973, Juang et 
al., 1996, Halberstadt et al., 2005, Bharat et al., 2005).             
 
1.3.2 Transplantation of Immunoisolation Devices at the Subcutaneous Site  
Due to the overwhelmingly poor transplantation outcomes at the unmodified subcutaneous 
site the use of implantable devices, biomaterials, and matrices have been employed to alter 
the site to enhance the viability and function of subcutaneously transplanted islets. Following 
almost two decades since Paul Lacy’s group first attempted islet transplantation at the 
subcutaneous site, his group were the first to describe the use of an implantable device to 
improve graft success at the subcutaneous site (Lacy et al., 1991). 500 rat islets were 
immobilised in cross-linked alginate inside poly(acrylonitrile-co-vinyl chloride) hollow fibers of 
600 µm diameter. When implanted at the subcutaneous site of mice 4/5 maintained 
normoglycaemia for over 60 days. The authors do not discuss possible mechanisms but the 
hollow fibre may have provided a protective casing from mechanical force. It is also possible 
that the material stimulated angiogenesis thereby improving the supply of oxygen and 
nutrients to the islets and the diffusion of insulin from islets to the circulation. Another 
implantable immunoisolation device called the “Theracyte” composed of an inner 
immunoisolation membrane, an outer angiogenic membrane, and a mesh for stability has 
been described (Tatarkiewicz et al., 1999). A Theracyte device loaded with 1,500 rat islets was 
implanted subcutaneously into diabetic mice resulting in maintenance of normoglycaemia for 
an average of 94 days (Yang et al., 2002b). The authors suggested the vascularisation 
surrounding the device improved the graft outcome.         
 
One group have focused on the development of a pre-vascularisation approach by delivering 
basic fibroblast growth factor (bFGF) to the subcutaneous site to promote angiogenesis before 
implantation of the islets. Studies were carried out in syngeneic (Kawakami et al., 2000, 
Kawakami et al., 2001) allogeneic (Gu et al., 2001) non-discordant xenogeneic (Wang et al., 
2002) and discordant xenogeneic (Wang et al., 2003) transplantation models. All the studies 
involved the pre-vascularisation of a subcutaneous site for 1-2 weeks by sustained release of 
bFGF from an implanted device or gelatine microspheres. Devices were either removed before 




Xenogeneic islets transplanted in an agarose based macrocapsule resulted in graft success of 
up to 101 days. It was demonstrated that non-encapsulated islets failed due to rejection 
(Wang et al., 2003), suggesting the macroencapsulation provided immunoprotection. Islets 
implanted after pre-implantation of devices or microspheres containing no bFGF resulted in 
graft failure (Kawakami et al., 2001, Wang et al., 2002). This suggests that the bFGF-mediated 
neovascularisation observed was critical to graft success at the subcutaneous site in their 
model.   
 
One study has reported xenogeneic transplantation of pig islets into a subcutaneous site in 
humans without the use of immunosuppression or immunoisolation (Valdes-Gonzalez et al., 
2005). Sertoli cells which are immunoprivileged cells derived from the testes were co-
transplanted with the islets to confer immunoprivilege to the graft site. Approximately 17,000 
islet equivalents (IEQs) and 30-100 sertoli cells per IEQ were delivered into stainless steel mesh 
tubes pre-vascularised for 2 months at the subcutaneous site. This resulted in 50% of 
recipients with reduced insulin requirements and two patients achieving insulin independence 
for up to 2 months. The study was controversial as no non-human primate studies were 
carried out prior to the human studies. 
 
1.3.3 Transplantation of Microencapsulated Islets at the Subcutaneous Site 
Xenogeneic islets immunoisolated in alginate microcapsules or macrocapsules have been 
transplanted to the subcutaneous site in a series of studies by the laboratory of Dennis 
Dufrane. Islets were microencapsulated in 1% high viscosity, high-M, calcium-alginate capsules 
and transplanted at the subcutaneous site of rats to determine if it provides better 
biocompatibility, islet survival, and islet functionality than the intraperitoneal site (Dufrane et 
al., 2006). Capsule breakage and overgrowth of empty capsules was lower at the subcutaneous 
site. Viability, insulin content and in vivo insulin secretion (as measured by C-peptide levels) 
from microencapsulated pig islets was better at the subcutaneous site. The authors suggest 
that due to the reduced macrophage recruitment and therefore pericapsular overgrowth, 
maintenance of islet viability and function is better at the subcutaneous site.  
 
In a follow up study, a variety of alginates were tested for suitability for transplantation of 
microcapsules at the subcutaneous site (Veriter et al., 2010). The study compared 3% high 
viscosity, high-M calcium-alginate with 3% high viscosity, high-G calcium-alginate. High-G 
alginate capsules without islets were found to be permeable to 150 kDa molecules, induced 
fibrosis, and induced angiogenesis creating an oxygen tension of up to 25 mmHg. In contrast 




induce fibrosis, and induced angiogenesis creating an oxygen tension of up to 40 mmHg. Due 
to the advantages of high-M alginate it was selected for transplantation studies. 
Intraperitoneal transplantation of 8000 encapsulated pig islets into rats resulted in graft failure 
by day 10 whereas equivalent transplantations to the subcutaneous site resulted in 
maintenance of normoglycaemia for 60 days. This suggests that the high-M microcapsules are 
specifically suited to implantation at the subcutaneous site.   
 
Having established the optimal alginate for application at the subcutaneous site further 
experiments were carried out in non-human primates (Dufrane et al., 2010). 30,000 IEQs per 
Kg microencapsulated in 1% high-M alginate were implanted subcutaneously into diabetic 
cynomolgus monkeys resulting in blood glucose normalisation for only 2 weeks. A 
macroencapsulation device consisting of a decellularised collagen layer sandwiched between 
layers of 3% high-M alginate was also tested. Macroencapsulation of 50,000 IEQs implanted at 
a subcutaneous site resulted in maintenance of normoglycaemia for an average of 161 days.  
The authors do not offer a direct explanation of why the microcapsules failed and the 
macrocapsule succeeded. The inclusion of the collagen layer in the macrocapsule is suggested 
to provide mechanical support and promote islet cell adhesion. Perhaps of more significance is 
the use of 1.6 times the number of IEQs and the higher concentration of alginate in the 
macrocapsule. It was reported that 1% alginate was permeable to 150 kDa molecules but 3% 
alginate was not. The increased permeability in the microcapsules may have resulted in 
increased permeability to cytotoxic molecules and islet antigens leading to cell destruction and 
recruitment and activation of immune cells respectively. It is not possible to determine from 
this study if the geometric properties of the microcapsule or macrocapsule are superior at the 
subcutaneous site.     
 
1.3.4 Implantation of Angiogenic Devices at the Subcutaneous Site 
The proximity of the vasculature to islet grafts is thought to be a fundamental aspect of graft 
success at the subcutaneous site due to the relative availability of oxygen and nutrients to 
sustain graft viability and the diffusion of insulin into the circulation to confer graft efficacy. 
Several studies have been reported with the aim of promoting angiogenesis to provide a 
suitable environment for islet grafts. These do not attempt to immunoisolate islet grafts and 
are carried out with either syngeneic or immunodeficient animal models. Promotion of 
neovascularisation has been attempted using biomaterials alone such as steel mesh enclosures 
(Halberstadt et al., 2005, Pileggi et al., 2006) polymer sheets (Juang et al., 1996) or Thercyte 
devices (Tatarkiewicz et al., 1999). 3000 islets transplanted into a steel mesh enclosure pre-




rat recipients (Pileggi et al., 2006). Inside the steel mesh was a removable stopper which was 
removed before implanting the islets. The authors suggested that using a device to pre-
vascularise the subcutaneous site which is completely removed before implanting the islets 
may not be optimal. Removal of the whole device may result in damage to the integrity of the 
vascular structures and cause inflammation at the site. Using their device the vascularised 
steel mesh stays in place and only the stopper is removed, thereby creating a space for the 
islet tissue without damaging the newly formed vasculature.   
 
1.3.5 Other Approaches for the Subcutaneous Site 
Islets have been transplanted to the subcutaneous site in basement membrane extract (Bharat 
et al., 2005, Xu et al., 2011, Golocheikine et al., 2010). Subcutaneous transplantation of 250 
mouse islets in matrigel basement membrane extract supplemented with vascular endothelial 
growth factor (VEGF) and hepatocyte growth factor (HGF) into mice resulted in maintenance of 
normoglycaemia up to the end of the experiment at 30 days. Equivalent transplantation 
without supplementation of VEGF and HGF resulted in graft failure. Fibrin glue has also been 
used as a carrier solution for islet transplantation to promote revascularisation and islet 
functionality (Andrades et al., 2007, Kim et al., 2012). Co-transplantation with cells at the 
subcutaneous site such as adipose cells (Fumimoto et al., 2009) and fibroblasts in blood 
plasma (Perez-Basterrechea et al., 2009) have also been reported to improve graft efficacy due 
to enhanced vascularisation. Dispersed islets grown into a “cell sheet” and transplanted 
subcutaneously have also been described (Saito et al., 2011). The authors suggest that 
diffusion of oxygen and nutrients to a sheet of cells only a few cells thick may be better than 
that of cells in an islet. However a control group with an equivalent number of islets was not 
included in this study.       
 
1.3.6 Pre-Vascularisation of the Subcutaneous Site  
Revascularisation of islets takes 7-14 days (Merchant et al., 1997, Mendola et al., 1994). During 
this period islets are dependent on diffusion of oxygen and nutrients from the surrounding 
tissue to maintain viability and function (Olsson and Carlsson, 2005). When islets are co-
transplanted simultaneously with angiogenic devices, neovascularisation of the subcutaneous 
site is initiated upon transplantation and so there is a lag before a fully vascularised site is 
available to the islets. Alternatively when islets are transplanted into a pre-vascularised site 
the fully vascularised site is immediately available and therefore the graft is likely to maintain 
viability and become efficacious in a shorter time period. In a study using polyglycolide sheets 
it was found that pre-vascularised sheets cured a mouse at 3 weeks whereas islets 




1996). This study suggests that simultaneous co-transplantation with angiogenic devices may 
be sufficient for graft success but pre-vascularisation may accelerate the rate of blood glucose 
normalisation.  Conversely, in a study using the Theracyte device there was no difference in 
the time to normoglycaemia with islets transplanted into pre-vascularised devices or 
simultaneously co-transplanted in naïve devices (Tatarkiewicz et al., 1999).  Several other 
studies using a single simultaneous co-transplantation report robust graft success without pre-
vascularisation (Dufrane et al., 2010, Lacy et al., 1991, Golocheikine et al., 2010). Although 
many studies report the advantage of a pre-vascularised site compared to the unmodified 
subcutaneous site there is only anecdotal evidence that pre-vascularisation is more efficacious 
than simultaneous co-transplantation. This is of interest as pre-vascularisation followed by islet 
transplantation requires two separate surgeries where the second surgery is into a highly 
vascularised site prone to bleeding and inflammation. The pre-vascularisation approach may 
also impose timescale limits which may be problematic due to donor islet availability.  
 
1.4 Helper Cells for Islet Transplantation 
 
1.4.1 Islet Co-Transplantation 
The use of helper cells to improve islet transplantation outcome has been explored with 
several cell types. The most commonly co-transplanted cell type with islets are sertoli cells 
(Ramji et al., 2011, Li et al., 2010c, Yin et al., 2009, Korbutt et al., 1997). Sertoli cells are 
immunoprivileged cells derived from the testes which produce immunomodulatory factors 
including Fas ligand and transforming growth factor beta (TGF-β). Co-transplantation of sertoli 
cells with islets has been demonstrated to provide some protection against the alloimmune 
response. Hepatic stellate cells have also been used for co-transplantation due to their impact 
on revascularisation (Yin et al., 2007) and immunomodulatory capability (Chou et al., 2011, 
Yang et al., 2009, Yang et al., 2010a, Jara-Albarran et al., 2001). Hepatic stellate cells are able 
to induce apoptosis in T cells and stimulate regulatory T cell production. Co-transplantation 
with dendritic cells also provides immunomodulatory capacity by altering antigen presentation 
and T cell priming (Li et al., 2010b, Yang et al., 2008, Ali et al., 2000). Endothelial cells have 
been co-transplanted to enhance revascularisation (Kang et al., 2012, Pan et al., 2011) and 
have also been used as a cell coating to protect islets from the IBMIR (Kim et al., 2011a, Kim et 
al., 2009a, Johansson et al., 2005b). As a group, stem cells are the most commonly used cell 
type for co-transplantation with islets. Neural stem cells (Melzi et al., 2010, Olerud et al., 
2009), adipose tissue-derived stem cells (Ohmura et al., 2010, Cavallari et al., 2012), bone 
marrow cells (Sakata et al., 2010b, Sakata et al., 2010a, Figliuzzi et al., 2009, Lee et al., 2005), 




2010, Jacobson et al., 2008) have all been used in co-transplantation studies. Stem cells have 
been shown to have several functions which are advantageous for islet transplantation which 
will be discussed later in this thesis (1.6). 
 
1.4.2 Islet Co-Encapsulation 
Encapsulation of islets in biomaterial or scaffolds provides the possibility of integrating 
molecules or cells localised to the immediate environment of the islet to provide support and 
function to the graft. In comparison to non-encapsulated co-transplantation, co-encapsulation 
has the advantage that molecules and cells can be held in close proximity and are not able to 
disperse away from the islet. Integrating molecules into islet encapsulation devices typically 
requires modification of the molecule or the use of sustained release devices such as 
microspheres so that the agent does not diffuse out in an instant. There have been several 
attempts to incorporate immunosuppressants into encapsulation devices (Song et al., 2012, 
Pinto et al., 2010, Buchwald et al., 2010). Alginate has been simply mixed with unmodified 
anti-inflammatory molecules and cross-liked to create functionalised microcapsules. However 
this simple approach results in rapid diffusion out of the capsules (Bunger et al., 2005). Co-
encapsulation with degradable microspheres allows the release of molecules over a period of 
time and has been demonstrated with the antioxidant vitamin D3 (Luca et al., 2000) and the 
non-steroidal anti-inflammatory drug ketoprofen (Ricci et al., 2005). Bioactive devices have 
been used to enhance vascularisation by incorporation of VEGF (Vernon et al., 2012, Sigrist et 
al., 2003a, Sigrist et al., 2003b) and fibroblast growth factor (FGF) (McQuilling et al., 2011, 
Opara et al., 2010). Molecules have also been co-encapsulated with islets to protect against 
NO generated from pericapsular macrophages (Yang et al., 2005, Chae et al., 2004b, Wiegand 
et al., 1993). Islets have been co-encapsulated with immobilised haemoglobin to improve 
oxygen availability to the islets, resulting in improved graft outcome (Kim et al., 2005b, Chae et 
al., 2004a, Chae et al., 2002). Similarly, oxygen generating molecules (Pedraza et al., 2012, Wu 
et al., 1999) and even algal cells (Bloch et al., 2006a, Bloch et al., 2006b) have been co-
encapsulated with islets. The most commonly co-encapsulated cell type are sertoli cell cells 
which confer localised immunoprivilege to attenuate the overgrowth reaction (Yang et al., 
2002a, Calafiore et al., 2001, Yang and Wright, 1999, Korbutt et al., 1998, Luca et al., 2010). Co-
encapsulating with cells may be more advantageous than co-encapsulation with molecules as a 
continuous, unlimited and even physiological augmentation to the graft may be possible with 
cells. The integration of insulinotropic peptide glucagon-like peptide-1 (GLP-1) into 
microcapsules with islet has also been explored (Kim and Bae, 2004, Kim et al., 2005a). Some in 
vitro efficacy was demonstrated with this strategy however the full potential of GLP-1 




1.5 Glucagon-Like Peptide-1 and Islet Transplantation 
 
1.5.1 Glucagon-Like Peptide-1 and Islets  
Incretin hormones are rapidly released into the circulation within minutes of nutrient ingestion 
to potentiate the release of insulin. It is estimated that incretin release is responsible for 50-
70% of the total insulin secreted after oral glucose administration (Elrick et al., 1964). The 
incretin hormones are gastric inhibitory polypeptide (GIP) secreted from K cells and GLP-1 
secreted from L cells. The proglucagon gene is transcribed in L cells, α cells, and neurons in the 
caudal brainstem and hypothalamus (Mojsov et al., 1986, Drucker and Asa, 1988). Differential 
processing of proglucagon messenger ribonucleic acid (mRNA) by PC1/3 or PC2 results in the 
production of GLP-1 and glucagon respectively. In L cells PC1/3 is prevalent, leading to the 
production of GLP-1 and also other products of the proglucagon gene including glicentin, 
oxyntomodulin, intervening peptide-2, and GLP-2. Release of GLP-1 is stimulated by direct 
contact with nutrients in the intestine, neuronal stimulation, and endocrine factors. GLP-1 is 
inactivated by the ubiquitous proteolytic enzyme dipeptidyl peptidase-4 (DPP-IV) located on 
cell surfaces and in soluble form. It is estimated that half of the active GLP-1 is inactivated by 
DPP-IV before entry to the circulation (Hansen et al., 1999) and once in the circulation a 
further 50% is inactivated within 2 minutes. Fasting levels of circulatory GLP-1 are 5-10 pM and 
increase approximately 2-3 fold postprandially (Elliott et al., 1993).  
 
The GLP-1 receptor (GLP-1R) is a transmembrane G-protein-coupled receptor (GPCR) which is 
expressed in a wide range of tissues including α, β, and δ cells of the islet. GLP-1R agonists 
stimulate glucose-dependent insulin secretion in islets (Mojsov et al., 1987). The primary 
effector of GLP-1 induced insulin secretion is cAMP but GLP-1 also has direct effects on ion 
channels, intracellular Ca2+, ATP synthesis, and insulin granule exocytosis. Unlike sulphonylurea 
insulinotropic agents GLP-1 not only enhances insulin secretion but also mediates the 
replenishment of insulin stores. GLP-1 promotes insulin gene transcription, mRNA stability and 
synthesis resulting in replenishment of insulin stores (Alarcon et al., 2006). Other effects of 
GLP-1 signalling on islets include inducing increased pancreatic duodenal homeobox-1 (PDX-1) 
expression (Wang et al., 1999), glucose-dependent inhibition of glucagon (Nauck et al., 2002) 
and stimulation of somatostatin secretion (Fehmann and Habener, 1991). GLP-1R agonism 
stimulates β cell proliferation (Buteau et al., 2003) and neogenesis (Xu et al., 2006), and 
inhibits apoptosis (Li et al., 2003) resulting in increased β cell mass. PDX-1 has been suggested 
as a mediator for these processes as GLP-1R agonism in β-cell-specific PDX-1-/- mice is 
ineffective (Li et al., 2005). GLP-1 also has effects on non-islet cells including effects which 




production (Hvidberg et al., 1994), increase insulin sensitivity (Sandhu et al., 1999), reduce 
appetite (Toft-Nielsen et al., 1999), and reduce gastric emptying (Imeryuz et al., 1997). GLP-1 
also has cardioprotective (Read et al., 2012) and neuroprotective (During et al., 2003) effects. 
Similarly to GLP-1, GIP also stimulates glucose-dependent insulin secretion, insulin synthesis, β 
cell proliferation, and inhibits β cell apoptosis.  
 
There is evidence that GLP-1 is central to β cell development as GLP-1R -/- mice exhibit 
abnormal islet architecture, glucose intolerance, and impaired recovery from β cell damage 
(Ling et al., 2001). α cells predominantly express PC2, however under certain conditions PC1/3 
is expressed resulting in GLP-1 production α cells. The earliest pancreatic progenitor cells 
produce both PC2 and PC1/3 which suggests transient expression of GLP-1 is involved in islet 
development (Wilson et al., 2002). GLP-1 production in islets has been observed in response to 
partial pancreatectomy (De Leon et al., 2003), induction of streptozotocin (STZ) diabetes 
(Thyssen et al., 2006), islet isolation, and culture (Masur et al., 2005, Heller and Aponte, 1995). 
The production of GLP-1 in α cells is therefore a natural phenomenon which is observed in 
response to tissue damage. It is therefore likely that GLP-1 can be produced in the islet in 
order to promote regeneration and inhibit apoptosis. There is some evidence that GLP-1R 
agonists have anti-inflammatory properties.  Islets cultured in GLP-1R agonist exendin-4 were 
reported to have reduced production of pro-inflammatory cytokines such as IFN-γ, IL-17, IL-1β, 
and IL-2 (Cechin et al., 2011). In addition it was found that serine protease inhibitor 9 (PI-9) 
expression was induced in islets by exposure to exendin-4. PI-9 is able to inhibit the activity of 
granzyme B which is involved in cytotoxic T cell destruction. The presence of PI-9 therefore 
may inhibit T cell mediated autoimmune and alloimmune islet destruction. 
  
1.5.2 L Cells  
Due to the rarity of L cells and the complex anatomy of the intestinal epithelium, isolation of 
unmodified, homogeneous, primary L cells has not been established. Primary preparations 
containing L cells are heterogeneous and typically unsustainable. The foetal rat intestinal cell 
(FRIC) protocol isolates primary epithelial intestinal cells although it produces a heterogeneous 
and largely uncharacterised cell population (Brubaker and Vranic, 1987). Isolation of 
homogenous L cell populations is possible, however it requires using genetically modified 
mice. Transgenic mice with L cell specific expression of a fluorescent protein allow isolation of 
L cells from intestinal epithelium isolates by fluorescence-activated cell sorting (FACS) 
(Reimann et al., 2008).  Immortalized cell lines have been developed for studying L cells. The 
human cecal carcinoma cell line NCI-H716 has been used to study L cells, however it has been 




The STC-1 line was derived from intestinal tumours of transgenic mice expressing the rat 
insulin II promoter linked to both the simian vacuolating virus 40 large T antigen (SV40Tag) 
oncogene and the polyoma small T antigen oncogene (Rindi et al., 1990). Secretion of GLP-1 
(Abello et al., 1994) and GIP (Kieffer et al., 1995) from STC-1 cells has been confirmed 
suggesting the STC-1 line is heterogeneous, consisting of both L cells and K cells. STC-1 cells 
modified to express insulin under the GIP promoter have been shown to correct glycaemia in 
diabetic rodents (Han et al., 2007, Zhang et al., 2008). The GLUTag cell line was derived from 
intestinal tumours of transgenic mice expressing the SV40Tag oncogene under the rat 
glucagon promoter (Drucker et al., 1992). It has been suggested that the GLUTag cell line 
provides a good L cell model as GLUTag cells respond to regulatory mechanisms controlling 
GLP-1 secretion in accordance with primary L cells and in vivo models (Brubaker et al., 1998). 
GLUTag cells are considered to be homogenous L cells and have been demonstrated to secrete 
GLP-1 in response to several stimuli including glucose (Gribble et al., 2003) and insulin (Lim et 
al., 2009). GLUTag cells modified to express insulin under the GLP-1 promoter have been 
shown to express insulin but could not correct glycaemia in diabetic rodents (Bara et al., 2009).  
 
1.5.3 Glucagon-Like Peptide-1 for Diabetes Therapy 
In animal models of T2DM, GLP-1 therapy has been shown to promote β cell neogenesis (Xu et 
al., 1999), proliferation, and differentiation (Perfetti et al., 2000), inhibit apoptosis (Farilla et 
al., 2002), and delay diabetes onset (Wang and Brubaker, 2002).  A β cell is said to be glucose 
competent if the insulin secretory response is responsive and proportional to dynamic glucose 
levels (Kulkarni et al., 2002). GLP-1 has been shown to restore glucose competence to glucose 
resistant β cells (Holz et al., 1993). Several GLP-1 receptor agonists are in clinical development 
and exendin-4 (Byetta®) has been approved for treatment in T2DM patients (Furman, 2012). 
Exendin-4 is a GLP-1R agonist with a 50% amino acid homology to GLP-1 and has a longer half-
life of 6 h compared to the 1-2 minute half-life of GLP-1. Exendin-4 is recommended as an 
adjunctive therapy for patients unable to achieve adequate blood glucose control with 
metformin, sulfonylurea, thiazolidinediones or a combination of these. Therapy with such 
agents has been demonstrated to improve glycaemic control and also to induce weight loss 
due to GLP-1R agonist-mediated suppression of appetite (Zander et al., 2002). The use of GLP-
1R agonists could be relevant to specific strategies for treating T1DM. If β cell destruction 
could be halted before completion GLP-1R agonists may prove useful to exploit the full insulin 
secretory capacity of β cells, encourage β cell regeneration, and prevent β cell apoptosis. GLP-1 
has been shown to induce expression of anti-apoptotic proteins in β cells resulting in inhibition 
of apoptosis. Stimulation of the GLP-1 receptor has been shown to attenuate β cell apoptosis 




have 20-30% of normal insulin secretory capacity (Madsbad et al., 1980) which suggests 
intervention could be beneficial at this stage. GLP-1R agonism has been shown to delay 
diabetes onset in NOD mice (Zhang et al., 2007, Hadjiyanni et al., 2008). A study using 
combination therapy of GLP-1 and β cell neogenesis factor gastrin demonstrated that 
restoration of normoglycaemia and increase in β cell mass could be achieved in NOD mice with 
combination therapy but not with either GLP-1 or gastrin alone (Suarez-Pinzon et al., 2008). 
The authors also suggest that GLP-1 contributes to regulating the autoimmune response 
against β cells as autoantibodies were undetectable in some mice treated with GLP-1.    
 
1.5.4 Glucagon-Like Peptide-1 and Islet Transplantation  
The cohort of beneficial effects GLP-1 induces in β cells can be harnessed to improve islet 
transplantation. Pre-transplantation culture of islets in exendin-4 supplemented media can 
improve the rate of reversal of hyperglycaemia in mice (King et al., 2005). This suggests GLP-1 
may offer a protective advantage to islets in short term culture. It has been shown that 
transplanted foetal islet-like cell clusters have greater revascularisation, insulin producing cells 
(IPCs), and curative potential when recipients are treated with exendin-4 (Suen et al., 2006). 
This suggests GLP-1R agonism permits the growth, differentiation, and maturation of 
transplanted islet precursor cells. There are mixed reports concerning the capacity of GLP-1R 
agonists to induce β cell proliferation in transplanted islets. Induction of β cell proliferation has 
been demonstrated in islet grafts using a high dose of 100 mg.kg-1.day-1 (Tian et al., 2011). 
Another report has suggested administration of approximately 85 mg.kg-1.day-1 of GLP-1R 
agonist does not induce β cell proliferation (Crutchlow et al., 2008). Exendin-4 treatment in 
mouse islet graft recipients has also been reported to reduce the number of apoptotic β cells 
in the early post transplantation period (Sharma et al., 2006, Toyoda et al., 2008). 
 
Marginal mass islet transplantation in conjunction with long acting GLP-1R agonist liraglutide 
was reported to improve time to normoglycaemia, glucose tolerance and graft outcome in 
mice (Merani et al., 2008). Interestingly discontinuation of liraglutide resulted in reversal of the 
positive effect on glucose tolerance and delayed initiation of liraglutide treatment was 
ineffective. Reduced β cell apoptosis was observed 48 h post-transplantation and liraglutide 
attenuated the detrimental effect on graft outcome mediated by an immunosuppressive 
agent. Liraglutide has been suggested to have anti-apoptotic effects in human islets in culture 
(Toso et al., 2010). Islets pre-cultured with liraglutide transplanted into immunodeficient mice 
had no impact on graft outcome whereas systemic administration initiated upon 
transplantation resulted in improved graft outcome. The authors suggest that pre-treatment 




treatment in vivo offers better utility of liraglutide treatment. It has also been shown that 
administering DPP-IV inhibitor in the diet of islet graft recipients can improve graft outcome 
(Kim et al., 2008). In a study with NOD mice transplanted with islets and treated with DPP-IV 
inhibitor it was found that continuous treatment initiated before transplantation prolonged 
graft survival whereas initiation of treatment after transplantation did not (Kim et al., 2009b). 
The authors demonstrate that the DPP-VI inhibitor used also decreases the homing of T cells 
which is likely to contribute to the findings. Some studies have reported no impact on long 
term blood glucose with exendin-4 treatment for islet graft recipients (Crutchlow et al., 2008, 
King et al., 2005). However in these studies the islet number in the grafts were not stringent 
enough to detect an effect as the control grafts also maintained normoglycaemia.   
 
1.5.5 Glucagon-Like Peptide-1 Therapy for Clinical Islet Transplantation 
GLP-1R agonist treatment may be an alternative to exogenous insulin for clinical islet 
transplantation recipients with insulin requirements. Therapy with GLP-1R agonists have the 
advantage that the insulin response is potentiated but is still physiologically responsive 
resulting in more accurate glycaemic control than exogenous insulin therapy can achieve. As 
GLP-1 induces glucose-dependent stimulation of insulin secretion the risk of hypoglycaemia is 
reduced in comparison to drugs such as sulfonylureas. It has been established that 
transplanted islets are able to respond to GLP-1R agonism in humans although the response 
may be less than that of native islets in non-diabetic patients (Fung et al., 2006).  GLP-1 has 
been used in clinical islet transplantation patients with allograft dysfunction and exogenous 
insulin requirements (Froud et al., 2008). It was found that insulin requirements could be 
reduced by a third and 3/16 patients became insulin independent. However 4 patients 
discontinued treatment due to side effects. Systemic administration of GLP-1 is associated with 
side effects such as cramping and nausea (Elbrond et al., 2002, Kolterman et al., 2003). 
Another clinical study reported 39% reduction in insulin requirements over the treatment 
period (Ghofaili et al., 2007). However the effect was reversed once treatment ceased. This 
suggests GLP-1R agonism may have conferred a transient enhancement of GSIS but did not 
increase β cell mass which would have a lasting impact on glycaemic control. It has been 
reported that GLP-1R agonist treatment following clinical islet transplantation resulted in 5/5 
insulin independent patients compared to 1/5 without treatment at 18 months (Faradji et al., 
2008). This suggests that GLP-1R agonist treatment immediately post-transplantation may 
have a lasting effect as islets are most vulnerable in the early post-transplantation period.  
 
Due to the abundance of DPP-IV in the circulation which mediates the breakdown and 




promote β cell proliferation in rodents uses doses in the range of 50-100 µg.Kg-1.day (Li et al., 
2003, Ogawa et al., 2004). This dose range far exceeds the dose GLP-1R agonist dose used 
clinically for T2DM patients of 10 µg.day-1 (Calara et al., 2005). Additionally it has been 
reported that clinical islet transplantation recipients are more susceptible to the side effects of 
systemic GLP-1R agonist therapy (Froud et al., 2008). As a result it is unlikely that systemic 
administration of GLP-1R agonists could be used safely at doses high enough to stimulate β cell 
proliferation.  
 
1.5.6 Ectopic Expression of Glucagon-Like Peptide-1  
Genetically engineering islet cells to produce GLP-1 would provide the islets with a direct 
source of GLP-1. It may be possible to achieve highly stimulatory concentrations of GLP-1 by 
production of GLP-1 localised to the islets. The degradation of endogenous GLP-1 caused by 
the exposure to DPP-IV in the circulation would be greatly reduced or avoided completely. 
Ectopic expression of GLP-1 in β cells would result in production of the protein at the site of 
action requiring only intercellular transport to the site of action. It has been shown that mouse 
insulinoma (MIN6) cell line β cells ectopically expressing GLP-1 are resistant to the toxic effects 
of immunosuppressive drugs (D'Amico et al., 2005). GLP-1 expressing β cells had improved 
viability and functionality, and reduced apoptosis compared to controls when exposed to a 
toxic immunosuppressive agent. GLP-1 expression resulted in constitutive expression of anti-
apoptotic protein B-cell lymphoma 2 (Bcl-2). In accordance ectopic expression anti-apoptotic 
proteins X-linked inhibitor of apoptosis protein (XIAP) (Emamaullee et al., 2005, Plesner et al., 
2005) and Bcl-2 (Sutherland et al., 2004, Contreras et al., 2001) in islets has been shown to 
improve islet graft outcome. Systemic delivery of viral vectors has been used to deliver the 
GLP-1 gene into T1DM animal models. An adenoviral vector administered into the tail vein 
reversed the diabetic state of STZ diabetic mice and temporarily reversed the diabetic state of 
NOD mice (Liu et al., 2007). The vector was non-specific and probably expressed GLP-1 in 
indiscriminately infected cells. Another study used a specific adeno-associated vector which 
efficiently infects β cells and expressed GLP-1 under a β cell specific promoter (Riedel et al., 
2010). Intraperitoneal administration of the vector followed by STZ treatment resulted in 
protection against the development of diabetes. β cell specific expression of GLP-1 did not 
have an impact on circulating GLP-1 levels (Riedel et al., 2010). This suggests localised 
production of GLP-1 in islets results in higher enough concentrations of GLP-1 locally to impact 
β cell survival but without risk of increasing systemic GLP-1 to levels which may induce side 





Transduction of genes into isolated islets to confer expression of GLP-1 for islet transplantation 
has been reported. GLP-1 has also been expressed specifically in α cells in whole islets for 
transplantation studies (Wideman et al., 2006). α cells produce proglucagon which is 
converted into glucagon by PC2. Ectopic expression of PC1/3 in α cells therefore resulted in 
conversion of proglucagon into GLP-1. It was found that α cell production of GLP-1 resulted in 
improved GSIS, reduced apoptosis, and enhanced graft performance over 20 days. The authors 
suggest that GLP-1 secreted from α cells was able to diffuse across the interstitial space to 
stimulate GLP-1R on β cells. PDX-1 staining was reported to be increased in transduced grafts. 
Islets transduced to ectopically express GLP-1 have also demonstrated increased insulin 
secretion, protection from hydrogen peroxide induced cell damage, increased β cell 
proliferation in transplanted islets, and improved graft efficacy for at least 35 days (Chae et al., 
2012). The study used adenovirus vectors which typically have a short duration of gene 
expression of less than 14 days (Michou et al., 1997). The authors suggest that the short term 
GLP-1 expression is likely to confer an advantage in the early post-transplantation period when 
the islets are vulnerable. Gene transduction to confer the production of GLP-1 in diabetic 
animal models has shown some efficacy. However vectors can only express GLP-1 for a short 
period and there are several concerns about the safety of gene therapy. Isolation of islets 
allows the specific infection of only the graft tissue therefore limiting any off target expression 
in the host which could have unforeseen side effects. However safety problems associated 
with gene therapy such as insertional mutagenesis (Hacein-Bey-Abina et al., 2003) and 
immune reactivity (Raper et al., 2003) are still a concern for grafted islets. These issues are 
likely to hinder the translation of gene therapy for islet transplantation into the clinic.      
 
1.5.7 Co-Encapsulation with Glucagon-Like Peptide-1 
The incorporation of insulinotropic agents into polymers could be used to improve the insulin 
productivity of islets in encapsulation strategies for transplantation. The incorporation of 
sulphonylurea into polymers to enhance islet or β cell insulin secretion has been investigated 
(Park and Akaike, 2004, Kim et al., 2003, Park et al., 2002, Na et al., 2001, Park et al., 2001, 
Hwang et al., 1998). Improved insulin secretion has been reported by interacting 
sulphonylurea co-polymers with islets. One study described the co-encapsulation of a 
sulphonylurea co-polymer with islets in alginate microcapsules (Kim et al., 2003). A 
carboxylated moiety of the sulphonylurea glibenclamide was conjugated to a polysaccharide to 
confer water solubility to increase the bioavailability of agent. The co-polymer was shown to 
increase insulin secretion although not as much as would be expected from glibenclamide, 
suggesting the conjugation to the polymer inhibited the action of the glibenclamide moiety. It 





The incorporation of GLP-1 into islet encapsulation devices has been investigated. Unmodified 
GLP-1 encapsulated in commonly used biomaterials for islet encapsulation would readily 
diffuse out due to its low molecular weight. Consequently GLP-1 in zinc crystallized form was 
developed so that it could be encapsulated and provide slow release of GLP-1 by monomers 
shedding from the crystals. Zinc-crystallized GLP-1 was incorporated with islets in a poly(N-
isopropylacrylamide-co-acrylic acid) matrix in a hollow fiber macrocapsule. Insulin secretion 
was found to slowly increase over at least 7 days demonstrating the insulinotropic action of 
GLP-1 and the slow release of GLP-1 from the crystals. In a follow up study the crystallised 
form of GLP-1 was compared with a GLP-1-polymer conjugate in alginate microcapsules (Kim 
and Bae, 2004). Incorporation of free GLP-1 into alginate microcapsules resulted in poor 
capsule formation which the authors suggest may be due to the positive charges on the GLP-1 
molecules increasing the viscosity of the alginate. It was found that the stimulation observed 
with crystallised GLP-1 was further enhanced with GLP-1-polymer conjugate and could be 
sustained for up to 8 weeks. The authors suggest that the greater solubility of the GLP-1 
polymer conjugate enhanced the availability of GLP-1 for action on β cells. It was found 
however that after 5 weeks the increased insulin secretion dropped rapidly. It was suggested 
that exhaustion due to overstimulation of the islets may have caused the sudden drop in 
insulin secretion. Another experiment showed that the effect of the GLP-1-polymer conjugate 
gradually declined in response to glucose over an 8 week period. This suggests that the GLP-1 
was either being degraded or metabolised and therefore had limited longevity (Kim et al., 
2005a).  
 
GLP-1 has been immobilised in PEG hydrogel for co-encapsulation with islets (Lin and Anseth, 
2009). A photopolymerised cross-linked PEG hydrogel network provided a platform for 
incorporation of cysteine modified GLP-1. Islets or β cells encapsulated in GLP-1 functionalised 
PEG had higher viability, insulin secretion, and reduced apoptosis. However the production of 
free radicals during the photopolymerisation process can cause damage to cells, and the 
immunoprotective capability of photopolymerised PEG has not been fully elucidated (Cruise et 
al., 1999). Another conformal coating approach has been reported using a layer-by-layer 
approach with layers of PEG and GLP-1 conjugated to biotin, and held together with 
streptavidin (Kizilel et al., 2010). The coating was found to completely cover islets and also 
increase GSIS. Again the immunoprotective capability of this approach has not been fully 
validated in vivo. Other reports conceptualise the same approach as a transiently functional 
coating to limit islet damage in culture and from the IBMIR (Cabric et al., 2010, Wilson et al., 




into nanofibers and can be cross-linked to encapsulate cells have been developed (Khan et al., 
2012). Encapsulated rat insulinoma cells were found to have improved GSIS and proliferation, 
and were resistant to cytokine mediated cell death. The encapsulation is readily degradable 
and therefore is intended to act as a scaffold as opposed to an immunoprotective device.  
 
1.6 Mesenchymal Stem Cells and Islet Transplantation 
 
1.6.1 Mesenchymal Stem Cells 
MSCs are adult pluripotent stromal cells which are characterised by their ability to 
differentiate into mesodermal lineages including osteoblasts, adipocytes, and chondroblasts 
(Dominici et al., 2006). The capacity for self-renewal, ability to adhere to plastic, and the 
expression or absence of specific surface antigens also defines MSC characterisation. When 
adhered to plastic, MSCs have a spindle-shaped, fibroblast-like morphology. MSCs are most 
commonly derived from bone marrow, however they can be found in the stroma of almost all 
vascularised adult tissues and organs (da Silva Meirelles et al., 2006). Stromal cells are the 
connective tissue cells of tissues and organs which are commonly lymphoid in origin. MSCs 
however are non-lymphoid stromal cells which have the capacity to secrete stromal 
components in order to support adhesion, proliferation, and survival of distinct cell subsets 
(Uccelli et al., 2008). As a result MSCs play an important role in tissue repair and regeneration.  
 
1.6.2 Mesenchymal Stem Cell Therapy for Type 1 Diabetes 
MSCs are amenable to therapeutic utility as they are easily accessible, expandable in vitro, and 
can be preserved without significant loss of function (Parekkadan and Milwid, 2010). MSCs 
have been considered safe to transplant for some therapeutic applications and have been used 
in clinical trials for cardiovascular (Ripa et al., 2007), neurological (Lee et al., 2008), and 
immunological disease (Lazarus et al., 2005). There are safety concerns about the use of MSCs 
for therapeutic use due to the potential of self-renewing cell types to form cancer cells (Reya 
et al., 2001). However there have been no reports of tumour formation using human MSCs in 
clinical trials (Abdi et al., 2008). In the context of T1DM, MSCs have been experimentally 
applied therapeutically in a few different ways. The potential of MSCs to differentiate into 
other cell types makes them attractive for cell replacement therapy. In vitro differentiation of 
MSCs into IPCs has been reported by using specific culture medium enriched with insulin-
promoting factors. MSC derived IPCs have been transplanted to control blood glucose in 
diabetic animal models (Gabr et al., 2012). Several problems prevent the translation of MSC 
derived IPCs to clinical use, including the low proportion of differentiation to IPCs, restricted 




MSCs are known to home to damaged tissue and have been shown to migrate to the islets in 
diabetic animal models (Sordi et al., 2005, Lee et al., 2006d). Chemokine receptors on MSCs 
enable then to migrate towards chemokines secreted from the islets (Sordi et al., 2005). The 
ability of MSCs to migrate is advantageous as they can be delivered into the circulation with 
minimal surgery. Systemic administration of MSCs has been reported to delay onset of 
diabetes, improve glycaemic levels, reduce pancreatic insulitis, stimulate β cell regeneration 
and inhibit autoimmune destruction of β cells (Bassi et al., 2012, Ezquer et al., 2008, Fiorina et 
al., 2009). Experiments transplanting MSCs into NOD mice resulted in delay of onset in pre-
diabetic animals (Fiorina et al., 2009), temporary reversal of hyperglycaemia (Fiorina et al., 
2009), induction of T regulatory cells (Madec et al., 2009), and suppression of diabetogenic T 
cells and dendritic cell proliferation (Jurewicz et al., 2010). These studies suggest that due to 
the immunomodulatory function of MSCs, they are able to attenuate the autoimmune 
response in a T1DM model and therefore permit the survival and regeneration of β cells. MSCs 
have also been reported to induce β cell regeneration in STZ treated animals (Dong et al., 
2008, Lee et al., 2006d, Xu et al., 2012). This demonstrates that MSCs are not only able to 
prevent autoimmune β cell destruction but also actively promote regeneration of β cells. There 
is some evidence that surviving β cells in STZ treated rats can spontaneously regenerate (Jorns 
et al., 2001). It has also been suggested that α cells may be able to transdifferentiate into β 
cells after β cell ablation (Thorel et al., 2010). MSCs may facilitate these β cell regeneration 
processes. One study has reported MSC homing to the islets and differentiating into IPCs, 
although this remains unconfirmed (Ianus et al., 2003). However other studies have reported 
no impact on blood glucose by transplanting MSCs alone into diabetic animals (Longoni et al., 
2010, Urban et al., 2008, Rackham et al., 2011).  
 
1.6.3 Immunomodulation 
The immunomodulatory properties of MSCs make them an attractive candidate for 
therapeutic use in autoimmune diseases such as rheumatoid arthritis, lupus erythematosus, 
multiple sclerosis, and T1DM. The use of MSCs to inhibit rejection of allogeneic tissue such as 
skin grafts, graft-versus-host disease (GVHD), and islet transplantation is also being explored. 
In addition to suppression of the alloimmune response, suppression of the autoimmune 
response is also beneficial for islet transplantation as the autoimmune response can also 
target transplanted islet tissue (Prowse et al., 1986). The mechanism of immunomodulation by 
MSCs is thought to involve an initial cell contact phase and also the paracrine secretion of 
mediators which inhibit immune cell proliferation and responses. MSCs have been shown to 
induce cell cycle arrest in activated T cells (Glennie et al., 2005), stimulate the production of 




and inhibit B cell proliferation, activation, differentiation, and antibody production (Corcione 
et al., 2006).  
 
Rejection of islets is a predominantly T cell mediated process (Gill et al., 1989) and pro-
inflammatory cytokines such as of IFN-γ, TNF-α, and IL-1β contribute to loss of islets (Satoh et 
al., 2007). Several studies have demonstrated that co-transplantation of MSCs with islets can 
improve graft outcome by suppressing immune rejection in allogeneic models (Xu et al., 2012, 
Kim et al., 2011b, Huang et al., 2010, Berman et al., 2010, Longoni et al., 2010, Li et al., 2010a, 
Ding et al., 2009, Solari et al., 2009, Jacobson et al., 2008). MSC mediated effects on T cells in 
islet and MSC co-transplantation experiments have been reported. MSCs have been shown to 
suppress the secretion of pro-inflammatory cytokines IFN-γ (Longoni et al., 2010; Solari et al., 
2009) and TNF-α (Solari et al., 2009) from T cells in islet co-transplantation studies. It has been 
reported that matrix metalloproteases (MMPs) secreted by MSCs reduce surface expression of 
CD25 on responding T cells leading to inhibition of T cell proliferation and responsivity to 
activating factors such as IL-2 (Ding et al., 2009). MSCs have also been reported to increase 
regulatory T cell numbers (Li et al., 2010a, Xu et al., 2012, Solari et al., 2009, Berman et al., 
2010) and alter the composition of T cell subsets. MSCs specifically reduce CD25 expression on 
T effector cells resulting in apoptosis and impaired proliferative response. However MSCs do 
not reduce expression of CD25 on regulatory T cells but foster their survival and expansion (Xu 
et al., 2012).  The maturation and antigen presenting capability of dendritic cells have been 
shown to be inhibited by MSCs (Li et al., 2010a). MSCs have been co-cultured with allogeneic 
dendritic cells to alter the dendritic cell phenotype (Huang et al., 2010). When the MSC-
conditioned dendritic cells alone were co-transplanted with islets a delay in graft rejection was 
observed compared to islets transplanted alone or with non-conditioned dendritic cells. 
Soluble factors released from MSCs can reduce MHC class II and increase IL-10 expression in 
dendritic cells and enhance the ability of dendritic cells to suppress T cell responses.   
 
The immunomodulatory capabilities of MSCs in islet co-transplantation are multifaceted and 
provide some protection from the inflammatory and immune response. However some reports 
suggest MSCs are unlikely to be used as a standalone therapy and are more likely to be applied 
with the goal of reducing immunosuppressant doses (Xu et al., 2012). The synergistic effect of 
sub-therapeutic levels of immunosuppressants and MSCs has been demonstrated (Kim et al., 
2011b).  
1.6.4 Revascularisation 
Currently 2-4 pancreata are often needed to isolate enough islets for a single recipient for 




transplantation. Syngeneic transplantations in mice have been used to demonstrate the 
impact of co-transplanting MSCs in the absence of immune rejection. Minimal mass 
transplantations with as low as half the number of islets required for graft success in control 
grafts have been used to demonstrate improved graft efficacy by co-transplantation with MSCs  
(Rackham et al., 2011, Figliuzzi et al., 2009). The reduction of up to half of the islets equates to 
a large improvement in efficiency which could help improve the donor shortage in the clinic. 
Several studies have implicated MSC-mediated enhancement of revascularisation to the graft 
success of islet and MSC co-transplantations (Figliuzzi et al., 2009, Park et al., 2010a, Davis et 
al., 2012, Cavallari et al., 2012, Ohmura et al., 2010, Ito et al., 2010, Rackham et al., 2011). 
These studies have all reported increased vascular density in the islet graft when MSCs are co-
cultured or co-transplanted with islets. Upon transplantation islets are completely free from 
any vascular connection to the circulation and are therefore reliant on diffusion for oxygen and 
nutrients to maintain viability. In order to gain a sufficient supply of oxygen throughout the 
islet it is necessary for the islet to revascularise. Evidence of revascularisation has been 
observed as early as 2 days post transplantation, although it takes 10-14 days to complete the 
process (Menger et al., 2001). Delayed and insufficient vascularisation results in deprivation of 
oxygen and nutrients resulting in cell death which can lead to graft failure (Linn et al., 2006). 
MSCs have been shown to express angiogenic factors including VEGF, HGF, IL6, IL-8, and 
platelet-derived growth factor (PDGF) (Figliuzzi et al., 2009, Ito et al., 2010, Park et al., 2010a, 
Sordi et al., 2010a, Park et al., 2009, Golocheikine et al., 2010). Co-culture also been shown to 
increase angiogenic VEGF and angiopoietin receptor expression in islets (Park et al., 2010a). It 
has been demonstrated that ectopic expression of VEGF from transplanted islets can improve 
graft outcome by enhancing vascularisation (Cheng et al., 2007). MMP secreted from MSCs can 
facilitate the migration of endothelial cells, which may also enhance islet revascularisation 
(Ghajar et al., 2006).   
 
1.6.5 Immunological Discordance 
By the nature of MSC characterisation MSCs derived from different tissues share similar 
morphology and immunophenotype, however there is some evidence that MSCs derived from 
different tissues have different differentiation capacities (da Silva Meirelles et al., 2006) and 
secrete differing levels of trophic factors (Veriter et al., 2011). Although, it has been 
demonstrated that MSCs from various sources including kidney (Rackham et al., 2011), 
pancreas (Sordi et al., 2010a) bone marrow (Figliuzzi et al., 2009), and adipose tissue (Ohmura 
et al., 2010, Cavallari et al., 2012) improve graft outcome when co-transplanted with islets. 
This suggests that the beneficial properties of MSCs for islet co-transplantation may be shared 




are derived could be the recipient, donor, or a third party. Acquisition of allogeneic MSCs could 
be relatively easy compared with islets as cells are readily available from living donors in the 
case of bone marrow or adipose tissue-derived cells. However recipient tissue is typically 
preferable for transplantation as immunosuppression or immunoprotection are not necessary. 
MSCs derived from diabetic patients have been reported to have similar morphology, 
phenotype, and differentiation potential as those from non-diabetic controls (Phadnis et al., 
2009). This suggests that deriving MSCs from diabetic patients for co-transplantation therapy 
may be a viable option. There is some evidence that allogeneic MSCs are immunogenic (Nauta 
et al., 2006). If this is the case then rejection of the MSCs would probably inhibit any MSC-
mediated enhancement of islet graft survival. If MSCs are immunogenic autologous MSCs may 
be the preferred source. However mice infused with autologous MSCs from mice harbouring 
the NOD autoimmune condition caused visceral tumours in mice. This was not observed in 
mice infused with allogeneic MSCs from healthy donors. This suggests that MSCs from 
individuals with autoimmune conditions may not be appropriate for autografts (Fiorina et al., 
2009). 
 
There are mixed reports concerning the respective ability of allogeneic or syngeneic MSCs to 
modulate the immune response. Allogeneic but not autologous MSCs were able to delay the 
onset of diabetes in NOD mice. Similarly allogeneic but not autologous MSCs used to pre-treat 
dendritic cells were able to attenuate graft rejection (Huang et al., 2010). MSCs have been 
described as hypo-immunogenic as they lack MHC class II molecules and other classical co-
stimulatory molecules (Liechty et al., 2000, Devine et al., 2001, Pochampally et al., 2004, Tse et 
al., 2003). This may explain why allogeneic transplantation of MSCs is tolerated and maintains 
efficacy in some studies. Clinical studies of hematopoietic stem cells co-transplanted with 
MSCs to attenuate graft-versus-host disease (GVHD) have typically come from third party HLA 
mismatched donors (Le Blanc et al., 2008). One study found that syngeneic and allogeneic 
MSCs were equally efficacious for immunomodulation in islet co-transplantation (Longoni et 
al., 2010). Conversely, other studies have shown that syngeneic but not allogeneic MSCs co-
transplanted with allogeneic islets were able to improve graft outcome (Solari et al., 2009, Kim 
et al., 2011b).  
 
It has been demonstrated that co-transplantation with MSCs improves both syngeneic and 
allogeneic islet grafts (Longoni et al., 2010). The improvement in syngeneic islet grafts is likely 
to be related to the enhanced viability, vascularisation, and graft organisation. Whereas in 
allogeneic islet grafts MSCs are likely to provide the same advantages but also modulate the 




capabilities of MSCs, syngeneic rodent MSCs (Rackham et al., 2011, Ito et al., 2010, Solari et al., 
2009) and xenogeneic human MSCs (Cavallari et al., 2012, Park et al., 2010a) have been used 
to improve islet graft outcome. This suggests the immunological discordance of the MSC 
source may not be critical to MSC mediated enhancement of islet graft outcome in the 
absence of an alloimmune response.  
 
1.6.6 Co-Culture of Islets with Mesenchymal Stem Cells 
Isolation of islets removes the islets from an environment with a unique and responsive supply 
of factors to support islet viability and function. Islet vasculature and neuronal connections are 
severed removing the blood supply and neuronal innervations. Additionally damage can occur 
during isolation, including the effects of collagenase, mechanical force, and deprivation of 
oxygen, nutrients and survival factors. It has been proposed that a lack of trophic agents 
account for poor islet survival in culture conditions (Ilieva et al., 1999). Ideally islet culture 
should contain factors which sustain islet viability and function and also restrain further tissue 
damage and promote tissue regeneration. Studies have reported increased islet viability and 
function by co-culturing with factors (Ling et al., 1994) or other cell types (Miki et al., 2006). 
Co-culture with MSCs has also been shown to improve islet viability and function. Co-culture of 
islets with MSCs or with cell free MSC conditioned medium has been shown to lower ADP/ATP 
ratios and increase GSIS and viability (Park et al., 2010a). This suggests MSCs are able to act 
through paracrine mechanisms to enhance islet functionality.  
 
MSC-conditioned medium has been found to contain the growth factors HGF and TGF-β. Islets 
transduced with the HGF gene have improved preservation of β cell mass and graft efficacy 
when transplanted into diabetic animals (Dai et al., 2003, Garcia-Ocana et al., 2003, Lopez-
Talavera et al., 2004).  TGF-β1 plays a regulatory role in β cell development (Sanvito et al., 
1994) and has been shown to enhance β cell function when administered systemically in NOD 
mice (Luo et al., 2005). PDX-1 has been shown to be upregulated in islets by co-culture with 
MSCs (Park et al., 2010a). PDX-1 is known to increase β cell regeneration and proliferation 
(McKinnon and Docherty, 2001, Taniguchi et al., 2003). Co-culture with MSCs also increases 
expression of heme oxygenase-1 (HO) which is known to have cytoprotective effect on islets by 
suppressing oxidative stress (Lee et al., 2006a, Pileggi et al., 2001). Co-culture also been shown 
to increase anti-apoptotic signalling molecules XIAP, Bcl-2, and B-cell lymphoma-extra large 
(Bcl-xL), and also VEGF receptor expression (Park et al., 2010a). Besides its angiogenic 





Another aspect of the application of MSCs for improving islet transplantation is the influence 
of the microenvironment on MSC function. The differentiation potential of stem cells has been 
shown to be influenced by the microenvironment (Li and Xie, 2005). It has also been shown 
that pro-inflammatory cytokines stimulate the immunosuppressive capacity of MSCs 
(Krampera et al., 2006, Polchert et al., 2008), and hypoxic conditions stimulate the angiogenic 
capacity of MSCs (Efimenko et al., 2011, Hung et al., 2007). In a study with non-human 
primates failing grafts could be rescued by infusion of MSCs.  Interestingly the authors claim 
MSCs infused in stabilised grafts were ineffective and suggest the inflammatory environment 
of grafts undergoing rejection may be necessary to activate the immunomodulatory functions 
of MSCs. Treatment of MSCs with hyaluronic, butyric, and retinoic acid has been shown to 
enhance MSC secretion conferring improved islet co-transplantation outcome compared to co-
transplantation with non-treated MSCs (Cavallari et al., 2012). The secretion profile of MSCs is 
likely to be dependent on the stimuli in the microenvironment of transplanted MSCs or in the 
culture conditions of cultured MSCs. This is also likely to affect the impact MSCs have on islets 
in co-transplantation or co-culture.  
 
1.6.7 Mesenchymal Stem Cell Location and Differentiation 
There are conflicting reports about the location and phenotype of MSCs as the post-
transplantation period progresses. MSCs tagged with nanocrystal markers could be identified 
up to 3 weeks after transplantation with islets under the kidney capsule (Ito et al., 2010). It 
was found that some tagged MSCs also stained for an endothelial cell marker suggesting 
differentiation of MSCs into endothelial cells. There are other reports of the capacity for MSCs 
to differentiate into endothelial cells in vitro (Oswald et al., 2004) and in vivo (Silva et al., 
2005). Homing of green fluorescent protein (GFP)-tagged MSCs to the islets and differentiation 
into IPCs has been reported (Ianus et al., 2003). Conversely it has been reported that 1 month 
after infusion of GFP-expressing MSCs into cynomolgus monkeys, MSCs could not be detected 
in the islets but some signal could be found in the liver and lungs (Berman et al., 2010). Indeed 
in another study MSCs could not be detected under the kidney capsule of mice at 1 month but 
were detectable at 3 days (Rackham et al., 2011). Collagen fibres were identified at the site at 
1 month which may be beneficial to graft function (Jalili et al., 2011).There is some evidence 
that MSCs do not need to be administered locally with the islets. An islet co-transplantation 
study found MSCs could be administered either locally with the islets in the portal vein or 
systemically in the tail vein with equal efficacy (Longoni et al., 2010). It has also been reported 
that infusions of MSCs several days post-transplantation into the circulation can prolong graft 




main advantage of MSCs in this case were related to their immunomodulatory properties 
which can be applied systemically.   
 
Direct contact between islets and MSCs is not necessary to utilise some beneficial effect from 
MSCs. Indirect co-culture such as transwell systems prevent direct contact between the islets 
and MSCs by separation with a permeable membrane. MSC-induced improvement in islet 
viability and function by indirect co-culture (Jung et al., 2011, Karaoz et al., 2010) and with 
MSC conditioned medium (Park et al., 2010a) have been reported. One report suggests that 
co-transplantation with MSCs is not necessary as pre-transplantation treatment alone can 
improve graft outcome. Islets exposed to MSC-conditioned medium for 48 h enhanced graft 
outcome when transplanted in diabetic animals (Park et al., 2010a). In agreement with other 
reports (Robertson, 2004, Boker et al., 2001) the authors suggest that the preservation of islet 
viability in culture results in better quality islets and therefore improved graft outcome. It has 
also been shown that MSC co-culture can induce intra islet endothelial cell proliferation 
(Cavallari et al., 2012). Islet endothelial cell proliferation is likely to accelerate the rate of 
revascularisation post-transplantation. There is also some evidence to suggest direct co-
culture is superior to indirect co-culture with islet and MSCs (Jung et al., 2011).     
 
Islet transplantation to extra vascular sites such as under the kidney capsule has been reported 
to result in aggregation of the islets into an amorphous mass (Davalli et al., 1996, Biarnes et al., 
2002). MCS have also been reported to attenuate this process, enhancing the maintenance of 
islet morphology more similar to that of islets in their native site, and preserving endocrine 
and endothelial cell distribution (Rackham et al., 2011). The distribution of α and δ cells were 
found to be more similar to that of native islets in MSC co-transplanted grafts, which may 
facilitate the normal regulation of insulin secretion (Bosco et al., 1989, Hauge-Evans et al., 
2009). 
 
1.7 Minimilisation of Immunoisolation Devices 
 
Microencapsulation is the most commonly used islet immunoisolation method. However the 
diffusion distance to and from the islet and the increase in graft volume using microcapsules 
limit graft success and the choice of implantation site respectively. Based on an average islet 
diameter of 150 µm and a microcapsule diameter of 500 µm the diffusion distance is 250-175 
µm to and from the islet cells, assuming the islet is in the centre of the microcapsule. Using 




surface and as low as 0.15 mmHg at the centre of a microencapsulated islet in a 40 mmHg 
environment such as the intraperitoneal cavity (Johnson et al., 2009). Assuming the same islet 
and microcapsule dimensions, a microencapsulated islet graft would be approximately 37 
times the volume of a non-encapsulated islet graft. Consequently a 70 kg human recipient 
implanted with 10,000 islets per kg would need to receive around 45.8 mL of 
microencapsulated islets compared to 1.2 mL of non-encapsulated islet tissue. Infusion of 
immunoisolated islet grafts into the clinically preferred intraportal site requires the 
development of islet immunoisolation strategies which minimise the immunoisolation device 
and graft volume.   
 
1.7.1 Smaller Microcapsules 
Conventional methods of microcapsule production such as using an electrostatic microcapsule 
generator can typically produce capsules in the range of 150-1500 µm. One way to combat the 
limitations imposed by the size of microcapsules is to make them smaller. The diffusion of 
insulin secreted from glucose stimulated microencapsulated islets out of microcapsules has 
been shown to be more efficient using smaller capsules (Chicheportiche and Reach, 1988). 
Also a study using empty capsules reported that smaller capsules were more biocompatible 
than large capsules in relation to pericapsular overgrowth (Robitaille et al., 1999). However 
other studies have reported that reducing the size of the capsule can result in protrusion of the 
islets (Halle et al., 1994, De Vos et al., 1996b, De Vos et al., 1996a). Islet protrusion was 
reported to be found in 24% of 500 µm capsules and correlated with increased graft failure 
compared to 700 µm capsules (De Vos et al., 1996a). Conversely, a study using the same 
protrusion detection method reported no evidence of islet protrusion in 500 µm capsules 
(Strand et al., 2002). The authors suggested that the difference may be due to the 
inhomogeneous composition of their microcapsules. The use of mannitol as the osmolyte in 
the alginate and a low concentration of cations in the gelification solution produces capsules 
10 times more concentrated at the perimeter of the capsule (Thu et al., 2000). This may 
position the islets in the centre of the capsule upon gelification, thereby preventing islet 
protrusion.        
 
The safety of infusing small microcapsules intraportally has been explored. Infusion of 10,000 
capsules of 315 µm resulted in only a transient increase in intraportal pressure, whereas 
infusion of 10,000 capsules of 420 µm resulted in the death of 2/3 of recipient rats (Leblond et 
al., 1999). A study in pigs reported that the infusion of 10,000 400 µm microcapsules per kg 
induced a small and transient increase in intraportal pressure. Analysis of the liver gave similar 




encapsulated islet transplantation. In a study using high-M alginate microcapsules 
transplanted intraportally increasing overgrowth up to the end point of the experiment at 
week 6 was reported (Mathe et al., 2004). The biocompatibility of a range of alginate 
microcapsules implanted intraportally into rats has been described (Toso et al., 2005). It was 
found that capsules incorporating a polycation layer were the least biocompatible, Ba2+ cross-
linked capsules were more biocompatible than calcium cross-linked capsules, and there was no 
difference in biocompatibility between high-M or high-G alginate capsules. It has been shown 
that short term immunosuppression can attenuate capsule overgrowth at the intraportal site 
leading to a reduction in overall overgrowth in the long term (Toso et al., 2005, Mathe et al., 
2004).         
 
Rat islets immunoisolated with APA capsules of 250-350 µm have been transplanted into the 
peritoneal cavity of diabetic mice resulting in maintenance of normoglycaemia for 7 months 
(Lum et al., 1992). Pig islets immunoisolated in “small barium alginate microcapsules” and 
transplanted into the peritoneal cavity of diabetic rats resulted in maintenance of 
normoglycaemia for 9-385 days (Cappai et al., 1995). Dog islets immunoisolated in 300-400 µm 
alginate-PLO-alginate capsules were transplanted into the peritoneal cavity of diabetic dogs, 
resulting in maintenance of normoglycaemia in 2/3 of the dogs for 140-200 days (Calafiore et 
al., 1999). None of the transplantation studies into diabetic animals had a control group with 
larger microcapsules. Consequently it is impossible to draw any conclusions about the relative 
efficacy of smaller microcapsules. Allogeneic rat islets encapsulated in 350 µm alginate 
microcapsules have been implanted into the intraportal site of diabetic rats (Schneider et al., 
2003). This resulted into only a transient reduction in blood glucose at day 1. The authors 
proposed that the capsules occluded the blood vessels leading to hypoxia and islet death.       
 
1.7.2 Conformal Coating  
Conformal coating of islets involves applying a coating which conforms to the shape of the 
individual islet, thereby providing an immunobarrier or functional coating with minimal dead 
space. The potential advantages of conformal coating compared to conventional 
immunoisolation approaches such as microencapsulation are related to the reduced scale of 
the coating. Conformal coatings should permit better diffusion of oxygen, nutrients, glucose, 
and insulin by reducing the diffusion distance to and from the islet, therefore improving islet 
viability and functionality. Conformal coating of islets also leads to a negligible increase in graft 
volume, therefore conferring suitability for optimal sites such as the intraportal site.  Several 
methods of conformal coating for islets have been described with coating thickness ranging 





1.7.2.1 Interfacial Photopolymerisation 
Conformal coatings of cross-linked polyethylene glycol (PEG) can be formed on the islet 
surface by interfacial photopolymerisation (Sawhney et al., 1994, Cruise et al., 1998, Weber et 
al., 2006). A fluorescent dye photoinitiator such as eosin Y is absorbed onto the islet surface 
and the islets are then suspended in acrylated PEG solution. Using an argon laser the 
fluorescent dye is photoexcited generating a free radical which initiates polymerisation of the 
PEG prepolymers via the acrylate termini. This forms a conformal coating of cross-linked PEG 
hydrogel around the islet in the order of 10-50 µm thickness (Sawhney et al., 1994). 
Functionalisation of the coating has been described  with cell-matrix moieties incorporated 
into photopolymerised PEG hydrogel layers (Weber et al., 2008).  Islets coated by interfacial 
PEG photopolymerisation have been implanted to diabetic animal models (Hill et al., 1997, 
Cruise et al., 1999). Maintenance of normoglycaemia was reported in diabetic athymic mice for 
approximately 70 days when transplanted intraperitoneally with 5,000-8,000 coated pig islets 
(Cruise et al., 1999). 
 
1.7.2.2 Emulsification 
A conformal coating of alginate has been achieved by co-incubation of islets with a two-phase 
aqueous emulsification with alginate, ficoll, and PEG (Calafiore et al., 1999). The emulsion 
droplets engulf the islets in alginate which can then be cross-linked with gelification solution. 
The alginate coated islets were exposed to PLO then alginate to complete the coating. Wistar-
Furth rat islets transplanted intraperitoneally into diabetic Lobund-Wistar rats or CD-1 mice 
resulted in maintenance of normoglycaemia for 140 days using an unreported number of 
islets.      
 
1.7.2.3 Reactive Polyethylene Glycol 
PEG molecules with a reactive group have been used to immobilise PEG molecules onto the 
islet surface. PEG with an amine reactive end group such as isocyanate (Panza et al., 2000) or 
N-hydroxysuccinimide (Lee et al., 2002) react with the amine groups on the islet cell surface 
proteins or collagen layer to immobilise PEG onto the islet surface. Immobilisation of PEG has 
been shown to prevent splenocyte activation (Lee et al., 2004) and lymphocyte infiltration 
(Jang et al., 2004) but could not prevent infiltration of cytotoxic molecules. Reactive PEG has 
been the most widely investigated conformal coating in diabetic animal models (Contreras et 
al., 2004, Lee et al., 2006b, Lee et al., 2006c, Lee et al., 2006a, Lee et al., 2007, Yun Lee et al., 
2007, Wee et al., 2008, Jeong et al., 2011). Allogeneic transplantation of 1,200 activated PEG 




year in diabetic rats when coupled with a minimal dose of cyclosporine (Yun Lee et al., 2007). 
Under the same conditions non-coated islets rejected at day 12. Reactive PEG coating appears 
to be able to block direct cellular immune attack but does not provide protection from 
cytotoxic molecules released from recruited lymphocytes. The low dose of 
immunosuppressant may prevent the release of cytotoxic molecules from the recruited 
lymphocytes permitting survival of the graft. A similar coating has also been applied in an 
allogeneic transplantation model without immunosuppression (Lee et al., 2007).  1,200 rat 
islets coated 3 times with activated PEG transplanted under the kidney capsule of diabetic rats 
resulted in maintenance of normoglycaemia for 100 days in 3/7 of the recipients. Comparing 
the studies, increasing the thickness of the coating improved the immunoprotective capability 
of the immunobarrier. However complete immunoprotection may require a thicker or less 
permeable immunobarrier which can protect against cytotoxic molecules. Reactive PEG coated 
islets have also been implanted intraportally (Wee et al., 2008). Allogeneic transplantation of 
4,000 activated PEG coated rat islets resulted in maintenance of normoglycaemia for 28 days 
in diabetic rats with short term cyclosporine administration. The reduction in efficacy 
compared with similar studies using the kidney capsule site may be related to challenges at the 
intraportal site such as the IBMIR and the lymphocyte rich environment. 
 
1.7.2.4 Hydrophobic Polyethylene Glycol 
Amphiphilic molecules composed of a hydrophilic PEG molecule conjugated to a hydrophobic 
phospholipid molecule can be used to create a conformal coating. The hydrophobic portion of 
the PEG-lipid spontaneously integrates with the cell membrane of the islet surface, anchoring 
the PEG molecule. Hydrophobic PEG coating has been applied to diabetic animal model 
studies. Xenogeneic transplantation of 1,000 hydrophobic PEG coated hamster islets 
intraportally resulted in maintenance of normoglycaemia for only 6 days in diabetic mice 
(Teramura and Iwata, 2009b). In a syngeneic model, intraportal transplantation of 125 
hydrophobic PEG coated mouse islets resulted in maintenance of normoglycaemia for 100 
days in diabetic mice. Non-coated islets failed at 40 days which indicates that the coating may 
provide protection from acute challenges at the intraportal site such as the IBMIR. Conjugation 
of the thrombolytic protein urokinase to the PEG by deoxyribonucleic acid (DNA) hybridisation 
also improved the blood glucose stability in the first 20 days in the study. 
 
1.7.2.5 Functionalised Conformal Coatings   
Conformal coatings are amenable to functionalisation as a small amount of functional protein 




anchored into cell membranes by hydrophobic interaction can provide a base for the addition 
of linkers for attaching functional proteins or for building a layer-by-layer structures.  
 
One form of linker is an amine reactive group on the unbound end of the PEG molecule. This 
can be used to bind functional proteins engineered with thiol groups. Using a PEG-lipid, human 
soluble complement factor (Luan et al., 2011a), and urokinase and thrombomodulin (Chen et 
al., 2011a) have been immobilised onto the islet surface using this method. DNA hybridisation 
has also been used as a linker method and involves using PEG bound or anchored to the cell 
surface which is conjugated with a poly-adenosine (poly-A) DNA sequence. Attachments can 
then be made with a poly-thymine (poly-T) complementary DNA sequence conjugated to the 
molecule of choice. Functional structures or proteins such as anticoagulant-loaded liposomes 
(Chen et al., 2011b) and urokinase (Takemoto et al., 2011) have been immobilised on the islet 
surface using DNA hybridisation.  
 
It may be possible to encapsulate allogeneic islets in the recipients’ cells to prevent recognition 
of the foreign tissue. The immobilisation of cells onto the islet surface to create a cell 
encapsulation barrier has been demonstrated using a DNA hybridisation method (Teramura et 
al., 2010) and a streptavidin-biotin based conjugation method (Teramura and Iwata, 2009a, 
Marek et al., 2011). The biotin-streptavidin/avidin linker method involves using PEG bound or 
anchored to the cell surface which is conjugated with biotin. Attachments can then be made 
with streptavidin/avidin conjugated to the molecule of choice. Biotin-streptavidin/avidin based 
conjugation methods have been used to immobilise molecules such as urokinase and heparin 
(Teramura and Iwata, 2008), VEGF and heparin (Cabric et al., 2010), thrombomodulin (Wilson 
et al., 2010), and GLP-1 (Kizilel et al., 2010) onto the islet surface. The immobilisation of 
heparin onto islets has been reported to reduce thrombi, infarct, and thrombin antithrombin 
levels when transplanted intraportally into pigs (Cabric et al., 2007).  
 
The majority of the studies describing conformal coating functionalisation focus on anti-
coagulation and anti-complement factors which could be applied to attenuate the IBMIR for 
intraportal grafts. It has not yet been established if these approaches can be designed to 
provide long-term immunoprotection as well as short term post-transplantation functionality. 
Immobilisation methods such as PEG-lipid or DNA hybridisation rely on anchorage to proteins 
or lipids in the cell membrane to form a coating. Turnover of cell membrane components is 
likely to limit the longevity of such coatings. Layer-by-layer techniques involving multiple layers 





1.7.2.6 Layer-by-Layer Membranes 
A layer-by-layer membrane involves the deposition of sequential layers of polymers or 
proteins to yield an islet coating of desired thickness and characteristics. The layer-by-layer 
approach to immunoisolation allows for specialisation of the immunobarrier by altering the 
number of layers and the composition. For example, in a layer-by-layer coating the first layer in 
contact with the islet could contain ECM moieties, survival factors, growth factors, or 
insulinotropic factors. Several intermediate layers could be added to provide an 
immunobarrier with specific permeability. The outer layer might then be composed of anti-
inflammatory, anti-rejection, or angiogenic factors. 
 
Functional groups or conjugates on the exposed end of a reactive or anchored PEG molecule 
can be used to seed a layer-by-layer membrane such as alginate and PLL (Miura et al., 2006) or 
poly(vinyl alcohol) (PVA) (Teramura et al., 2007). Hydrophobic PEG has been used to seed a 
functional layer-by-layer coating using human soluble form complement receptor 1 (sCR1) and 
heparin to confer anti-complement activation and anti-coagulation activity respectively (Luan 
et al., 2011b). A layer-by-layer coating seeded on reactive PEG with multiple layers of biotin-
PLL-PEG conjugate and streptavidin has been tested in vivo (Wilson et al., 2008). Allogeneic 
transplantation of a “minimal mass” of 250 coated mouse islets intraportally resulted in 
maintenance of normoglycaemia for only 1 day. The same laboratory did a similar experiment 
with multiple layers of PEG-PLL conjugate and alginate (Wilson et al., 2011) resulting in 
maintenance of normoglycaemia in recipients for only 1 day. A higher proportion (47% vs. 
25%) became temporarily normoglycaemic compared to recipients of uncoated islets.  
 
Layer-by-layer polyion complex nanofilms have been studied extensively for the purpose of 
coating implantable biodevices (Tang et al., 2006). The principle of this method is to exploit the 
weak electrostatic forces in oppositely charged polymers in order sequentially build a 
multilayered film onto a surface. This approach has been adopted for conformal coating of 
islets by seeding directly onto the islet surface. Applying a polyion layer-by-layer coating to the 
islet surface can be problematic as most cationic polymers such as PLL are cytotoxic and if not 
effectively isolated from the cell membrane can cause damage. A layer-by-layer coating of 
reactive PEG and either PLL, poly(ethyleneimine), or poly(allylamine) were all found to 
decrease islet cell viability (Lee et al., 2007). Polyallylamine hydrochloride with poly(styrene 
sulfonate) (PSS) (Krol et al., 2006) have been used as materials for a layer-by-layer coating of 






1.8 Aims and Objectives 
Microencapsulated islet transplantation into the intraperitoneal site is the most common 
approach for immunoisolated islet transplantation. However it is suboptimal and hence there 
is a need to develop novel approaches to enhance immunoisolated islet graft outcome. The 
overall aim of the thesis was to improve the efficacy of immunoisolated islets. This was 
achieved by a variety of strategies as outlined below. 
 
 Site  
The subcutaneous site may offer superior graft outcome for microencapsulated islet grafts. 
The relative ability of equivalent microencapsulated islet grafts implanted intraperitoneally 
and subcutaneously to maintain normoglycaemia in diabetic mice will be explored. 
 
 Co-encapsulation with helper cells  
Cells which secrete factors which are beneficial to islet viability and function are likely to 
improve graft outcome when co-encapsulated with islets for transplantation. 
 
o L cells  
L cells secrete GLP-1 which has been shown to enhance β cell insulin secretion, insulin 
synthesis, and survival. The impact of incorporating L cells with islets in microcapsules on graft 
outcome will be explored using a minimal mass diabetic transplantation model.     
 
o MSCs 
MSCs co-transplanted with islets have been shown to improve graft outcome in non-
encapsulated islet grafts. The impact of incorporating MSCs with islets in microcapsules on 
graft outcome will be explored using a minimal mass diabetic transplantation model.     
 
 Nano-scale encapsulation  
Microcapsules are too large to be implanted into smaller capacity sites such as the kidney 
subcapsular site which enables better support of islet graft viability and efficacy. A novel 
conformal coating will be examined for its ability to permit islet graft viability and function in 
syngeneic transplantations and providing immunoprotection in allogeneic transplantations.   
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All procedures were carried out in the UK in accordance with the UK Animals Scientific 
Procedures Act 1986. All animals were procured from Harlan (Huntingdon, UK) or Charles River 
(Margate, UK), housed on a 12 h light/dark cycle and had access to food and water ad libitum 
except when fasted. All surgeries were carried out under isofluorane anaesthesia (1-5% 
isofluorane, 95% oxygen, 1 L.min-1) and 30 µg.kg-1 buprenorphine (Vetergesic, Reckitt 
Benckiser Healthcare, Hull) was administered subcutaneously before surgery.  Surgical tools 
were cleaned and autoclaved for all procedures and the surgical area shaved and sanitised 
with a chlorhexidine gluconate based antimicrobial skin cleanser (Hibiscrub, Molnlycke Health 
Care, Dunstable). Surgery was completed by suturing incisions with 4-0 VICRYL (Ethicon, 
Johnson and Johnson), ear marking, and transferring mice to a 37°C incubator to recover. ICR 
mice are an outbred strain which were used for in vitro studies. C57BL/6J and BALB/C mice are 
inbred strains with defined immunological discordance which were used in combination for 
syngeneic and allogeneic transplantation studies as appropriate.  
 
2.1.2 Isolation of Mouse Islets 
Mice were killed by cervical dislocation, the abdomen exposed by laparotomy, and the liver 
was inverted to reveal the common bile duct. The ampulla of vater was clamped to close the 
route from the common bile duct to the duodenum. 2.5 mL collagenase (1 mg.mL-1 type XI 
from clostridium histolyticum in modified Eagle’s medium (MEM) (Sigma, Pool, UK)) was 
injected into the common bile duct to distend the pancreatic tissue. Pancreata were excised 
and stored in groups of 2-3 per 50 mL falcon tube, on ice for <60 min before incubation in a 
water bath at 37°C for 10 min.  Following the enzymatic digestion the tissue was washed and 
centrifuged (340 g, 10°C, 75 sec) 3x in supplemented MEM (10% Newborn Calf Serum (NCS), 
100 U.mL-1 penicillin, 100 ng.mL-1 streptomycin (Sigma)). The tissue was resuspended in 
supplemented MEM and filtered in a 450 µm mesh to remove the large pieces of exocrine 
tissue and undigested tissue. Following centrifugation (365 g, 10°C, 90 sec) the tissue was 
resuspended in 15 mL Histopaque 1077 (polysucrose solution at a density of 1.077 g.mL-1 
(Sigma)) and 10 mL supplemented MEM was gently added to create a density interface.  
Centrifugation (1900 g, 10°C, 24 min) was carried out with slow acceleration and no brake so 
not to disturb the density interface, and resulted in the accumulation of islets at the density 
Materials and Methods 
63 
 
interface and exocrine fragments in the pellet. Islets were collected, washed and centrifuged 
(365 g, 10°C, 90 sec) 3x in supplemented MEM. To further purify the islets sedimentation was 
carried out 6x by resuspending the islets in 25 mL supplemented MEM and allowing the islets 
to settle for 4 min on ice, then discarding the top 10 mL containing the remaining small 
exocrine fragments. Islets were cultured overnight (37°C, 5% CO2) in supplemented Roswell 
Park Memorial Institute (RPMI) medium (10% foetal bovine serum (FBS) (Sigma) and 100 U.mL-
1 penicillin, 100 ng.mL-1 streptomycin) at a density of 3-4 pancreata of islets per 2 x 9 cm Petri 
dishes before either encapsulation or culture. 
 
2.1.3 Models of Type 1 Diabetes 
A diabetic state was induced in mice by glucose mimetic toxins which are selectively taken up 
through the GLUT-2 transporter on β cells. Streptozotocin (STZ) is an alkylating agent which 
causes DNA damage and was used unless stated otherwise. 180 mg.kg-1  STZ (Sigma) carried in 
sterile citrate buffer (10 mM citric acid, 150 mM NaCl, pH 4.5) was administered 
intraperitoneally. Alloxan administration results in the accumulation of reactive oxygen species 
and β cell death. 75 mg.kg-1 alloxan tetrahydrate (Sigma) carried in phosphate buffered saline 
(PBS) (Sigma) was administered through the tail vein. For tail vein injections mice were 
anaesthetised by isofluorane and the tail was warmed in 37°C water to enlarge the tail vein. 
The tail was dried and the alloxan tetrahydrate was injected using a 1 mL syringe with a 29G 
needle. Induction of diabetes with STZ or alloxan was 4-7 days before transplantation and 
animals with blood glucose of >20 mM were used for transplantation. 
 
2.1.4 Animal Monitoring 
Diabetic mice were monitored for weight and non-fasting blood glucose with a blood glucose 
meter (Accucheck aviva, Roche, Burgess Hill, UK) 3x per week. Measurements were taken at 
10:00 am on Monday’s, Wednesday’s, and Friday’s. Blood was drawn from a needle prick in 
the extremity of the tail with a 30G needle. Mice exceeding 15% loss of weight in 3 days or 
20% loss of weight overall were killed. 1 unit of insulin (Caninsulin, Intervet, Walton, UK) was 
administered with an insulin syringe (Terumo MYINJECTOR 29G x ½”, Somerset, NJ, USA) to 
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2.2 Tissue Culture 
 
2.2.1 Culture of Mouse Islets 
Mouse islets or microencapsulated islets were picked and counted with a pipette into groups 
of 150 islets in 6 cm Petri dishes or 400 islets in 9 cm dishes (≈7 islets per cm2). 
Islets/microencapsulated islets were cultured in supplemented RPMI (11.1 mM glucose) in a 
tissue culture incubator (37°C, 5% CO2). The media was changed 3x per week. 
 
2.2.2 Cryopreservation of Cells 
Cells were cryopreserved to make cell stocks for long term storage. Cells were resuspended in 
4°C cryopreservation solution (90% FBS, 10% dimethyl sulfoxide (DMSO) (Sigma)) to yield a cell 
density of 1x106 cells.mL-1. 1 mL volumes were transferred to 2 mL screw-top cryotubes and 
these were transferred to an isopropanol freezing container which was incubated at -80°C 
overnight. Cryotubes were then transferred to liquid nitrogen (-196°C) for long term storage.  
Cells were recovered from cryopreservation in order to reinitiate cell culture. Cryotubes were 
removed from liquid nitrogen and defrosted in a water bath for 3 min at 37°C. Cells were 
washed in culture media twice and then seeded into a T25 culture flask (Nunc, Thermo 
Scientific, Roskilde, Denmark).  
 
2.2.3 Passage of Cells 
Cells were passaged in order to keep cells within a density range for normal cell growth. 
Adherent cells were passaged every 2-4 days or when 80-100% confluent. Culture media was 
removed, cells were washed in calcium and magnesium free PBS (Sigma) and then enough 
trypsin solution (0.05% trypsin, 0.02% ethylenediaminetetraacetic acid (EDTA) (Sigma) to cover 
the cells was added. Cells were incubated in a tissue culture incubator for 3-5 min to disrupt 
cell adhesion and then the flask was agitated by hand to detach the remaining cells. Culture 
media was added to stop the reaction and the cells were centrifuged for 3 min at 300g. The 
supernatant was discarded and the cells were triturated in fresh culture media before a 
proportion was re-seeded back into the culture flask supplemented with fresh media. The 
proportion of cells re-seeded was between 1/3 and 1/5 depending on the growth 
characteristics of the cell type. 
 
2.2.4 Estimation of Cell Number 
Detached and triturated cells were filtered through a sterile 40 µm cell strainer (BD 
Biosciences, Oxford) to yield a single cell population. A 10 µl sample was loaded into a 
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Neubauer haemocytometer chamber enclosed with a cover slip. Cells were counted in 4x 1 
mm2 areas and the average was used to estimate the number of cells per mL in the original 
population.    
 
2.3 Immunoisolated Islet Transplantation 
 
2.3.1 Microencapsulation Materials 
Materials for microencapsulation were made with sterile and endotoxin-free materials and 
where possible sterile conditions. All solutions were made with deionised, distilled, 0.1 µm 
sterile filtered, endotoxin-free water (<0.005 Endotoxin Units.mL-1) (Hyclone, Logan, UT, USA) 
and all compounds excluding the alginate were “BioUltra” grade from Sigma. Ultrapure (UP) 
saline (154 mM NaCl, 1 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)) and 
gelification solution (0.15 M mannitol, 1 mM HEPES, 1 mM BaCl2, 50 mM CaCl2) were made by 
adding the compounds to 1 L of water and then adding endotoxin-free sodium hydroxide 
(NaOH) (Sigma) to attain pH 7.35-7.45 by sampling. 2% alginate was made by adding 1 g 
ultrapure low viscosity high-G (≥60%) sodium alginate (PRONOVA™ UP LVG, FMC corp., 
Drammen, Norway) to 25 mL water (4% alginate) and mixing at 4°C for >16 h in a 50 mL falcon 
tube. Mannitol solution (600 mM mannitol, 2 mM HEPES) was made in 40 mL water and 
adjusted to pH 7.35-7.45 with endotoxin-free NaOH by sampling. Mannitol solution was then 
added to the alginate to make up to 50 mL (2% alginate, 300 mM mannitol, 1 mM HEPES) and 
the solutions were mixed at 4°C for >1 h and the pH was measured and adjusted to pH 7.35-
7.45 by sampling. Saline and gelification solution were sterile filtered in 1 L 0.22 µm 
polyethersulfone (PES) vacuum filters (Merck Millipore, Billerica, MA, USA) and the alginate 
was filtered in a 50 mL Steriflip™ 0.22 µm PES vacuum filter (Millipore). Alginate was aliquoted 
in volumes of ≈1 mL into endotoxin-free, sterile 2 mL microcentrifuge tubes. All solutions were 
stored at 4°C. 
 
The day before microencapsulation the nozzle was checked for blockage and then the 
glassware, arm, rod, and nozzle parts of the bead generator were soaked for >16 h in 10 g.L-1 E-
toxa clean (Sigma) in a 2 L beaker to remove residual endotoxin. The equipment and beaker 
were then rinsed thoroughly in tap water, then deionised water, and finally autoclaved and dry 
cycled in an autoclave.       
   
2.3.2 Microencapsulation 
Microcapsules were made in an electrostatic bead generator which was custom built at the 
Norwegian University of Science and Technology, Norway (Figure 2). Islets and/or cells were 
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transferred to a sterile and endotoxin-free microcentrifuge tube, vortexed, centrifuged (300 g, 
5 min), and put on ice. The islets and/or cells were washed 2x in 1 mL 4°C UP saline and then 
the saline was removed to leave the islets in 100 µl. To prevent islets attaching to the inside of 
the pipette tip a 200 µl pipette tip was exposed to RPMI supplemented with FBS and then 
washed 2x in UP saline. The islets were then taken up in the 100 µl with the pipette tip and 
transferred into a 2 mL syringe containing 900 µl 2% alginate. The islets were mixed with the 
alginate to create a homogenous solution of 1.8% alginate with dispersed islets throughout. 
Some leading 1.8% alginate without islets or cells was injected into the delivery tubing to 
prevent the islets from gathering at the alginate meniscus. The alginate-islet and/or cell 
suspension syringe was then attached to the polythene delivery tubing (0.58 inner diameter, 
Portex, Smiths Medical, Kent) to create a continuous solution with the leading alginate. The 
suspension was delivered to the electrostatic bead generator at 10 mL.h-1 by a syringe pump 
(WPI, Florida, USA) through the delivery tubing to a 0.2 mm nozzle (Mars Matic 750 M07 
Drafting Point, Staedtler, Bridgend, UK). Droplets were electrostatically pulled with a 
differential charge of 7 kV into the gelification solution causing gelification by cross-linking of 
the alginate with Ba2+ and Ca2+ ions to create microcapsules. Microcapsules were 
approximately 500 µm in diameter and were inhomogeneous with higher density towards the 
outside of the capsule. The capsules were cultured overnight in serum-free RPMI-1640 (100 
units.mL-1 penicillin, 100 ng.mL-1 streptomycin).  
 




Figure 2. Schematic of electrostatic bead generator producing alginate microcapsules. 
 
2.3.3 Microencapsulated Islet Transplantation 
Mice were anaesthetised, administered analgesic, and the surgical area was shaved and 
sanitised. For intraperitoneal transplantation a small incision was made in the skin and then 
the linea alba of the peritoneum. For subcutaneous transplantation a small incision was made 
in the skin above the proximal femur and a subcutaneous pocket was fashioned down to the 
knee joint. The graft was delivered in <500 µl serum-free RPMI with a sterile, endotoxin-free 
1000 µl pipette. Incisions were sutured and the animal was placed in a recovery incubator. 
 
2.3.4 Microencapsulated Islet Recovery 
Mice were killed by cervical dislocation and the skin was dissected laterally all the way around 
the abdomen. The skin was pulled back to reveal the entire thorax and abdomen and 5 mL 
saline was injected to distend the peritoneal cavity. The mouse was placed in a 9 cm Petri dish 
and the peritoneum was cut longitudinally from the sternum allowing the saline to carry the 
capsules into the Petri dish. The peritoneal cavity was flushed with saline and then inspected 
under a microscope where the remaining capsules were picked with forceps. Capsules 
recovered from the subcutaneous site were picked with forceps. Capsules were washed in 
saline and cultured in 2 mM glucose supplemented Dulbecco’s modified Eagle’s medium 
(DMEM) (Gibco, Gaithersburg, MD, USA) for >1 h in a tissue culture incubator before further 
assessment. 













n. Syringe pump controller
o. Syringe pump display
p. Bead generator controller
q. Bead generator display
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2.3.5 Nano-Scale Islet Encapsulation 
The layer-by-layer coating exploits the charge of the cell membranes of the islet perimeter and 
the charge of the polysaccharide materials. The negatively charged cell membrane serves as a 
bed for electrostatic interaction with positively charged chitosan-phosphorylcholine (PC). The 
negatively charged alginate then interacts with the deposited chitosan-PC to form a chitosan-
PC-alginate bilayer. The required number of chitosan-PC-alginate bilayers could be built up 
sequentially. The outmost bilayer was composed of chitosan-PC-chondroitin-4-sulfate-PC. PC 
groups were linked to chitosan (low molecular weight, 75% deacetylation (Sigma)) and 
chondroitin-4-sulfate (Sigma) by reductive amination of PC glyceraldehyde as described by 
Miyazawa and Winnik (Miyazawa and Winnik, 2002). Solutions of 1 mg.mL-1 chitosan-PC, 
sodium alginate (low viscosity alginic acid sodium salt from brown algae (Sigma)), and 
chondroitin-4-sulfate-PC were prepared in Hank’s buffered salt solution (HBSS) supplemented 
with 2 mM CaCl2 and 0.2 µm sterile filtered.  The nano-scale encapsulation was carried out 
with the islets in a 1.5 mL microcentrifuge tube on ice. Islets were suspended in the 
polysaccharide solutions for 5 min at a time and washed with supplemented HBSS by 
sedimentation 2x after each exposure to remove unabsorbed polysaccharide.  
 
2.3.6 Non-Encapsulated and Nano-Scale Encapsulated Islet Transplantation 
Islets or nano-scale encapsulated islets were kept on ice before centrifuging into a pellet 
within PE50 polyethylene tubing (Becton Dickinson, Sparks, MD) coated with a siliconising 
reagent (Sigmacote, Sigma) to prevent islet attachment. To centrifuge the islets the tubing was 
bent in half and the islets were delivered into one end of the tubing. The tubing was placed in 
a centrifuge tube with the bend at the bottom. The tube was then centrifuged (200g, 2 min) so 
that the islets gathered in a pellet at the bend. The tubing was then attached to a Hamilton 
syringe (Fisher, Pittsburg, PA) at one end without allowing any air bubbles to form and the 
tubing was cut at the pellet at the other end, ready for transplantation. Sequential lumbar 
incisions were made through the skin then the peritoneum of the anaesthetised recipient, 
then the left kidney was externalised and kept moist with PBS. An incision in the kidney 
capsule was made by dragging a needle across the surface, the end of the tubing was inserted 
under the capsule and the islets were delivered. The incision in the capsule was heat-sealed 
with a cauteriser (Bovie, Clearwater, FL, USA), the kidney internalised, the peritoneum and skin 
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2.3.7 Glucose Tolerance Test  
Mice were fasted for 16 h and the basal blood glucose was measured. 2 g.kg-1 sterile glucose 
solution (1.67 M glucose in PBS) was administered intraperitoneally and blood glucose 
measurements were taken after 15, 30, 60, 90, and 120 min post-administration. 
 
2.3.8 Nephrectomy 
Nephrectomy of the graft bearing kidney of cured mice was carried out to confirm the 
underlying diabetic state and the function of the graft. Sequential lumbar incisions were made 
through the skin and the peritoneum of the anaesthetised recipient, then the left kidney was 
externalised and kept moist with PBS. Connective tissue around the kidney was dissected away 
to expose the renal artery, renal vein, and the ureter. The ureters and the vessels were 
clamped and tied off below the clamp using a tied suture. Using a sterile disposable scalpel 
(Swann morton limited, Sheffield, UK) the vessels were cut above the clamp to remove the 
kidney. The tie was internalised and the peritoneum and skin sutured.  
 
2.4 Immunohistochemistry and Cell Staining 
 
2.4.1 Fixation of Tissues  
Fixation of tissues preserves the tissue structure and protein composition by cross-linking with 
paraformaldehyde. Tissues were fixed in fixation solution (4% paraformaldehyde in PBS) for 2 
h, washed in PBS and then exposed sequentially for 1 h at a time to 30%, 50%, and 70% 
ethanol. Samples could be stored at this stage or immediately paraffin-embedded.   
 
2.4.2 Paraffin-Embedding of Microencapsulated Islets 
Paraffin-embedding integrates fixed tissue into paraffin blocks ready for sectioning. Fixed 
microencapsulated islets in 70% ethanol in 1.5 mL tubes were first exposed to 80% ethanol 
with 0.75% eosin to stain the sample. The sample was further dehydrated in 95% then 100% 
ethanol for 5 min each, and then exposed to xylene for 3 min. After removing the xylene 60°C 
molten paraffin wax (Paraplast, Sigma) was poured over the sample to fill the tube. Tubes 
were incubated at 60°C for 4-16 h to allow full penetration of the wax into the sample. Tubes 
were incubated at 4°C for 4-16 h to solidify the wax, then using a corkscrew the entire paraffin 
mould was removed from the tube with the capsules at the tip. The tip was cut off and was re-
melted in a block mould on a 60°C hot plate. Molten wax was poured over the mould and a 
cassette was placed on top. More molten wax was added on top of the cassette lid and the 
block was incubated at 4°C for 4-16 h before removing the mould.      




2.4.3 Paraffin-Embedding of Graft-Bearing Kidneys 
The area of tissue of the kidney containing the graft was dissected under a microscope and 
then processed using a Leica TP1020 tissue processor. The tissue was placed in a cassette and 
then exposed to 90% industrial methylated spirit (IMS), 3x 100% IMS, 6.6% IMS in xylene, 2x 
xylene, and molten paraffin wax on an automated program for 120 min for each treatment. 
The tissue was then embedded in a paraffin wax block using a mound and cassette.   
 
2.4.4 Sectioning of Embedded Tissues 
Blocks were stored at 4°C for >4 h prior to sectioning. Blocks were mounted onto a microtome 
(Leica Microsystems, Milton Keynes) by the cassette and cut with a 34° microtome blade (MB 
DynaSharp, Thermo Scientific) held at 5° by progressing the block forward by 5 µm to produce 
each section. Sections were transferred to a 40°C water bath and then mounted onto slides 
(Superfrost Plus, Thermo Scientific).   
 
2.4.5 Haematoxylin and Eosin Staining 
Haematoxylin and eosin stain for the nucleus and cytoplasm respectively to aid the 
visualisation of cell morphology. Slides were put on a 60°C heat plate for 5 min to melt the 
wax, de-waxed by exposure to xylene for 2x 5 min, rehydrated by sequential exposure to 
100%, 95%, and 70% ethanol for 5 min each and then rinsed in tap water. To stain for 
haematoxylin, slides were exposed to haematoxylin (Sigma) for 5 min, rinsed in tap water for 5 
min, de-differentiated by dunking the slides 4x in 1% acid alcohol and rinsed again in tap water 
for 5 min. Slides were then exposed to eosin for 5 min and then rinsed in tap water for 5 min. 
Slides were then dehydrated in 70%, 95%, and 100% ethanol, then xylene 2x for 5 min each. A 
cover glass was mounted onto each slide using DPX mountant (Sigma).   
 
2.4.6 Immunostaining 
Slides were de-waxed and rehydrated as described above. Slides were exposed to 3% 
hydrogen peroxide (Sigma) for 10 min to block endogenous peroxidise activity, and then rinsed 
in tap water for 5 min. Slides were transferred to a humidified chamber and individual sections 
were circled with a hydrophobic barrier pen (Invitrogen). The following immunostaining steps 
were separated by rinsing steps with Tris-buffered saline (TBS) (50 mM Tris (Sigma), 150 mM 
NaCl). As kidney sections were used in some experiments which contains high levels of 
endogenous biotin a blocking stage was carried out with a biotin blocking system (Dako 
Cytomation, Ely) as standard. Sections were exposed to avidin for 10 min to bind endogenous 
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biotin and then with biotin for 10 min to saturate the avidin. Blocking buffer (10mg.mL-1 bovine 
serum albumin (BSA), 15 mM NaN3, in TBS) was added for 10 min to prevent non-specific 
antibody binding, and then poured off the slide before adding the primary antibody for 1 h at 
room temperature or for 16 h at 4°C. Biotin conjugated secondary antibody was added for 40 
min then the slides were washed in TBS for 10 min. To detect antibody binding, sections were 
exposed to streptavidin horseradish peroxidise (Streptavidin-HRP) (Dako) to bind biotin on the 
secondary antibody. Sections were exposed to 3,3'-diaminobenzidine (DAB) and hydrogen 
peroxide (Dako) causing oxidation of DAB by HRP resulting in brown staining. Sections were 
monitored for staining development and the reaction was stopped by rinsing with tap water. 
Sections were then counterstained with haematoxylin, dehydrated, and mounted with cover 
glass.      
 
2.4.7 Fluorescent Microscopy 
Capsules were washed in PBS then incubated for 5 min at room temperature in 10 pg.mL-1 
fluorescein diacetate (FDA) (Sigma) in PBS. The capsules were washed twice in PBS then 
viewed under a fluorescence microscope. Recorded images were focused at the largest cross-
section of the microcapsule with 478−495 nm excitation and 510−555 nm emission filters to 
visualise live FDA stained cells.  
 
2.4.8 Confocal Microscopy 
Microcapsules were stained with live/dead (FDA/propidium iodide (PI)) staining and visualised 
using a Zeiss LSM 510 confocal microscope with a C-Apochromat 10x/45W objective and 
software by LSM 510, release 2.02 (Carl Zeiss, Oberkochen, Germany). Recorded images were 
focused at the largest cross-section of the microcapsule through 478−495 nm and 530−560 nm 
excitation filters and 510−555 nm and 573−648 nm emission filters to visualise FDA and PI 
staining respectively.   
 
2.5 Cell Content and Secretion 
 
2.5.1 Adenosine Triphosphate Assay 
The CellTiter-Glo® luminescent cell viability assay (Promega, Southampton, UK) was used to 
measure the ATP content of microencapsulated islets. The assay is based on the principle that 
in the presence of ATP, recombinant luciferase catalyses the conversion of luciferin to 
oxyluciferin which generates luminescence. Detecting the intensity of the luminescence gives a 
relative measure of the ATP concentration. Combined with simultaneous measurements from 
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a range of samples with known ATP concentration to make a standard curve, the ATP 
concentration of unknown samples can be deduced.  
  
CellTiter-Glo® substrate was diluted in CellTiter-Glo® buffer and added in 50 µl volumes to the 
wells of a black walled, transparent bottomed 96-well plate. ATP standards of 0, 1, 10, and 100 
pM ATP (Sigma) were added to the reagent in duplicate. Unknown samples were added and 
after shaking for 2 minutes the luminescence was repeatedly recorded every 2 min for 1 h 
using a luminometer (Vertitas, Promega Biosystems, Southampton, UK).  The maximum 
luminescence for each well was included for analysis and values were converted from relative 
light units (RLU) to ATP values using the standard curve.   
 
2.5.1 Deoxyribonucleic Acid Content Assay 
The Quant-iT™ PicoGreen® dsDNA reagent (Invitrogen) was used to estimate the number of 
cells in microcapsules by measuring the DNA content of the microcapsules. The reagent is an 
ultrasensitive stain which fluoresces at specific excitation and emission wavelengths when 
bond to double stranded DNA. The DNA content of unknown samples is determined by the 
intensity of the fluorescence relative to a range of samples with known DNA content. 
 
Samples were prepared by picking 50 capsules then washing and resuspending in 200 µl of ice 
cold tris-EDTA buffer (10 mM tris-HCl, 1mM EDTA, pH 7.5). The capsules were ruptured with a 
29G insulin syringe, homogenised by sonication, and incubated at 4°C for >16h. Unknown 
samples and standards of 0, 0.1, 1, 10, 100 ng DNA were added in duplicate in 100 µl volumes 
into the wells of a black walled transparent bottomed 96-well plate. 100 µl of reagent was 
added to each well and after 2 min the fluorescence in each well was measured with 480 nm 
excitation and 520 nm emission filters using a microplate reader (Hidex Chameleon, Turku, 
Finland). Samples containing microcapsules without cells were used as a baseline and the 
number of cells calculated from the DNA content assuming each cell contains 3.5 pg DNA.  
 
2.5.2 Glucose-Stimulated Insulin Secretion 
Islets were pre-incubated in 2 mM supplemented DMEM for >1 h. Groups of 10 islets were 
picked into 1.5 mL tubes and the residual medium was removed using an insulin syringe. 
Samples were incubated in a water bath at 37°C in 600 µl sub-stimulatory glucose solution (2 
mM glucose in Gey & Gey buffer (5 mM KCl, 111 mM NaCl, 27 mM NaHCO3 220 µM KH2PO4, 50 
mM CaCl2, 1 mM MgCl26H2O, 0.5 mg.mL
-1 BSA (Sigma) bubbled with 95% O2, 5% CO2 for 5 
min)). After 1 h tubes were agitated, pulse centrifuged, and 300 µl sub-stimulatory samples 
were collected and 300 µl 38 mM glucose Gey & Grey buffer was added resulting in a 
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stimulatory glucose concentration of 20 mM. After 1 h tubes were agitated, pulse centrifuged, 
and 500 µl stimulatory glucose samples were collected and both sample set were stored at -
20°C. 
 
2.5.3 Insulin Content 
Insulin content samples were collected following GSIS and processed on ice. 100 µl acid alcohol 
(1% HCL, 70% ethanol) was added to the islets in 100 µl Gey & Gey buffer. The islets in solution 
were pushed through a 29G insulin syringe to rupture the capsules and homogenise the 
samples. The samples were sonicated for 10 sec and incubated at 4°C for 16 h before being 
stored at -20°C.  
 
2.5.4 Insulin Perifusion 
The dynamic rate of insulin secretion from islets was assessed by an in-house multi-channel 
perifusion system. Perifusions were carried out in a 37°C heated room with 37°C buffers to 
maintain physiological temperature.  Each channel consists of a chamber in which the islets are 
placed on 1 µm nylon filters in filter holders (Swinnex, Millipore, Cork, Ireland). Test 
substances in supplemented (0.5 mg.mL-1 BSA) Gey & Gey buffer were perifused over the islets 
through the camber by peristaltic pumps. Perifused samples were collected every 2 min and 
stored at -20°C. 
 
2.5.5 Insulin Radioimmunoassay 
The insulin concentration of GSIS, insulin content and perifusion samples was determined by 
an in-house radioimmunoassay. The assay is based on the competitive binding of radiolabeled 
insulin and sample insulin to an insulin antibody. A greater concentration of sample insulin 
results in less radiolabeled insulin binding to the antibody and visa versa. Detecting the 
amount of radioactivity bound to the precipitated antibody gives a relative measure of the 
insulin concentration of the sample insulin. Combined with simultaneous measurements from 
a range of samples of known concentration to make a standard curve, the insulin 
concentration of unknown samples can be deduced.  
 
Standard samples (0.04, 0.08, 0.16, 0.32, 0.64, 1.25, 2.5, 5.0, 10.0 ng.mL-1) were prepared by 
serial dilution of 10 ng.mL-1 insulin (Sigma) in borate buffer (133 mM boric acid, 68 mM NaOH, 
10 mM EDTA (Sigma), 0.5 mg.mL-1 BSA). Unknown samples were diluted in borate buffer to an 
estimated insulin concentration of 0.5 ng.mL-1, and then standards in triplicate and unknown 
samples in duplicate were added to LP3 tubes. I125-labelled insulin was diluted to give a count 
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per minute of 10,000 per 100 µl. Insulin primary antibody was derived from Hartley guinea pigs 
challenged with bovine insulin and was used at a concentration of 1:60,000. I125-labelled insulin 
and insulin antibody were added to all standards, samples and relevant controls (Table 1). 
Following 48 h of incubation at 4°C γ-globulin solution (γ-globulin (Sigma), 30% PEG, Tween 20 
(Sigma)) was used to precipitate the antibody and the tubes were centrifuged at 15,000 g for 
15 minutes at 4°C. Following aspiration of the supernatant to remove unbound insulin, 
samples were read in a γ counter (WIZARD2, Perkin Elmer, Waltham, USA).  
 
 Buffer (µl) Antibody (µl) Tracer (µl) Standard (µl) Sample (µl) 
Total 
Radioactivity 
  100   
Non-specific 
binding 
200  100   
Maximum 
binding 
100 100 100   
Standards  100 100 100  
Samples  100 100  100 
Table 1. Preparation of the controls, unknown samples and standards for the insulin 
radioimmunoassay. 
 
2.5.6 Glucagon-Like Peptide-1 Enzyme-Linked Immunosorbent Assay  
The GLP-1 peptide enzyme-linked immunosorbent assay (ELISA) (Millipore) is based on the 
capture of active GLP-1 from the sample by a monoclonal antibody immobilised in the wells of 
a microplate, and the subsequent binding of an anti-GLP-1 alkaline phosphatase conjugate. 
Exposing the conjugate to methyl umbelliferyl phosphatase generates the fluorescent product 
umbelliferone. By simultaneously assaying known concentrations of GLP-1 to create a standard 
curve, the concentration of GLP-1 from unknown samples can be interpolated. On the day of 
the assay, samples and standards were defrosted on ice. The assay was carried out according 
to the manufacturer’s protocol. Briefly, wells were washed, then non-specific binding or assay 
buffer were added to the wells. Standards, quality control samples and unknown samples in 
duplicates were added to wells with assay buffer, and the plate was sealed and incubated (4°C, 
24 h). Following incubation and washing, anti-GLP-1 alkaline phosphatase conjugate was 
added and incubated (20°C, 2 h). After washing, methyl umbelliferyl phosphatase substrate 
was added and incubated in the dark (20°C, 20 min). Stop solution was added to arrest 
phosphatase activity and the plate was read in a fluorescence plate reader (Hidex Chameleon) 
with an excitation/emission wavelength of 355 nm/460 nm.  




2.6 Statistical Analysis  
 
The statistical analyses were carried out using SigmaPlot 12.0 software (Systat Software Inc., 
Hounslow, UK). For parametric data comparing two groups the t-test was used and for >2 
groups analysis of variance (ANOVA) using the Holm-Sidak post hoc test was used. For non-
parametric data comparing two groups the Mann-Whitney Rank Sum Test was used and for >2 
groups the Kruskal-Wallis ANOVA on Ranks (Dunn’s method) was used. For survival curves the 
Kaplan-Meier Survival Analysis (Log-Rank) was used. n indicates the number of data points the 
statistical analysis was performed on. Unless stated, n is the number of experiments or the 
number of mice as appropriate. Where statistics were performed on pooled observations the 
number of experiments or mice are also stated in brackets (e.g. n=18(3) indicates 18 pooled 
data points from 3 experiments/mice were used for statistical analysis). All data are expressed 
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3 Immunoisolation of Islets in High Guluronic Acid 
Barium-Alginate Microcapsules does not Improve 




The conventional implantation site for microencapsulated islets is the intraperitoneal site. The 
site has a large capacity and implantation requires a simple procedure. However 
microencapsulated islet grafts require over double the number of islets compared with non-
encapsulated islet grafts at sites such as under the kidney capsule. Additionally, retrieval of 
microencapsulated grafts would involve a highly invasive procedure. Taken together the 
intraperitoneal site is suboptimal for microencapsulated islet transplantation and alternative 
sites may offer superior graft outcomes. Due to its large capacity, the subcutaneous site is 
suitable for microcapsules and also benefits from minimally invasive implantation and easy 
graft retrieval, which would be advantageous for clinical use. The stability of some 
microcapsules has been reported to be greater in the subcutaneous site than the 
intraperitoneal site (Dufrane et al., 2006, Thanos et al., 2007) and transplantation of 
microcapsules into the subcutaneous site of diabetic animals was reported to be more 
efficacious than transplantation to the intraperitoneal site (Veriter et al., 2009). Microcapsules 
of low viscosity and high guluronic acid (G) alginate cross-linked with BaCl2 without a 
polycation coating have demonstrated high stability (Martinsen et al., 1989), low 
immunogenicity (Kulseng et al., 1999), and graft success when transplanted to the 
intraperitoneal site in mouse allograft models (Bohman and King, 2008). However, large 
numbers are required to reverse hyperglycaemia when transplanted to the intraperitoneal 
site. In this study we investigated whether the subcutaneous site could provide a viable 
alternative using microcapsules which have previously proven successful at the intraperitoneal 
site. 
 
3.2 Materials and Methods 
 
3.2.1 Animals 
Male inbred mice of the C57 black 6J strain (C57BL/6J) aged 6-8 weeks were used as islet 
donors and male C57BL/6J mice weighing 25g (8-10 weeks) were used as recipients. Diabetes 
was induced by tail vein injection of alloxan and blood glucose measurements were made over 
28 days following transplantation. 




3.2.2 Islet Transplantation 
Isolated islets from several mice were pooled and half were used for non-encapsulated 
transplantation and half for microencapsulated transplantation. Diabetic animals received 700 
non-encapsulated or microencapsulated syngeneic islets either subcutaneously or 
intraperitoneally. In addition, one individual diabetic mouse received 1750 microencapsulated 
syngeneic islets subcutaneously. To investigate islet viability, function, and morphology at each 
site without the confounding factor of hyperglycaemia, microencapsulated transplantations 
were also carried out in normoglycaemic mice. Simultaneous transplantations of 200 
microencapsulated syngeneic islets to the intraperitoneal site and 100 to the subcutaneous 
site were carried out. 100 microencapsulated islets were also cultured in vitro as controls. 
After 7 or 28 days the microcapsules were recovered and analysed.  
 
3.2.3 Insulin Measurements 
Insulin secretion and insulin content samples were from groups of 10 encapsulated islets 
explanted from each mouse or picked from each culture dish.  
 
3.2.4 Adenosine Triphosphate Assay 
Samples for the ATP content assay were from groups of 10 microencapsulated islets explanted 
from each mouse or picked from each culture dish. Samples were prepared by homogenising 
groups of 10 microencapsulated islets in 50 µl volumes of media using a fine gauge insulin 
syringe. The homogenate was added directly to the assay buffer and then measured using a 
luminometer according to the standard protocol. 
 
3.2.5 Histological Scoring 
Microencapsulated islets were fixed, embedded, sectioned, and haematoxylin and eosin 
stained. Islet sections were evaluated by blinded scoring of 168±28 islets per graft. Islets were 
scored on a scale of 1-4 as follows; 1: 0-25% loss of islet shape and structure with no 
fragmented cells; 2: 25-50% loss of islet shape and structure with some fragmented cells; 3: 
50-75% loss of islet shape and structure with many fragmented cells; 4: 75-100% loss of shape 
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3.3 Results  
 
3.3.1 Efficacy of Microencapsulated Islets at the Subcutaneous and Intraperitoneal 
Sites 
There was no improvement in the hyperglycaemic state of alloxan-diabetic mice implanted 
subcutaneously with 700 non-encapsulated islets or microencapsulated islets (Figure 3). 
Microencapsulated islets implanted intraperitoneally reduced the blood glucose for up to 28 
days with mean values consistently less than 11 mM (Day 0 vs. day 1, 3, 7, 14, 21 and 28 
(P<0.001 Repeated measures ANOVA, n=4-7). In the non-encapsulated intraperitoneal group, 
25% of the transplantations resulted in blood glucose concentrations of less than 11 mM, but 
the mean values for the group were consistently above 17 mM with 75% of the mice remaining 
overtly hyperglycaemic. The mouse transplanted with 1750 microencapsulated islets 
subcutaneously failed to maintain normoglycaemia. 
 
Figure 3. Blood glucose 
measurements of diabetic mice 
with intraperitoneal and 
subcutaneous grafts.   
Subcutaneous non-encapsulated 
(black squares, solid line, n=7), 
subcutaneous microencapsulated 
(white squares, dotted line, n=5), 
intraperitoneal non-encapsulated 
(black circles, solid line, n=4), and 
intraperitoneal 
microencapsulated (white circles, 




3.3.2 Function and Viability of Recovered Microencapsulated Islets 
To establish how rapidly islet function failed and to remove potential secondary effects of 
hyperglycaemia on islet function, microencapsulated islets were transplanted into 
normoglycaemic mice and recovered to determine the functionality and viability of the islets. 
Grafts were recovered at 7 days at which point the grafts from the diabetic mice had stabilised 
the recipients’ blood glucose.    
 
3.3.2.1 Insulin Secretion  
There were no differences between basal insulin secretion between the islet treatment groups 
(P=0.228, ANOVA on Ranks, n=5) (Figure 4). However, stimulated insulin secretion was lower in 
islets recovered from the subcutaneous site than either cultured islets or islets recovered from 
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the intraperitoneal cavity. There was no difference between the stimulated insulin secretion 
from cultured islets and those recovered from the intraperitoneal site.   
 
Figure 4. Insulin secretion of 
microencapsulated islets recovered 
from the intraperitoneal and 
subcutaneous sites.  
Islets were exposed to 2 mM (black) 
and 20 mM (white) glucose 7 days 
following culture or transplantation. 
*P<0.05 vs. in vitro, #P<0.05 vs. 









Figure 5. Insulin and adenosine triphosphate content of microencapsulated islets recovered 
from the intraperitoneal and subcutaneous sites.  
A. Insulin content of microencapsulated islets cultured or transplanted for 7 days. *P<0.05 vs. 
in vitro, #P<0.05 vs. intraperitoneal (One way analysis of variance, n=8-11). B. Adenosine 
triphosphate content of microencapsulated islets recovered after 7 days of culture or 
transplantation. *P<0.05 vs. in vitro, #P<0.05 vs. intraperitoneal (One way analysis of variance, 
 n=4-6). 
 
3.3.2.2 Insulin and Adenosine Triphosphate Content 
Islets recovered from the subcutaneous site had lower insulin content than both cultured islets 
and intraperitoneal graft islets (Figure 5).The intraperitoneal graft islets had lower ATP content 
than cultured islets, and subcutaneous graft islets had lower ATP content than both cultured 





























































































































3.3.3 Morphological Scoring of Microencapsulated Islets  
The morphology of microencapsulated islets recovered from normoglycaemic animals after 28 
days was histological evaluated by blinded scoring of islet sections (Figure 6). There was no 
difference between the frequencies of each score for the intraperitoneal islets. In contrast 
islets from the subcutaneous site had significantly fewer scores of 1 (near normal morphology) 
compared to scores of 3 and 4 (poor morphology), suggesting a greater frequency of cell death 
in islets implanted in the subcutaneous site.  
 
 
Figure 6. Histological scoring of microencapsulated islet sections recovered from 
intraperitoneal and subcutaneous grafts. 
A. Histological scoring of sections from intraperitoneal (black) and subcutaneous (white) 
microencapsulated islets recovered after 28 days. Islets were scored for cell death; 0-25% (1), 
25-50% (2), 50-75% (3), 75-100% (4). *P<0.05 vs. (1) (n=4). B. Examples of haematoxylin and 




The subcutaneous site offers a number of potential advantages for clinical transplantation of 
encapsulated islets, including ease of implantation, sufficient capacity for the encapsulated 
graft material, and the opportunity to retrieve or replace the graft with ease.  In the present 
study we used a mouse model of diabetes to compare transplantation outcomes and graft 
survival between the intraperitoneal and subcutaneous implantation sites.   
 
Intraperitoneal transplantation of 700 microencapsulated islets restored normoglycaemia for 
up to 28 days, confirming our previous studies using the same capsule composition in which 
hyperglycaemia was reversed in syngeneic (Bohman et al., 2006), allogeneic, and 
spontaneously diabetic NOD mice (Bohman and King, 2008). In contrast, non-encapsulated 
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intraperitoneal grafts did not restore normoglycaemia, demonstrating that microencapsulation 
is advantageous at the site. Similar findings have been reported previously (Bohman and King, 
2008, Korbutt et al., 2004) and it has been suggested that microencapsulation protects the 
graft from exposure to the mechanical stress subjected to free-floating islets in the peritoneal 
cavity. The presence of a high degree of mechanical stress in the intraperitoneal site is 
consistent with reports of a higher proportion of broken capsules compared to capsules 
implanted at the subcutaneous site (Dufrane et al., 2006, Thanos et al., 2007). In the present 
study we did not observe any broken capsules, indicating our capsules are stable upon 
implantation into the site. The microcapsule may also improve islet survival and function by 
providing a stable matrix for the islet which is more similar to that of the native islet 
environment than in the intraperitoneal environment. In accordance, the application of a 
matrix surrounding islets has previously been shown to benefit islet viability and function 
(Schrezenmeir et al., 1993, De Carlo et al., 2010).  
 
There are a number of possible causes for the failure of non-encapsulated subcutaneous islet 
grafts including immune destruction, mechanical stress, and a poor supply of oxygen and 
nutrients at the site. Subcutaneous transplantation of both encapsulated and non-
encapsulated islets failed to reduce the blood glucose of diabetic mice, indicating graft failure 
from the outset. The transplantations in the current study were syngeneic and additionally 
capsules recovered from mice at both sites were free from overgrowth when observed by eye, 
indicating a lack of immunological interference. Studies using non-encapsulated grafts at the 
unmodified subcutaneous site have reported graft failure in syngeneic (Fumimoto et al., 2009, 
Juang et al., 1996, Kawakami et al., 2000) or immune-deficient (Tatarkiewicz et al., 1999) 
animal models, indicating that the host immune response is not the limiting factor in graft 
success. Several studies have suggested that poor vasculature is the limiting factor and have 
demonstrated improved graft survival by co-transplanting angiogenic devices or materials 
(Dufrane et al., 2010, Lacy et al., 1991, Golocheikine et al., 2010), or using pre-vascularised 
devices (Tatarkiewicz et al., 1999, Juang et al., 1996, Pileggi et al., 2006).  
 
The failure of microencapsulation to improve islet graft outcomes at the subcutaneous site 
suggests that protection from mechanical stress and provision of a stable matrix which is likely 
to contribute to graft success at the intraperitoneal site, is not of primary importance in the 
maintenance of graft function at the subcutaneous site. This is consistent with the different 
physical environments at the respective implantation sites, with intraperitoneal graft islets 
more likely to be free floating in the intraperitoneal fluid whereas subcutaneous islets are 
likely to be held stationary by direct contact between the skin and muscle. In accordance with 
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this, graft success has been improved at the subcutaneous site by encapsulating islets in 
macrocapsules or other devices but the improvement has generally been attributed to the 
biomaterial stimulating angiogenesis (Lacy et al., 1991, Tatarkiewicz et al., 1999, Juang et al., 
1996) rather than by providing mechanical protection or a stable matrix. Indeed it has been 
demonstrated that transplantation of non-encapsulated islets to a pre-vascularised 
subcutaneous site without the use of any biomaterial device is sufficient to reverse the 
diabetic state (Kawakami et al., 2000, Kawakami et al., 2001). This indicates that 
neovascularisation is the predominant factor in the success of islet transplantation at the 
subcutaneous site, and confirms our observations that provision of mechanical protection or a 
stable matrix may not be as important at the subcutaneous at they are at the intraperitoneal 
site.  
 
It cannot be ruled out that using a larger number of islets may have yielded better transplant 
outcomes at the subcutaneous site. However using a relatively large dose suitable for the 
intraperitoneal site we were unable to detect any impact of microencapsulation on graft 
efficacy. Additionally we have anecdotal evidence that implantation of 1750 
microencapsulated islets also failed to induce normoglycaemia. Even if a greater number of 
islets were to be effective it would be difficult to justify using more islets than required for 
microencapsulated islet grafts implanted in the intraperitoneal cavity. One of the reasons for 
exploring the subcutaneous site is because the number of microencapsulated islets required at 
the intraperitoneal site is over double the number required for non-encapsulated grafts at 
sites such as under the kidney capsule. Given the donor shortage it is critical that alternate 
sites for islet transplantation have similar or better efficiency to current clinical protocols. 
However it should be possible to justify the use of a greater number of islets for 
immunoisolated grafts as immunosuppressant-free islet transplantation is highly desirable.  
 
Although intraperitoneal implantation of microencapsulated islets was successful in reversing 
hyperglycaemia, the site is suboptimal and detrimental to islet viability. Islet ATP content of 
microencapsulated islets transplanted intraperitoneally was reduced by 55% from controls 
maintained in culture within 7 days of implantation, and 48% of the islets contained 50-100% 
dead cells after 28 days. However, microencapsulated islets transplanted subcutaneously 
showed an even more pronounced loss of viability and function. At 7 days GSIS was reduced by 
68%, insulin content was reduced by 59%, and ATP content was reduced by 82% from controls 
maintained in culture. In addition 78% of the islets had 50-100% dead cells at 28 days. These 
observations suggest that relative graft success is likely to be related to the respective ability 
of the site to support the viability and function of the microencapsulated islets.  




The low viscosity, high-G barium-alginate microcapsules used in the current study were 
selected due to their resistance to mechanical stress, inert properties and also on the basis of 
their success at the intraperitoneal site. Using these microcapsules we were unable to utilise 
the subcutaneous site for successful islet transplantation.  A study by Veriter et al. (2010) 
reported that high-M calcium-alginate microencapsulated pig islets transplanted into diabetic 
rats were able to reverse the diabetic state when transplanted subcutaneously but not 
intraperitoneally. The authors did not offer suggestions of why the intraperitoneal grafts failed, 
however it was reported in a previous study that compared to the subcutaneous site a higher 
proportion of broken capsules was observed in similar high-M calcium-alginate 
microencapsulated islets transplanted in the peritoneal cavity (Dufrane et al., 2006). The 
strength of high-M calcium-alginate microcapsules may not be enough to tolerate the 
intraperitoneal site leading to capsule breakage. Microcapsules with the highest mechanical 
strength are made with alginate with >70% G content and cross-linked with Ba2+ (Martinsen et 
al., 1989).  
 
The relative success at the subcutaneous site between the current study and the study by 
Veriter et al. (2010) indicates that the success of microencapsulated islets transplanted to the 
subcutaneous site may be dependent upon the selection of the alginate and composition of 
the microcapsules. Indeed implanting high-M calcium-alginate discs was reported to be more 
biocompatible, less permeable, and induced a greater level of neovascularisation and oxygen 
tension than high-G calcium-alginate discs at the subcutaneous site (Veriter et al., 2010). The 
authors infer the most likely cause of graft success with high-M calcium-alginate microcapsules 
at the subcutaneous site is enhanced induction of neovascularisation. However, a direct 
comparison of the graft efficacy of high-G calcium-alginate microencapsulated islets and high-
M calcium-alginate microencapsulated islets transplanted subcutaneously was not reported.  
 
Another factor impacting graft outcome at the subcutaneous site may be the source of the 
islet tissue. The study by Veriter et al. (2009) used pig islets xenotransplanted into rats 
whereas the current study used syngeneic islets transplanted into mice. It is possible that 
xenogeneic tissue which elicits a stronger immune reaction in the host may also provoke a 
stronger angiogenic response. Interestingly there is some crossover of signalling pathways 
between the inflammatory response and angiogenesis (Mor et al., 2004). Pancreatic insulitis 
has been reported to increase blood flow in islets (Carlsson et al., 1998) and inflammatory 
tissue is prone to induce new vessel formation in conditions such as bacterial infection 
(Kilcullen et al., 1998), rheumatoid arthritis (Esposito et al., 2004), and cancer (Chen et al., 
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2005). However the relative capacity of syngeneic and xenogeneic islets to induce angiogenesis 
has not been reported. 
 
In summary, the subcutaneous site has a number of features that make it attractive as an 
implantation site for encapsulated islets to treat diabetic hyperglycaemia. Our study suggests 
that using low viscosity, high-G barium-alginate microcapsules in an unmodified subcutaneous 
site is unsuitable to maintain encapsulated islet function and viability. Consequently the 
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4 Co-Encapsulation of Islets with an L Cell Line Improves 




GLP-1 increases insulin secretion (Mojsov et al., 1987), insulin synthesis (Alarcon et al., 2006), β 
cell proliferation (Buteau et al., 2003) and neogenesis (Xu et al., 2006), and protects β cells 
against apoptosis (Li et al., 2003). Additionally GLP-1 may have anti-inflammatory and 
immunosuppressive functions (Cechin et al., 2011).  Consequently GLP-1 therapy can be used 
to improve islet transplantation outcomes. Systemic delivery of GLP-1R agonists causes side 
effects (Kolterman et al., 2003) and cannot be administered clinically at doses high enough to 
mediate β cell proliferation. Consistent stimulation of β cell proliferation in vivo would greatly 
enhance graft sustainability. Due to the higher doses required for full utilisation of GLP-1, 
delivery localised close to the islets may be preferable. High doses delivered locally to the islets 
may avoid GLP-1 inactivation in the circulation and also provide GLP-1-mediated benefits 
which require high concentrations such as stimulation of β cell proliferation. With localised 
delivery this may be achievable without accumulating systemic GLP-1 levels at sufficiently high 
concentrations to cause side effects. Islet localised delivery of GLP-1 can be achieved by 
ectopic expression, however due to safety concerns and limited expression longevity this 
approach is unlikely to be developed in the clinic. GLP-1 protein can also be co-encapsulated 
with islets however as GLP-1 will readily diffuse out of conventional biomaterials it must be 
altered in order to immobilise it for sustained release. Modification of proteins can result in 
unforeseen functional variation which may compromise the therapeutic efficacy or safety of 
GLP-1. Additionally, the longevity of GLP-1 action with protein delivery is ultimately limited by 
the amount of protein incorporated to begin with.  It has been shown that GLP-1R agonist 
treatment is beneficial to islet function in culture (King et al., 2005) and when initiated 
immediately post-transplantation. It has also been shown that discontinuation of treatment 
can reverse the beneficial effect on grafts (Merani et al., 2008). Consequently a continuous 
supply of GLP-1R agonist throughout culture and the post-transplantation period may offer the 
most benefit.  
 
As an alternative to systemic delivery, localised ectopic expression or localised protein delivery 
of GLP-1, a cell-based delivery system could utilise GLP-1 secreting L cells co-encapsulated with 
islets. Cellular delivery of GLP-1 would provide unmodified GLP-1 continuously within the 
device for the lifetime of the L cells. Additionally L cells in transplanted devices would be 
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responsive to physiological cues such as blood glucose levels, therefore providing GLP-1 under 
physiologically appropriate circumstances, and hence reducing the risk of overstimulation. 
Protein incorporation into encapsulation materials can alter the properties of the material and 
may result in altered encapsulation device performance in vivo. Conventional islet 
encapsulation approaches such as alginate microencapsulation are designed for cell 
encapsulation. Therefore incorporation of L cells is unlikely to compromise the function of such 
immunoisolation devices. Co-encapsulation of L cells with islets is an attractive concept. The 
potential benefits of co-encapsulation of islets and L cells in alginate microcapsules for islet 
transplantation have been investigated using an L cell line as an experimental model.             
 
4.2 Materials and Methods 
 
4.2.1 Animals 
Male ICR mice aged 6-8 weeks were used to isolate islets for in vitro experiments. Male 
C57BL/6J mice aged 6-8 weeks were used as islet donors and STZ diabetic male C57BL/6J mice 
weighing 25g (8-10 weeks) were used as recipients. 
 
4.2.2 L Cell Culture and Seeding 
GLUTag and STC-1 cells were cultured in fully supplemented low glucose (5.6 mM) DMEM. L 
cell co-encapsulated islets were cultured in fully supplemented RPMI islet culture medium 
(11.1 mM). Matrigel (BD) was used as an attachment factor for seeding L cells in experiments 
to prevent the loss of cells due to washing during experiments. Matrigel was defrosted for 16 h 
on ice at 4°C and then diluted 1/100 in serum-free RPMI. 200 µl of diluted matrigel was added 
to wells of a 24-well plate (Nunc) and the plate was incubated at 37°C for >30 min to solidify 
the matrigel coating. Prior to seeding the L cells, the residual diluted matrigel was removed by 
aspiration, and the L cells were strained and counted. The desired number of cells was then 
added to the matrigel coated wells of a 24-well plate. The volume was made up to 1 mL per 
well in low glucose RPMI and the plate was returned to the incubator to allow the cells to 
attach for >16 h before starting co-culture experiments. 
 
4.2.3 L Cell Secretion 
The medium of the seeded L cells was removed and the cells were washed with 1 mL glucose-
free 138 buffer (138 mM NaCl, 4.5 mM KCl, 4.2 mM NaHCO3, 1.2 mM NaH2PO4, 2.6 mM CaCl2, 
1.2 mM MgCl26H2O, 10 mM HEPES, 1 mg.mL
-1 BSA, Sigma). The test substrates were added in 
250 µl 138 buffer and the plate was returned to the incubator for 2 h. Following secretion the 
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plate was put on ice, 750 µl of ice cold glucose-free 138 buffer was added to each well and the 
samples were transferred from the wells into 1.5 mL tubes on ice. Samples were centrifuged at 
300g for 5 min at 4°C and the supernatant was collected, snap frozen on dry ice, and stored at 
-80°C. GLP-1 secretion was measured using an ELISA. 
 
4.2.4 L Cell Conditioned Buffer and Co-Culture 
The medium of the seeded L cells was removed, the cells were washed with 1 mL glucose-free 
138 buffer. 200 µl of 11 mM glucose 138 buffer was added to each well, and the plate was 
returned to the incubator for 2 h.  For L cell conditioned buffer experiments the buffer was 
transferred to wells containing 10 microencapsulated islets in 50 µl of 11 mM glucose 138 
buffer and the plate was returned to the incubator for 1 h. For co-culture experiments after L 
cell incubation 10 microencapsulated islets were added to each well in 50 µl of 11 mM glucose 
138 buffer and the plate was returned to the incubator for 1 h. Following islet incubation the 
plate was put on ice, 750 µl of ice cold glucose-free 138 buffer was added to each well and the 
samples were transferred from the wells into 1.5 mL tubes on ice. Samples were centrifuged at 
300g for 5 min at 4°C and the supernatant was collected and stored at -20°C. Insulin secretion 
was measured using a RIA. 
 
4.2.5 L cell and Islet Co-Encapsulation  
L cells were encapsulated with islets with 8x105 or 4x106 cells per mL of alginate to yield a 
density of 1 islet and approximately 50-100 or 400-500 L cells per capsule respectively as 
estimated by DNA measurements. Following culture overnight islet containing microcapsules 
were either picked and cultured or picked and transplanted.  Capsules were assessed with the 
GSIS assay and insulin secretion and content were measured with a RIA. Some microcapsules 
were stained with live/dead (FDA/PI) staining and visualised using a confocal microscope. 
 
4.2.6 Transplantation 
Islets isolated from several animals were pooled and half were used for islet alone 
encapsulation and half for islet and L cell co-encapsulation. A minimal mass of 250 capsules in 
serum-free RPMI medium were delivered into the peritoneal cavity using an endotoxin-free, 
sterile pipette. Mice were considered cured when the average of 4 consecutive blood glucose 
measurements was ≤11.1 mM and if the average of the final 4 consecutive measurements was 
≤11.1 mM.  
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4.2.7 Post-Transplantation Studies 
The mice were killed by cervical dislocation at the study end-point and the capsules were 
recovered. Insulin secretion and insulin content samples were measured from groups of 10 
encapsulated islets explanted from each mouse or picked from each culture dish. Some 




4.3.1 Co-Encapsulation and Secretion of L Cells 
4.3.1.1 Microencapsulation of L Cells 
The compatibility of L cells in an alginate microencapsulated environment was assessed by 
measuring the DNA content of L cells in microcapsules over time. Microencapsulation of 4x106 
cells per mL of alginate resulted in approximately 400-500 cells per capsule. Both STC-1 and 
GLUTag cells survived the microencapsulation process and grew within capsules, as 
demonstrated by increasing DNA content which reached a plateau at day 7 and 3 for STC-1 and 
GLUTag encapsulated cells respectively (Figure 7). Accordingly, encapsulated cells on day 8 had 
larger individual points of FDA fluorescent staining compared to day 1 confirming cell growth. 
Co-encapsulated islets and L cells had strong FDA staining in both islets and cells. 
Microencapsulated L cells cultured long term (>3 weeks) were observed with cells growing on 
the surface of capsules and even causing capsule breakage at 6-8 weeks.  




Figure 7. Microencapsulated L cell growth and islet co-encapsulation. 
Representative confocal microscope images of microencapsulated STC-1 cells with live/dead 
staining post-encapsulation on: A. day 1 B. day 8. C. Growth curve of STC-1 (white circles, 
dotted line) and GLUTag (black circles, solid line) microencapsulated with 4x106 cells per mL of 
alginate. *P<0.05 vs. previous data point (Two way repeated measures analysis of variance, 
n=3(1)).  STC-1 and GLUTag growth curves were significantly different (P<0.001). D. 
Representative confocal microscope image of co-encapsulated mouse islets with 4x106 GLUTag 
cells per mL of alginate with live/dead staining on day 1.  
 
4.3.1.2 Glucagon-Like Peptide-1 Secretion from L Cells 
The L cell lines were tested for GLP-1 secretion in the presence of glucose, FBS and diprotin A 
(DPA). Glucose was used to stimulate insulin secretion and DPA was used to inhibit any 
potential DPP-IV activity in FBS. Both L cell lines secreted basal GLP-1 which could be increased 
by stimulation with glucose (Figure 8). GLUTag cells had a higher level of glucose-stimulated 
GLP-1 secretion than STC-1 cells. Supplementation with FBS did not reduce detectable GLP-1 in 
GLUTag cells but did in STC-1 cells. The reduction observed in the STC-1 cells could be 
recovered with DPA treatment. Treatment with DPA alone did not alter detectable GLP-1 from 

















































































































Figure 8. Glucagon-like 
peptide-1 secretion from L 
cells. 
GLP-1 secretion of 1x106 
GLUTag (white) or STC-1 
(black) cells per well in 138 
buffer with bovine serum 
albumin in the absence of 
glucose or supplemented 
where stated with glucose (11 
mM), 10% foetal bovine 
serum or 100 µM diprotin A. 
*P<0.05 (One way analysis of 
variance on ranks, n=6-17(1-
3), #P=0.001 (Mann-Whitney 







4.3.2 Co-Culture and Co-Encapsulation of L cells 
4.3.2.1 Conditioned Buffer and Co-Culture of L Cells 
Microencapsulated islets were co-cultured with L cells seeded in the wells of culture plates to 
assess the impact of L cell co-culture on islet insulin secretion. 2x105 GLUTag or STC-1 cells per 
well conditioned buffer or co-culture with 2x105 or 1x106 GLUTag or STC-1 cells per well did not 
impact insulin secretion in microencapsulated islets (Figure 9). After L cell incubation the 
glucose in the buffer was measured with a blood glucose meter. The starting concentration 
was 11 mM glucose and the final concentration was 10.9±0.08 mM (n=7).  
 
Figure 9. Microencapsulated islet insulin secretion with L cell conditioned buffer and L cell 
co-culture. 
Microencapsulated islets were exposed to: A. Conditioned buffer from empty wells (Control) 
or wells with 2x105 GLUTag or STC-1 cells. P=0.774 (One way analysis of variance, n=6(1)) B.  
Co-culture with empty wells (Control) or wells with 2x105 GLUTag or STC-1 cells. P=0.523 (One 
way analysis of variance, n=6(1)) C. Co-culture with empty wells (Control) or wells with 1x106 




































































































4.3.2.2 Inhibition of L cell Derived Glucagon-Like Peptide-1 with Exendin-9 
To investigate a potential mechanism for the lack of stimulatory effect of GLP-1 from GLUTag 
cells on the insulin secretion of islets, we used GLP-1R agonist exendin-4 and GLP-1R 
antagonist exendin-9. Microencapsulated islets respond to exendin-4 by increasing insulin 
secretion (Figure 10). Exendin-9 in combination with exendin-4 resulted in reduced stimulation 
compared to exendin-4 alone. Exendin-9 alone treatment resulted in reduced insulin secretion 
compared to glucose alone treatment. Insulin secretion was not increased compared to 
exendin-9 alone treated by co-culture with GLUTag cells.          
 
Figure 10. Insulin 
secretion of 
microencapsulated islets 
in response to GLUTag 
cells, exendin-4 and 
exendin-9. 
All treatments were in 138 
buffer supplemented with 
11 mM glucose and where 
indicated 1x106 GLUTag 
cells per well, 10 nM 
exendin-4, and 100 nM 
exendin-9. *P<0.05 vs. 
Control, #P<0.05 vs. 
Exendin-4 (One way 





4.3.2.3 Co-Encapsulation of Islets with GLUTag Cells 
Islets were co-encapsulated with GLUTag cells to determine the impact on insulin secretion 
and insulin content. 3 days after encapsulation, glucose stimulated insulin secretion was 
increased from controls in islets that were co-encapsulated with 0.8x106 GLUTag cells per mL 
of alginate (Figure 11). Islets co-encapsulated with 4x106 GLUTag cells per mL of alginate had 
higher basal insulin secretion at day 3 and lower glucose stimulated insulin secretion at day 14 
than controls. Glucose stimulated insulin secretion was increased at day 14 compared to day 3 
in both islets encapsulated alone (P<0.001, ANOVA on ranks, n=19) and islets co-encapsulated 
with 0.8x106 GLUTag cells (P<0.001, ANOVA, n=15). At day 3, insulin content was lower in islets 
co-encapsulated with 4x106 GLUTag cells per mL of alginate compared with islets 


































































Figure 11. Insulin secretion and insulin content of co-encapsulated islets and GLUTag cells. 
Islets were microencapsulated alone (Control, n=19(4)) or co-encapsulated with 8x105 (0.8 
GLUTag, n=15(3)), or 4x106 (4 GLUTag, n=9(2)) GLUTag cells per mL of alginate. 
Microencapsulated islets were exposed to 2 mM (black) and 20 mM (white) glucose at: A. 3 
days B. 14 days post-encapsulation. Insulin content was measured at: C. day 3 and D. day 14 
post-encapsulation. *P<0.05 vs. Control (One way analysis of variance on ranks, n=9-19(2-4)). 
 
4.3.3 Transplantation of Islets Co-Encapsulated With GLUTag Cells  
 
4.3.3.1 Pilot Study of Co-Encapsulated Islets and GLUTag Cells Transplanted into Diabetic 
Mice 
The impact of incorporation of GLUTag cells into microcapsules with islets for transplantation 
into diabetic mice was assessed in a pilot study (n=2). A minimal mass of 250 islets were 
encapsulated alone or with GLUTag cells into the peritoneal cavity of diabetic mice (Figure 12). 
Both recipients of GLUTag co-encapsulated islet grafts and one recipient with islets alone 
cured at week 2 and maintained normoglycaemia for 8 weeks. The stimulated insulin secretion 
from recovered capsules at 8 weeks was higher in GLUTag co-encapsulated islets than islet 
alone encapsulated islets. Islets but not GLUTag cells stained positively for FDA in recovered 
















































































































































Figure 12. Pilot study of co-encapsulated islets and GLUTag cells transplanted into diabetic 
mice. 
Diabetic mice were implanted with syngeneic intraperitoneal grafts of 250 encapsulated islets 
alone or 250 islets co-encapsulated with 8x105 GLUTag cells per mL of alginate. A. Blood 
glucose measurements of individual mice with microencapsulated islet alone grafts (black 
circles, solid line) or GLUTag co-encapsulated islet grafts (white circles, dotted line). B. Insulin 
secretion of recovered microcapsules from microencapsulated islet alone grafts (Control) or 
GLUTag co-encapsulated islet grafts (GLUTag) exposed to 2 mM (black) and 20 mM (white) 
glucose. *P=0.030 (One way analysis of variance, n=12(2)). C. Fluorescein diacetate stained 
microscope images of GLUTag co-encapsulated islet recovered at 8 weeks (200 µm scale bar).     
 
4.3.3.2 Expanded Study of Co-Encapsulated Islets and GLUTag Cells Transplanted into 
Diabetic Mice 
The pilot study of GLUTag cell co-encapsulated islet transplantation into diabetic mice was 
expanded. Overall, recipients in both the islet encapsulated alone and the GLUTag co-
encapsulated islet groups did not cure and resulted in graft failure by 4 weeks (Figure 13). The 
average blood glucose of the recipients was no different overall between groups but the 
average blood glucose was lower in the GLUTag co-encapsulated islet recipient group at 2 time 




























































Figure 13. Graft outcome of diabetic mice transplanted with islets co-encapsulated with 
GLUTag cells. 
Diabetic mice were implanted with syngeneic intraperitoneal grafts of 250 encapsulated islets 
alone (black circles, solid line, n=7) or 250 islets co-encapsulated with 8x105 GLUTag cells per 
mL of alginate (white circles, dotted line, n=7). A. Average blood glucose 
measurements.*P<0.05 vs. islet alone group (Two way repeated measures analysis of variance, 
multiple comparisons versus control group (Holm-Sidak method)). B. Percentage of cured 




GLP-1 has multiple beneficial effects on β cells including stimulating glucose-dependent insulin 
secretion, proliferation, islet neogenesis and protecting β cells against apoptosis. It was 
hypothesised that incorporating GLP-1 secreting L cells with islets into microcapsules would 
provide the islet with a constant, physiologically regulated source of GLP-1, thereby improving 
islet survival, function and graft outcome in models of transplantation for T1DM. It was 
established that the L cell lines STC-1 and GLUTag were tolerant to the microencapsulation 
process and proliferated in microcapsules. Long term survival of L-cells and therefore secretion 
of GLP-1 in microcapsules is desirable as local delivery of GLP-1 could potentially provide an 
advantage in culture and post-transplantation for the lifetime of the graft. It was also observed 
that after 1 or 2 weeks the cell number of encapsulated L cells reached a plateau, suggesting 
the capacity of the capsule had been reached. However, eventually cells were observed on the 
outside of capsules and broken capsules were observed suggesting the L cells were able to 
overcome the capacity if the capsules. In a transplantation setting this would be 
disadvantageous as protruding cells would cause an inflammatory reaction and broken 
capsules would negate the immunoprotective capacity of the microcapsules. Additionally, 
aggressive growth of L cells co-encapsulated with islets would use oxygen and nutrient 
resources, resulting in islet starvation. The aggressive growth observed in microcapsules after 
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mouse tumour cell lines which are also observed to grow rapidly in conventional adherent 
culture. L cell lines would never be used in a clinical setting however they do provide a 
convenient model for L cells in the current study. Encapsulated GLUTag cells reached a growth 
plateau at a lower density than STC-1 cells which suggests they may have less aggressive 
growth and therefore may be more suitable for proof of principle co-encapsulation and 
transplantation studies.     
 
The secretion of GLP-1 from the L cell lines could be stimulated by glucose, with a higher level 
secreted from GLUTag cells than STC-1 cells. Interestingly the cell lines responded differently 
to FBS, with GLUTag cell GLP-1 secretion remaining unchanged and STC-1 cell GLP-1 secretion 
being reduced. FBS was included as it is used under standard culture conditions and is 
necessary for longer term studies. However FBS can contain DPP-IV which inactivates GLP-1, 
therefore the impact of FBS in the GLP-1 secretion studies was of interest.  In the STC-1 line, 
FBS decreased glucose stimulated GLP-1 secretion, indicating that DPP-IV may have been 
present in the FBS. Accordingly, addition of the DPP-IV inhibitor DPA was able to reverse the 
effect. The same effect was not seen in the GLUTag cell line, with FBS not affecting GLP-1 
secretion. It should be noted that this experiment was not carried out simultaneously with the 
STC-1 FBS experiment. Thus it is currently not possible to conclude whether the differences 
seen between the two cells lines are due to their respective responses to the contents of FBS, 
or whether the DPP-IV content of the FBS differed sufficiently between the two experiments to 
yield these disparate results.   
 
The secreted factors from L cells were transferred onto microencapsulated islets in 
conditioned buffer experiments and microencapsulated islets were co-cultured with L cells. 
The conditions were similar to the conditions for the GLP-1 secretion studies which allowed 
the theoretical amount of GLP-1 being produced to be estimated. Stimulation of insulin 
secretion from microencapsulated islets in the L cell conditions was not detected in any of the 
experiments. The highest number of cells used for co-culture was 1x106 GLUTag cells which 
resulted in a highly confluent well surface. This number of cells should produce GLP-1 in the 
range of 400-500 pM, and it has been shown that as little as 100 pM GLP-1 in 10 mM glucose 
media can stimulate approximately a 40% increase in insulin secretion in islets (Goke et al., 
1993). Therefore it is surprising that co-culture of islets with GLUTag cells did not stimulate 
insulin secretion.  As microencapsulated islets were used, the ability of GLP-1 to diffuse 
through the cross-linked alginate should be considered. GLP-1 has a molecular weight of 3.2 
kDa and exendin-4 has a molecular weight of 4.3 kDa. We have shown that exendin-4 is able to 
stimulate the insulin secretion of microencapsulated islets, therefore it is likely that GLP-1 
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should readily diffuse through alginate. Resource limitation may be a factor preventing 
stimulation of insulin secretion in the experiments. It is possible that although the secreted 
GLP-1 does have a positive effect on islet insulin secretion the L cells have used the oxygen and 
nutrients in the buffer which acts to limit insulin secretion. The glucose concentration did not 
change due to L cell culture, therefore ruling out glucose as a limiting factor. Additionally, the 
lower cell density co-culture condition did not yield better results. Another possibility is that 
the L cells also secrete a factor which has negative implications on insulin secretion. Peptide-YY 
is secreted from L cells including STC-1 cells (Geraedts et al., 2009, Hand et al., 2012) and has 
been shown to inhibit the insulinotropic action of GIP and also directly inhibit insulin secretion 
in islets (Bertrand et al., 1992). STC-1 cells are reported to secrete approximately 1.6 fmol PYY 
per 1x106 cells (Hand et al., 2012) which would equate to around 150 pM in our conditions. It 
has been shown that 100 pM PYY can inhibit insulin secretion in the perfused rat pancreas 
(Bertrand et al., 1992), therefore PYY may be an inhibitory factor on insulin secretion in our 
experiments. Another possibility is that the islets are secreting a factor which inhibits GLP-1 
secretion from the L cells. There is some evidence that somatostatin inhibits GLP-1 secretion 
from L cells (Brubaker, 1991). This scenario seems unlikely as the conditioned buffer 
experiments would not be affected and in the co-culture experiments at the point the 
encapsulated islets are transferred the L cells have already produced stimulatory levels of GLP-
1.  
 
To investigate the hypothesis that GLUTag cell derived GLP-1 was stimulating insulin secretion 
but another factor or factors were cancelling out the effect, studies were carried out with the 
GLP-1 antagonist exendin-9. Exendin-9 alone inhibited insulin secretion but the effect could be 
cancelled out with exendin-4. It has been reported that GLP-1 is locally produced in α cells in 
adult islets which is likely to cause basal GLP-1R stimulation (Masur et al., 2005). Exendin-9 
therefore can inhibit basal insulin secretion but exendin-4 counteracts the effect. A similar 
effect was not observed with L cell produced GLP-1 which suggests either that it does not 
stimulate the GLP-1R or the concentration is too low to counteract the effect of exendin-9. If 
GLUTag-derived GLP-1 does not stimulate the GLP-1R then it is possible the gene is mutated 
which is can occur in a long-lived transformed cell lines. In opposition to this theory the ELISA 
could detect active GLP-1 which suggests at least the active site is not mutated. Another 
possibility is that GLP-1 does stimulate the GLP-1R but another factor secreted from the L cells 
prevents downstream signalling.  
 
Despite the poor response of islets to L cells in acute studies it was investigated if co-
encapsulation could be beneficial. Co-encapsulation locates the L cells in closer proximity to 
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the islet which may result in a higher islet localised GLP-1 concentration. It also allows for 
convenient long term co-culture in comparison to adherent cell culture where cells must be 
sub-cultured every few days and the islets are at risk of direct overgrowth by the L cells. It was 
found that with islets co-encapsulated with 0.8x106 GLUTag cells per mL of alginate had 
increased insulin secretion at day 3 compared to islets encapsulated alone. It is possible that 
the closer proximity of the L cells to the islets and the longer time period compared to the co-
culture experiments resulted in the difference in outcome. Another possibility is that the 
microencapsulated environment stimulates the L cells to produce more GLP-1. There was also 
a trend increase in GSIS with islets co-encapsulated with 4x106 GLUTag cells per mL of alginate 
at 3 days. However basal insulin secretion was also increased and insulin content was 
decreased suggesting aberrant insulin secretion. By day 14 the insulin secretion of 0.8x106 
GLUTag cells per mL of alginate capsules was not different to controls. Both control and 
0.8x106 GLUTag cells per mL of alginate co-encapsulated islets had increased insulin secretion 
compared to day 3 without a decline in insulin content. There are reports demonstrating 
approximately a 25% increase in the GSIS of microencapsulated islets after a period of culture 
(King et al., 1999). However a >300% increase was observed in control microencapsulated 
islets in the current study, but it is not clear by what mechanism. At 14 days the GSIS of 4x106 
cells per mL of alginate co-encapsulated islets were poor. This is likely to be related to the 
expansion of GLUTag cells in the capsules using resources to the detriment of the islets.  
 
The enhancement of insulin secretion mediated by the incorporation of GLUTag cells with 
islets into microcapsules suggested that the approach may improve graft efficacy in a diabetic 
transplantation model. A pilot study was established to determine the strategy for a larger 
study using 250 microencapsulated islets as a minimal mass model. It was found that GLUTag 
co-encapsulated islets showed a trend for improved graft efficacy for up to 8 weeks and 
enhanced GSIS in recovered capsules compared to islets encapsulated alone. Interestingly the 
L cells in explanted capsules were not alive after 8 weeks in vivo which suggests the benefit of 
the L cells could be during culture and the early transplantation period. The data from the pilot 
study suggested the model was appropriately stringent and a benefit could be observed by co-
encapsulating with L cells. As a result the pilot was expanded, however, the same trends were 
not repeated in the blood glucose measurements and there was no overall difference between 
GLUTag co-encapsulated group and the islet alone group. The time to graft failure showed a 
trend for faster failure in the islet alone group but was not significantly different. The in vitro 
insulin secretion, blood glucose data of the pilot study and differences in blood glucose at 2 
time points in the full study suggest that GLUTag cells could provide some benefit when co-
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encapsulated with islets. In that case the minimal mass model may have been too stringent 
and the data from pilot study was not representative of the model.  
 
Co-encapsulation of L cells with islets improved islet insulin secretion but the mechanism is 
unclear. Using a stringent minimal mass model L cells were unable to improve 
microencapsulated graft outcome. If it were apparent that L cells did improve 
microencapsulated islet transplantation there would be major hurdles limiting the 
development of such an approach for clinical islet transplantation. Isolation of purified primary 
L cells is not currently possible and there are few descriptions of primary human intestinal 
epithelial cell isolation (Beaulieu and Menard, 2012). L cells are a rare cell type in primary 
human intestinal epithelial cell populations and therefore some form of cell sorting would 
have to be optimised to get a good purity of L cells. Exploiting the phenotype of naturally 
occurring cells presents a far more complicated system then conventional drug delivery due to 
the number of different factors which are secreted from a single cell type and the dynamic 
secretion responses to environmental cues. L cells were used in the current study as a vehicle 
for localised delivery of a single molecule of interest, GLP-1. Conceptually, localising L cells with 
islets should provide GLP-1 mediated benefits to islet survival and function. However 
attempting to demonstrate the concept has resulted in some unexpected results which 
probably represents the complexity of the interaction between the assorted L cell secretions 
and islet responses.                   
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5 Co-Encapsulation of Islets with Mesenchymal Stem 




Recently there have been several studies reporting the benefit of co-transplanting MSCs with 
non-encapsulated islets to improve graft efficacy in animal models (Figliuzzi et al., 2009, Ito et 
al., 2010, Sordi et al., 2010b, Rackham et al., 2011, Jacobson et al., 2008, Ding et al., 2009, 
Solari et al., 2009, Longoni et al., 2010, Berman et al., 2010). MSCs are pluripotent cells located 
in the perivascular niche of the majority of vascularised organs (da Silva Meirelles et al., 2006) 
which can differentiate into mesenchymal cell types. Native MSCs promote tissue repair by 
simultaneously secreting trophic factors and inhibiting inflammatory and immune responses 
(Xu et al., 2008). Accordingly the beneficial effects of MSCs in islet co-transplantation have 
been attributed to improving graft revascularization (Figliuzzi et al., 2009, Ito et al., 2010, Sordi 
et al., 2010b, Rackham et al., 2011) and suppressing immune or inflammatory responses 
(Jacobson et al., 2008, Ding et al., 2009, Solari et al., 2009, Longoni et al., 2010, Berman et al., 
2010). Recently it has been suggested that MSCs can also improve graft outcome by 
maintaining islet organization and morphology (Rackham et al., 2011).  
 
Immunoisolation of the islets by microencapsulation in alginate offers the prospect of 
restoring physiological glycaemic control without the need for immunosuppression. 
Microencapsulation prevents the passage of cells in or out of the capsule which protects the 
islet from immune rejection but also prevents any direct cellular contact with the host or other 
islets in the graft. Microencapsulation completely prevents islet revascularisation and 
therefore  can function as a tool to study its role in graft success (Bohman et al., 2006). 
Additionally, microencapsulation prevents islets from aggregating and therefore can also be 
used to study the role of islet morphology preservation on graft success. Microencapsulation 
therefore offers an isolated-graft model of islet transplantation which excludes some of the 
factors impacting non-encapsulated islet transplantation. Microencapsulated islet grafts also 
have the advantage of yielding greater insight into the mechanisms of graft success as it is 
possible to retrieve individual encapsulated islets for functional and morphological 
assessment. 
 
Microencapsulated islet transplantation is suboptimal with at least double the number of islets 
necessary to cure diabetic animals compared to non-encapsulated islet grafts (Siebers et al., 
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1993). In the current study we investigated whether co-encapsulation with MSCs could 
improve microencapsulated islet graft efficiency. We also used microencapsulation as an 
isolated-graft model of islet transplantation with the aim of determining whether the effects of 
MSCs are sustained in the absence of MSC-mediated enhancement of revascularization and 





Male ICR aged 6-8 weeks were used to isolate islets for in vitro experiments. Male C57BL/6J 
mice aged 6-8 weeks were used as islet donors and STZ diabetic male C57BL/6J mice weighing 
25g (8-10 weeks) were used as recipients. 
 
5.2.2 Mesenchymal Stem Cells 
I am grateful to Pedro Chagastelles (Universida de Federal do Rio Grande do Sul, Porto Alegre, 
RS, Brazil) and Chloe Rackham (King’s College London) for isolating and characterising the 
MSCs. A brief description of the isolation and characterisation methods are detailed below.  
 
5.2.2.1 Mesenchymal Stem Cell Isolation 
Kidney-derived MSCs were isolated from C57BL/6J mice, immunophenotyped for MSC markers 
and validated for pluripotency as previously described (Rackham et al., 2011). Briefly, the 
kidneys were cut into small pieces and digested for 30-45 min at 37°C with 1 mg.mL-1 
collagenase type 1 in calcium and magnesium free Hank’s balanced salt solution (HBSS, PAA 
Laboratories, Pasching, Austria) with 10 mM HEPES. Following trituration the cells were 
centrifuged for 10 min at 400 g, resuspended in DMEM (10% FBS, 100 units.mL-1 penicillin, 100 
ng.mL-1 streptomycin) and cultured at 37 °C, 5% CO2. Non-adherent cells were removed during 
4-6 passages and once an aesthetically uniform population of cells emerged the cells were 
characterised. 
 
5.2.2.2 Mesenchymal Stem Cell Immunophenotyping 
The MSCs were assessed for the presence or absence of specific cell surface markers which 
indicate a mesenchymal stem cell phenotype. MSCs were washed in PBS and then incubated 
for 30 min with fluorescein isothiocyanate (FITC)- or phycoerythrin (PE)-conjugated antibodies 
for CD11b, CD31, CD44, CD45, CD73, CD90.2 and stem cell antigen-1 (BD Pharmingen, San 
Diego, CA, USA). Cells were analysed for antibody binding in a fluorescence activated cell 
sorter (BD Pharmingen). Cells were negative for CD11b, CD31 and CD45 which are markers for 
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macrophages, endothelial cells, and haematopoietic cells respectively, and positive for CD44, 
stem cell antigen-1, CD73, CD90.2 which are characteristic of MSCs.  
 
5.2.2.3 Mesenchymal Stem Cell Differentiation  
To confirm a pluripotent phenotype, MSCs were cultured in an induction medium of DMEM 
containing 20% FBS, 2.5 μg.mL-1 insulin, 100 μM indomethacin, 5 μM rosiglitazone and 10 nM 
dexamethasone to induce adipocyte formation. MSCs were cultured in an induction medium 
of DMEM containing 10% FBS, 10 mM β-glycerophosphate, 5 μg.mL-1 ascorbic acid and 10 nM 
dexamethasone to induce osteocyte formation. The cells were able to differentiate in vitro into 
both adipocyte- and osteoblast-like cells as determined by Oil Red O and Alizarin Red S staining 
respectively.    
 
5.2.2.4 Mesenchymal Stem Cell Culture 
MSCs were cultured in 5.6 mM glucose DMEM supplemented with 10% FBS, 100 units.mL-1 
penicillin, 100 ng.mL-1 streptomycin, and 20 mM L-glutamine. Cells were subcultured every 3-4 
days and MSCs up to passage 12 were used for experiments. 
 
5.2.2.5 Islet and Mesenchymal Stem Cell Co-encapsulation  
MSCs were encapsulated with 8x105 or 4x106 cells per mL of alginate to yield a density of 
approximately 50-100 or 400-500 MSCs per capsule respectively as estimated by DNA content 
measurements, and 1 islet per capsule. 
 
5.2.3 In vitro Assessment of Islets Co-Encapsulated with Mesenchymal Stem Cells 
Insulin secretion and insulin content samples were from groups of 10 encapsulated islets 
picked from each culture dish. Insulin was measured by RIA. 
 
5.2.4 Transplantation of islets Co-Encapsulated with Mesenchymal Stem Cells 
Islets isolated from several animals were pooled and half were used for islet alone 
encapsulation and half for islet and MSC co-encapsulation. A minimal mass of 350 capsules in 
serum-free RPMI medium were delivered into the peritoneal cavity using an endotoxin-free, 
sterile pipette. Mice were considered cured when the average of 4 consecutive blood glucose 
measurements was ≤11.1 mM and the average of the final 4 consecutive measurements was 
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5.2.5 Post-Transplantation Studies 
The mice were killed by cervical dislocation 6 weeks after transplantation. Individual capsules 
and capsules in small aggregates were counted and the numbers of capsules in large 
aggregates were estimated. Insulin secretion and insulin content samples were from groups of 
10 encapsulated islets explanted from each mouse or picked from each culture dish. In 
addition, capsules were histologically examined as outlined below. 
 
5.2.5.1 Microcapsule and Islet Histology  
60-180 capsules recovered from each mouse were fixed in 10% formaldehyde, rinsed in graded 
concentrations of ethanol, embedded in paraffin, and cut into 5 µm sections. Microcapsule 
sections were stained with haematoxylin and eosin. Microcapsules (13-51 per graft) were 
scored for overgrowth on an increasing scale of 1-4 where 1 represents little or no overgrowth 
and 4 represents heavy overgrowth. Islet sections from recovered capsules (13-51 per graft) 
were assessed for islet section area using Image J software (Rasband, National Institute of 
Health).  
 
5.2.5.2 Mesenchymal Stem Cell Histology  
Haematoxylin and eosin stained microcapsule sections from recovered capsules (13-51 per 
graft) or cultured capsules from day 1-3 (9-13 per encapsulation) were assessed for MSC 
survival by counting the number of cells with a nucleus and normal morphology against the 
number of missing or anucleated cells. 10-30 capsules recovered from each mouse were 
stained with FDA. The number of FDA positive MSCs was estimated from images of 
microcapsules focused on a single plane.  
 
5.2.5.3 Immunostaining  
Microcapsule sections from recovered capsules (1-6 per graft) were stained with insulin or 
glucagon to count β and α cell number per islet section respectively and detect MSC 
phenotype. Insulin staining was carried out with rabbit polyclonal anti-insulin primary (1:1000) 
(Gene Tex, Irvine, CA, USA) with goat anti-rabbit immunoglobulin G (IgG) secondary (Alpha 
Diagnostic International, San Antonio, TX, USA). Glucagon staining was carried out with mouse 
monoclonal anti-glucagon primary (1:1000) (Sigma) with a biotinylated universal link 
secondary (Dako, Glostrup, Denmark). Staining was developed with Dako Liquid DAB + 
substrate chromogen system (Dako). 
 
 





5.3.1 In vitro Function of Islets Co-Encapsulated with Mesenchymal Stem Cells 
MSCs were co-encapsulated with islets at a density of 8x105 or 4x106 cells per mL of alginate to 
determine the impact on islet insulin secretion and insulin content. Co-encapsulation of islets 
with MSCs increased stimulated insulin secretion compared with encapsulated islets alone at 
both MSC densities (Figure 14). The insulin secretion of islets co-encapsulated with 4x106 MSCs 
per mL was higher than islets co-encapsulated with 8x105 MSCs per mL. Co-encapsulation of 
islets with MSCs at a density of 4x106 MSCs per mL of alginate increased insulin content 
compared with islets encapsulated alone at day 3.  
 
Figure 14. Insulin secretion and content of islets microencapsulated alone or co-
encapsulated with mesenchymal stem cells. 
Encapsulated islets alone (e-islets) were compared to co-encapsulated islets with 8x105 
mesenchymal stem cells per mL of alginate (e-islets+0.8 MSC) and 4x106 mesenchymal stem 
cells per mL of alginate (e-islets+4 MSC). A. Insulin secretion of encapsulated islets at day 3 
post-encapsulation in 2 mM (black) and 20 mM (white) glucose solutions. *P<0.05 vs. e-islets, 
#P<0.05 vs. e-islets+0.8 MSC (One way analysis of variance with Holm-Sidak post hoc test n=17-
18(3)). B. Insulin content of encapsulated islets at day 3. *P<0.05 vs. e-islets, (Kruskal-Wallis 
One Way Analysis of Variance on Ranks (Dunn’s method), n=18-19(3)). 
 
5.3.2 In vivo Function of Islets Co-Encapsulated with Mesenchymal Stem Cells 
To determine the efficacy of islets co-encapsulated with MSCs in a transplantation setting, 
4x106 MSCs per mL of alginate co-encapsulated islets were transplanted into syngeneic STZ 
diabetic mice. Co-encapsulation of islets with MSCs improved the graft outcome compared to 

















































































Mesenchymal Stem Cell Co-Encapsulation 
104 
 
significantly lower on day 21, 35, and 42 (Figure 15).  At 6 weeks 71% of the co-encapsulated 
group were cured compared with 16% of the islet alone group. 
 
 
Figure 15. Graft outcome of diabetic mice transplanted with islets co-encapsulated with 
mesenchymal stem cells. 
Mice were transplanted with 350 encapsulated islets alone (black circles, solid line, n=6) or 350 
islets co-encapsulated with 4x106 mesenchymal stem cells per mL of alginate (white circles, 
dotted line, n=7). A. Average blood glucose measurements.*P<0.05 vs. islet alone group (Two 
way repeated measures analysis of variance, multiple comparisons versus control group 
(Holm-Sidak method)). B. Percentage of cured mice. P<0.05 (Kaplan-Meier Survival Analysis 
(Log-Rank)).  
 
5.3.3 Ex Vivo Islet Function and Histology 
Encapsulated islets were recovered from mice at 6 weeks after transplantation for functional 
and histological assessment of the islets.  Stimulated insulin secretion and insulin content were 
higher in recovered islets that had been co-encapsulated with MSCs compared with islets 
encapsulated alone (Figure 16). Islets stained positively for insulin and glucagon with glucagon 
positive cells located on the islet periphery in both groups. The islet area and number of β cells 
per islet section were higher in the islets co-encapsulated with MSCs compared to islets 



















































Figure 16. Insulin secretion, insulin content, and islet area of recovered islets co-
encapsulated with mesenchymal stem cells. 
Capsules were recovered at 6 weeks and control encapsulated islets alone (e-islets) were 
compared to co-encapsulated islets with 4x106 MSCs per mL (e-islets+MSCs). A. Insulin 
secretion of capsules exposed to 2 mM (black) and 20 mM (white) glucose. *P<0.05 vs. e-islets 
(Mann-Whitney Rank Sum Test, n=6-7). B. Insulin content of recovered capsules. *P<0.05 vs. e-
islets (Mann-Whitney Rank Sum Test, n=6-7). C. The islet area. *P<0.001 vs. e-islets (Mann-
Whitney Rank Sum Test, n=5-7). D. The number of β cells per islet section. *P=0.004 vs. e-islets 
(t-test, n=8-12(3-5)). E. The number of α cells per islet section (n=8-10(3-5)).  
 
5.3.4 Capsule Recovery and Overgrowth 
The number of capsules recovered and the amount of pericapsular overgrowth indicate the 
capsule stability and biocompatibility respectively. The number of capsules recovered from the 
mice was not different between groups (Figure 17). Recovered capsule sections were scored 

















































































































































































Figure 17. Capsule recovery and overgrowth score of recovered islets co-encapsulated with 
mesenchymal stem cells. 
Capsules were recovered at 6 weeks and control encapsulated islets alone (e-islets) were 
compared to co-encapsulated islets with 4x106 mesenchymal stem cells per mL (e-
islets+MSCs). A. Number of capsules recovered. P=0.634 (One way analysis of variance, n=6-7) 
B.  Overgrowth score of recovered capsule sections. Control encapsulated islets alone (black) 
were compared to co-encapsulated islets with 4x106 mesenchymal stem cells per mL (white). 
P>0.05 (Two way analysis of variance n=5-7)). 
 
5.3.5 Mesenchymal Stem Cell Histology  
Encapsulated islets were recovered from mice at 6 weeks after transplantation for functional 
and histological assessment of the islets. A smaller percentage of MSCs in capsule sections and 
fewer FDA stained MSCs per capsule were found in capsules recovered from mice compared to 
capsules cultured for 1-3 days (Figure 18). MSCs did not stain positively for insulin or glucagon.     
 
 
Figure 18. Survival of mesenchymal stem cells. 
Co-encapsulated islets with 4x106 mesenchymal stem cells per mL either cultured for 1-3 days 
(in vitro) or recovered at 6 weeks from transplanted mice (ex vivo) were assessed. A. The 
percentage of mesenchymal stem cells in capsule sections, *P<0.001 vs. in vitro (Mann-
Whitney Rank Sum Test, n=3-7)). B. The number of fluorescein diacetate stained mesenchymal 
stem cells counted per capsule image *P<0.001 vs. in vitro (Mann-Whitney rank sum test, 
n=13-24(3-7)). C. Representative image of islet and mesenchymal stem cell co-capsules 
recovered from mice at 6 weeks. Merged bright field and fluorescein diacetate cell stained 
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5.4 Discussion  
 
Co-encapsulation of islets with MSCs improved the GSIS and insulin content of islets in vitro. 
Several groups have also reported benefits from co-culturing non-encapsulated islets with 
MSCs including increasing insulin secretion (Park et al., 2010b, Jung et al., 2011, Park et al., 
2009), insulin content (Jung et al., 2011), viability (Park et al., 2010b, Jung et al., 2011, Karaoz 
et al., 2010), and reducing apoptosis (Park et al., 2010b, Karaoz et al., 2010). 
Microencapsulation of MSCs results in the random distribution of cells throughout the capsule. 
Consequently a small proportion may be located at the islet periphery by chance although the 
vast majority of MSCs would not be in direct contact with the islet. It has been demonstrated 
that direct co-culture with MSCs is not necessary to improve islet viability and function either 
in vitro (Jung et al., 2011, Karaoz et al., 2010), or in vivo (Park et al., 2010a). In agreement, the 
mechanism of MSC-mediated enhancement of islet viability and function in our model is likely 
to be mostly through stimulation by soluble factors. Using a higher density of MSCs resulted in 
higher GSIS and a trend for higher insulin content at day 3 indicating a dose-response 
interaction. It has been shown that co-transplantation of MSCs pre-conditioned to produce 
more secretions were able to improve graft efficacy more than MSCs without pre-conditioning 
(Cavallari et al., 2012). It is likely that increasing the concentration of secreted MSC factors will 
increase the positive effects on islets, although it may be possible to over stimulate the islets. 
Additionally, where MSCs share the same environment as the islets, increasing the number of 
MSCs may be detrimental to islet viability and function due to the MSCs competing against the 
islets for limited resources such as oxygen and nutrients.  
 
We validated the incorporation of MSCs co-encapsulated with islets in vitro and proceeded to 
translate the system into a transplantation setting in diabetic mice. Transplantation of a 
minimal mass of 350 islets alone into STZ diabetic mice resulted in a gradual decline in graft 
efficacy. The model was based on using 50% of the number of islets necessary for robust graft 
efficacy, and resulted in a similar pattern of graft failure reported in a related study (Bohman 
et al., 2006). The islet and MSC co-encapsulation group had significantly lower average blood 
glucose as early as 3 weeks post-transplantation and a greater proportion of the mice were 
cured by six weeks. The ex vivo assessment between the groups revealed a similar pattern to 
the in vitro data, with higher GSIS, higher insulin content, greater islet area, and a greater 
number of β cells in the islet and MSC co-encapsulation group. This finding demonstrates that 
the beneficial effects of co-encapsulating islets with MSCs observed in vitro is sustained in vivo 
for at least 6 weeks. MSCs appear to enhance the survival of islet cells as demonstrated by the 
larger islet area in islet and MSC co-encapsulated graft sections. Interestingly the number of β 
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cells is greater in the islet and MSC co-encapsulation group islets than the islet alone group 
islets, but the number of α cells is the same. It is possible that an islet cell type selective 
advantage is mediated by MSCs. However a more obvious explanation may be that there is 
proportionally more cell death in the β cell rich islet core of transplanted islets (MacGregor et 
al., 2006). Preservation of β cell survival is causally linked to the increase in islet insulin 
secretion and content observed in islet and MSC co-encapsulated graft islets. It is unclear if 
enhanced survival is the only cause of the greater amount of insulin produced and secreted or 
if the MSCs are enhancing the insulin production and secretion capability of the β cells.   
 
The beneficial effect of MSCs in a number of transplantation models has been attributed to 
several mechanisms. It has been suggested that the transplantation of MSCs without islets can 
reduce the blood glucose concentration of STZ diabetic rodents (Ezquer et al., 2008, Dong et 
al., 2008, Lee et al., 2006d, Xu et al., 2012). The explanation for this finding was attributed to a 
small proportion of infused MSCs migrating to the pancreas and predominantly encouraging β 
cell regeneration, although there is some evidence of a small number of MSCs 
transdifferentiating into IPCs. In the current study microencapsulation resulted in the random 
distribution of MSCs throughout the capsule. By chance a few MSCs will be located at the 
periphery of the capsule. We have observed MSCs located at the periphery of the capsule 
escaping using time-lapse microscopy (data not shown). However, the vast majority of 
microencapsulated MSCs are trapped within the cross-linked alginate and have been observed 
to only move within the defined space created during the cross-linking of the alginate.  In total 
approximately 25,000 to 32,000 MSCs were transplanted in a single graft and it is likely that a 
very negligible proportion of those would be located at the periphery of the capsules and 
therefore at risk of escape. MSC therapy for STZ diabetic rodents has been efficacious with as 
few as 500,000 cells (Ezquer et al., 2008), however other studies have reported using a few 
million (Dong et al., 2008, Lee et al., 2006d) or even up to 12 million cells (Xu et al., 2012). 
Given the large number of MSCs that have been reported for MSC therapy and the negligible 
chance of MSCs escaping from microcapsules, it is highly likely that the improvement in 
glycaemic control observed in the current study was not due to MSCs migrating to the 
pancreas and inducing endogenous β cell regeneration. 
 
The improved performance of islets co-transplanted with MSCs has also been attributed to the 
immunosuppressive effects mediated by cytokine (Solari et al., 2009, Longoni et al., 2010, 
Berman et al., 2010) or metalloproteinase (Ding et al., 2009) secretion. The attenuation of the 
alloimmune response by MSCs is not relevant to the current study as both the islets and MSCs 
were syngeneic. In addition to regulating the alloimmune response MSCs have also been 
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implicated in suppressing the inflammatory response (Oh et al., 2008, Jung et al., 2011). The 
interaction between the inflammatory response and MSCs is relevant to the current study and 
may be reflected by the capsule recovery data at six weeks. The number of capsules recovered 
was equal for both groups which suggests that co-encapsulation with MSCs does not have a 
significant effect on capsule stability and biocompatibility. Poor biocompatibility results in 
overgrowth which is detrimental to islet survival and function and also may increase the 
chance of capsules becoming adhered in the tissues in the peritoneal cavity. There was also no 
difference in overgrowth between the groups which suggests that microencapsulated MSCs do 
not have a major impact on the inflammatory process which causes overgrowth. Consequently 
the suppressive effects of MSCs on inflammation are unlikely to be a major influence in our 
model.  
 
Microencapsulation effectively impedes the formation of blood vessels connecting the islet to 
the general circulation. Co-transplantation with MSCs improved graft success and ex vivo islet 
function without revascularisation. This finding suggests that the effect MSCs exert on 
revascularisation is not essential to improving graft outcome by co-transplantation. Most islet 
and MSC co-transplantation studies have used the subcapsular kidney site which has an 
oxygen tension of 12-16 mmHg, which is hypoxic relative to the 40 mmHg oxygen tension of 
native islets (Carlsson et al., 2000). The intraperitoneal site has a higher oxygen tension of 40 
mmHg (Renvall and Niinikoski, 1975)  although due to the absence of revascularisation and 
poor diffusion through the alginate, hypoxia is an often cited cause of graft failure of 
microencapsulated islets at this site (Vaithilingam and Tuch, 2011, De Vos et al., 1999). It has 
been demonstrated that the oxygen tension of islets in small 180 µm diameter capsules is 
reduced by 55-73% compared to the oxygen tension outside of the capsule (Chen et al., 2012). 
In addition, mathematical modelling studies have suggested the oxygen tension in the core of 
islets in 500 µm alginate microcapsules in a  40 mmHg environment may be as low as <2 
mmHg (Avgoustiniatos and Colton, 1997, Johnson et al., 2009). It is likely that the oxygen 
tension of microencapsulated islets transplanted intraperitoneally is at least as hypoxic as non-
encapsulated subcapsular kidney grafts. Therefore there is an equal need for alleviation of 
hypoxia by revascularisation at both sites. We have demonstrated that revascularisation is not 
essential to gaining an advantage by co-transplanting with MSCs in hypoxic conditions. 
Therefore this indicates that the advantage we have observed in the absence of 
revascularisation is also likely to play a role in co-transplantation at the subcapsular kidney 
site. 
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Microencapsulation effectively preserves the morphology and organisation of the islets 
(Bohman and King, 2008). Several previous studies have indicated that under the kidney 
capsule, non-encapsulated islet alone grafts form into an amorphous mass of islet cells post 
transplantation (Davalli et al., 1996, Rackham et al., 2011, Biarnes et al., 2002). A previous 
study in our lab found that co-transplantation with MSCs prevented islet aggregation and 
preserved morphology more similar to that of native islets (Rackham et al., 2011). Aggregation 
of islets is likely to limit the diffusion of oxygen and nutrients. Indeed it has been observed that 
small islets are more efficacious than large islets for transplantation (Su et al., 2010, Lehmann 
et al., 2007). Graft tissue divided into small subunits is likely to have better availability of 
oxygen and nutrients than graft tissue in one aggregated mass. Microencapsulation keeps the 
islets in the graft fully isolated from each other and therefore preserves islet morphology. In 
the current study, islet alone transplantation had diminished graft success and ex vivo islet 
function compared to islet and MSC co-encapsulated grafts despite the preservation of islet 
morphology in both groups. This finding suggests that the effect MSCs exert to preserve islet 
morphology is also not essential to improving graft outcome by co-transplantation.  
      
The outcome of microencapsulated islet transplantation in animal models is suboptimal (De 
Vos et al., 1999) with at least double the number islets necessary for graft success in animal 
models compared to non-encapsulated grafts (Siebers et al., 1993). Indeed in the current study 
we observed approximately a 10 fold reduction in insulin secretion and MSC viability which is 
likely to be related to the poor diffusion of oxygen and nutrients to microencapsulated islets 
implanted in the intraperitoneal environment. Our findings suggest that the efficiency can be 
greatly improved using a simple co-encapsulation strategy. MSCs are considered safe for 
infusion into humans and have been used in clinical trials. Consequently co-encapsulation of 
islets with MSCs may be a route worth perusing in higher animals. However our studies were 
carried out with syngeneic transplantations and the next logical step would be to carry out 
allogeneic transplantations. Microcapsules are designed for immunoprotection of their cellular 
contents so it might be predicted that an allogeneic transplantation would yield similar results 
to syngeneic transplantations. Indirect activation of T cells by allogeneic islet antigens from 
microencapsulated islets can cause an inflammatory environment with activation of 
macrophages and cytokine production. It is possible that the immunomodulatory cytokines 
secreted from MSCs may inhibit T cell responses to allogeneic islet antigens, attenuating the 
inflammatory reaction, and thereby contributing the enhanced graft outcome. It is possible 
that MSCs could attenuate the pericapsular overgrowth response which can be detrimental to 
graft outcome.       
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The improvement in insulin secretion at 6 weeks ex vivo suggests that the advantage of MSCs 
is not limited to the immediate post-isolation period but can be sustained in vivo. Co-
encapsulation results in the continuous exposure of the islets to the MSCs which may confer 
an advantage for the lifetime of the graft. Indeed a proportion of recovered encapsulated 
MSCs were found to be viable after 6 weeks in vivo. The positive effect is triggered by the 
initial exposure to the MSCs but it unclear if the continued exposure is necessary to sustain the 
effect, although our data show it is not detrimental. It has been shown that islets cultured in 
MSC conditioned medium have enhanced graft functionality, suggesting co-transplantation is 
not necessary to utilise MSCs for islet transplantation (Park et al., 2010a). Although MSCs are 
being used in clinical trials the long term safety of MSC therapy has not been established. 
Therefore an MSC and islet co-culture approach without direct implantation of MSCs may be 
favoured for clinical islet transplantation. 
 
Co-encapsulation of islets with MSCs robustly improved islet function in vitro and graft 
function in vivo, confirming that MSCs can improve the efficacy of microencapsulated islet 
transplantation. Using an isolated-graft model we were able to eliminate the impact of MSC-
mediated enhancement of revascularisation, preservation of islet morphology and putative 
effects of the MSCs on the endogenous pancreas. From this we are able to confirm that the 
improvement in islet insulin secretion and insulin content observed in vitro is sustained in vivo 





6 Nano-Scale Encapsulation Improves Allogeneic Islet 




The implantation site of immunoisolated islet grafts is typically limited by the relatively large 
size of immunoisolation devices. Microcapsules are the most commonly used immunoisolation 
device for islet transplantation which increase the graft volume by around 40 fold. 
Consequently microencapsulated grafts are only suitable for large sites such as the 
intraperitoneal cavity. As a result the development of islet immunoisolation strategies which 
minimise overall graft volume are desirable. Islet conformal coatings conform to the shape of 
the islet and thereby limit unnecessary increase in volume. If such coatings can be developed 
to provide immunoisolation they may be suitable for preferred sites such as the intraportal site 
in allogeneic islet transplantation.  
 
A nano-scale layer-by-layer conformal coating approach has been developed in our lab (Zhi et 
al., 2010). The encapsulation was formed by sequential adsorption of chitosan then alginate to 
form electrostatically complexed bilayers. The desired number of bilayers was added followed 
by a final bilayer composed of chitosan and PC modified chondroitin-4-sulfate. The properties 
of alginate have been fully described in this thesis (1.2.4). The most significant property of 
alginate with regard to the nano-scale encapsulation is the negative charge of the polymer 
which allows electrostatic interaction with the positively charged polymers such as chitosan. 
The properties and relevant applications of the other materials used in the coating are 
described below.   
 
6.1.1 Nano-Scale Encapsulation Materials     
 
6.1.1.1 Chitosan 
Chitosan is formed by deacetylation of chitin which is a structural element of the exoskeleton 
of crustaceans and cell walls of fungi.  The amino groups in chitosan are positively charged in 
acidic solution conferring water solubility and an affinity for negatively charged surfaces such 
as cell membranes. Chitosan is also biocompatible and non-toxic which makes it amenable to 
use in implantable applications such as wound healing, drug and gene delivery, and tissue 
engineering. Chitosan has been used as an immunoisolation material for islet transplantation 




hydrate which solidifies at >37°C was used in the study. 500 rat islets suspended in the solution 
were injected under the kidney capsule of diabetic mice resulting in maintenance of 
normoglycaemia for 28 days. Control islets rejected within 7 days which suggests that chitosan 
per se is able to function as an immunobarrier in a non-discordant xenograft islet 
transplantation model.    
 
6.1.1.2 Chondroitin Sulfate 
Chondroitin sulfate is a glycosaminoglycan present in the ECM which is widely distributed and 
abundant in mammalian tissues. It is a structural component of cartilage and is often derived 
from cartilage. It is also used to treat cartilage related pathologies such as osteoarthritis. It has 
been established that chondroitin sulfate has immunomodulatory and anti-inflammatory 
effects (du Souich et al., 2009) and there is some evidence to suggest it has anti-oxidant 
properties (Campo et al., 2006). Chondroitin sulfate has been used as a biomaterial in islet 
transplantation studies. A microencapsulation approach using agarose and PSS based capsules 
with a chondroitin sulfate coating has been described (Takagi et al., 1994). 1000 encapsulated 
hamster islets were intraperitoneally implanted in diabetic mice resulting in maintenance of 
normoglycaemia for 77 days. Non-encapsulated grafts were rejected in 7 days and agarose 
microcapsules without PSS were rejected in 32 days. No experiment was performed to 
decipher the impact of the chondroitin sulfate coating. The authors did offer the suggestion 
that as chondroitin sulfate is degraded in the body it may have limited functional longevity. 
One step microcapsules composed of an alginate and chondroitin sulfate mixture have been 
reported (Campos-Lisboa et al., 2008). 3,500 microencapsulated human islets were implanted 
intraperitoneally into diabetic mice resulting in maintenance of normoglycaemia for 60 days. 
Non-encapsulated islet grafts failed within 3 days. An alginate alone control microcapsule 
group was not included so the impact of chondroitin sulfate cannot be determined from this 
study.    
 
6.1.1.3 Phosphorylcholine 
Phosphorylcholine (PC) is the hydrophilic, uncharged head group found on some phospholipids 
which can be bound to polymers to mimic a biomembrane surface which is resistant to non-
specific adsorption. Protein adsorption can result in coagulation, complement activation, and 
lymphocyte activation. Consequently PC modification has been applied to implantable devices 
to provide haemocompatibility (Iwasaki and Ishihara, 2005). Glucose sensors for an artificial 
pancreas have been coated with PC-modified polymer to prevent protein absorption to 




chamber has been described which prevented protein adsorption in vivo and permitted 
diffusion of insulin (Yang et al., 2004).  
  
6.1.2 Polysaccharide Multilayer Nanoencapsulation of Insulin-Producing β Cells 
Grown as Pseudoislets for Potential Cellular Delivery of Insulin 
The nano-scale encapsulation approach developed 
in our laboratory was tested in vitro using self-
assembling islet-like aggregates (pseudoislets) 
generated from MIN6 β cells (Zhi et al., 2010). 
Coating or encapsulation of cells requires the use 
of non-toxic materials which can be applied under 
physiological conditions. The encapsulation 
strategy effectively coated the islets as 
demonstrated by electron microscopy and 
fluorescence microscopy. No immediate reduction 
in cell viability was detected upon encapsulation 
and the encapsulated cells remained viable for 
over 5 weeks. An islet coating should ideally 
prevent the infiltration or adsorption of cytotoxic 
antibodies but permit the diffusion of insulin. 
Coating with an outer bilayer of chitosan-alginate partially prevented antibody adsorption 
compared to non-coated pseudoislets. However with an outer bilayer of chitosan-chondroitin-
4-sulfate the adsorption of antibody was further reduced. When stimulated with glucose or 
glucose and protein kinase C (PKC) activator phorbol myristate acetate (PMA), pseudoislets 
coated with 3 bilayers where found to be responsive to the stimuli, but insulin secretion was 
found to be 20-30% reduced compare to non-coated controls. The authors suggested that the 
nano-scale encapsulation may partially inhibit the diffusion of insulin.  
 
6.1.3 Islet Nano-scale Encapsulation for Islet Transplantation 
The current study involved a group of experiments testing a similar nano-scale encapsulation 
approach with the inclusion of PC modification of chitosan (Figure 19). Chondroitin-4-sulfate-
PC has been shown to effectively reduce protein adsorption. Chitosan is amenable to PC 
modification and may provide further resistance to protein adsorption. The sulfate group of 
each chondroitin-4-sulfate disaccharide unit is able to form a strong complex with positively 
charge chitosan to provide a durable outer layer.  
Figure 19. Schematic of nano-scale 















A series of in vitro studies were carried out by Dr Zhi which are detailed in the publication in 
the appendix (P173). To summarise, fluorophore tagged chitosan or PLL was incorporated into 
the nano-scale encapsulation to confirm islet coverage. Fluorescence could be detected for 
over 10 days and increasing the number of layers resulted in an increase in fluorescence. 
Transmission electron microscopy also confirmed coverage and a coating thickness of around 
80 nm with 4 bilayers. Using live/dead staining no difference was observed between coated 
islets at 1 week or 4 weeks, suggesting long term compatibility of the nano-scale 
encapsulation. There was no difference in apoptosis levels between control and coated islets 
at 48 h. The incorporation of alginate protected islets from apoptosis when exposed to a 
cocktail of cytokines. The incorporation of chondroitin-4-sulfate in the coating protected islets 
from apoptosis when exposed to blood serum containing complement proteins and 
antibodies. The nano-scale encapsulation also prevented the adsorption of a fluorophore 
tagged MHC class II antibody.  
 
These studies show that the nano-scale encapsulation effectively coats and is biocompatible 
with islets. The nano-scale encapsulation also offers some protection against infiltration of 
cytokines, complement, and antibodies. Following the encouraging results from the in vitro 





6.2.1 Animals  
Islets isolated from male Bagg albino C inbred mice (BALB/c) aged 6-8 weeks were used for 
perifusion studies. Male C57BL/6J mice aged 6-8 weeks were used as islet donors for syngeneic 
transplantations and male BALB/c mice aged 6-8 weeks were used as islet donors for 
allogeneic transplantations. STZ diabetic male C57BL/6J mice weighing 25g (8-10 weeks) were 
used as recipients for all transplantations.  
 
6.2.2 Nano-Scale Islet Encapsulation 
Islets were nanoencapsulated by the sequential adsorption of chitosan-PC then alginate to 
form electrostatically complexed bilayers. This was repeated until the desired number of 
bilayers was reached. A final bilayer composed of chitosan-PC and chondroitin-4-sulfate-PC 






Islets or nano-scale encapsulated islets were cultured for >16 h before perifusion then picked 
in groups of 40 per chamber. Islets were perifused with Gey & Gey buffer with 2 mM glucose 
from 0-10 min, 20 mM glucose from 10-30 min, and 2 mM glucose from 30-50 min.    
 
6.2.4 Non-Encapsulated and Nano-Scale Encapsulated Islet Transplantation 
Non-encapsulated and nano-scale encapsulated islets were both transplanted under the 
kidney capsule of diabetic mice. Mice were considered cured if blood glucose concentrations 
were ≤11.1 mM on at least 2 consecutive measurements and did not revert to hyperglycaemia 
for the remainder of the study. Reversion to hyperglycaemia was defined as the point at which 
2 consecutive measurements and all following measurements were >11.1 mM. Graft rejection 
was defined as 2 consecutive measurements >20 mM.  
 
6.2.5 Glucose Tolerance Test 
Glucose tolerance tests were carried out in cured animals at 14 days. Weight-matched, non-
diabetic, non-transplanted male C57BL/6J mice were used as controls. 
 
6.2.6 Nephrectomy 
Transplanted mice were killed when graft rejection was confirmed and the graft-bearing 
kidney removed for histological analysis. Mice which did not revert to hyperglycaemia by day 
28 had the graft-bearing kidney nephrectomised on or after day 28. Nephrectomised mice with 
2 consecutive blood glucose readings >20 mM were considered diabetic and were killed. 
 
6.2.7 Histology  
Nephrectomised kidneys were fixed in neutral-buffered formalin and the graft-bearing area of 
the kidney was paraffin-embedded and sectioned.  Immunostaining was carried out by Dr Z. 
Zhi by insulin staining of β cells to show the persistence and morphology of recovered grafts. 
The lymphocyte infiltration of grafts was also assessed by CD3 staining for T cells, and CD68 
staining for macrophages. The results of the histology are detailed in the results section and 











6.3.1 Functional Assessment of Nano-Scale Encapsulated Islets In Vitro 
The dynamic insulin secretion of non-encapsulated and nano-scale encapsulated islets were 
assessed by perifusion. There were differences between the insulin secretion profile of non-
encapsulated islets and islets nano-scale encapsulated with 2 bilayers and 4 bilayers (Figure 
20A and 20B, respectively). There were also differences between the insulin secretion profile 
of islets nano-scale encapsulated with 2 bilayers and 4 bilayers (Figure 20C). The pattern and 
reversibility of the stimulated glucose response was similar in all groups.  
Islets were exposed to 2 mM 
glucose from 0-10 min, 20 mM 
glucose from 10-30 min, and 2 
mM glucose from 30-50 min. 
These data are from a single 
experiment with three conditions 
but are displayed with separate 
plots for each combination of 
pairs of conditions (*P<0.05, Two 
way analysis of variance, n=4(1)). 
A. Non-encapsulated islets (black 
circles, solid line) and 2 bilayer 
nano-scale encapsulated islets 
(white circles, dotted line). B. 
Non-encapsulated islets (black 
circles, solid line) and 4 bilayer 
nano-scale encapsulated islets 
(white circles, dotted line). C. 2 
bilayer nano-scale encapsulated 
islets (black circles, solid line) and 
4 bilayer nano-scale encapsulated 



































































































Figure 20. Dynamic insulin 





6.3.2 Functional Assessment of Nanoencapsulated Islets In Vivo 
 
6.3.2.1 Nano-Scale Encapsulation with 2 Bilayers 
To determine the curative potential of nano-scale encapsulated islets in the absence of 
allogeneic immune challenge, syngeneic transplantations were performed. 300 non-
encapsulated islets or nano-scale encapsulated islets with 2 bilayers were transplanted under 
the kidney capsule of diabetic mice. In both groups the mice were cured by day 14 and there 
was no difference overall between the groups (Two way repeated measures ANOVA, P=0.585, 
n=3-4) (Figure 21A). Removal of the graft bearing kidney resulted in reversion to 
hyperglycaemia in all mice. Insulin staining of recovered graft sections of non-encapsulated 
and nano-scale encapsulated grafts had similar morphology. To determine the ability of the 
nano-scale encapsulation to protect against allogeneic immune challenge, allogeneic 
transplantations were performed. In preliminary experiments, 300 non-encapsulated islets or 
nano-scale encapsulated islets with 2 bilayers were transplanted under the kidney capsule of 
diabetic mice. In both groups the mice were initially cured by day 4, however the non-
encapsulated group reverted to hyperglycaemia by day 10 and the non-encapsulated group 
reverted to hyperglycaemia by day 16 (Figure 21B).  
 
 
Figure 21. Blood glucose of mice transplanted with syngeneic or allogeneic islets nano-scale 
encapsulated with 2 bilayers. 
A. Blood glucose of diabetic mice with syngeneic transplantation of 300 non-encapsulated 
islets (black circles, solid line, n=3) or nano-scale encapsulated islets with 2 bilayers (white 
circles, dotted line, n=4). Recipients were nephrectomised at 28 days as indicated by the 
arrow. B. Blood glucose of diabetic mice with allogeneic transplantation of 300 non-
encapsulated islets (black circles, solid line, n=5) or nano-scale encapsulated islets with 2 
bilayers (individual plots for each mouse, white circles, dotted lines, n=2).  
 
6.3.2.2 Nano-Scale Encapsulation with 4 Bilayers 
Due to the failure of islets nano-scale encapsulated with 2 bilayers to fully protect against 
rejection it was decided to increase the number of bilayers in the nano-scale encapsulation. 













































under the kidney capsule of diabetic mice. In the non-encapsulated group the mice were 
initially cured by day 6 however they rejected by day 13 (Figure 22). The nano-scale 
encapsulated group were cured by day 10, 2 mice rejected on day 16 and 24, but the rest of 
the mice were cured up to day 28. There was a difference overall between the groups up to 
the last measurement for the control group (day 0-17) (Mann-Whitney Rank Sum Test 
P<0.001, n=7-9). By day 28, 71% of the nano-scale encapsulated graft recipients were cured 
compared to 0% of the non-encapsulated graft recipients (Figure 22). The proportion of cured 
mice was greater in the nano-scale encapsulation group compared to the non-encapsulated 
group. There was no difference in the glucose tolerance of cured nano-scale encapsulated islet 
graft recipients and non-diabetic mice (Figure 22). Insulin staining of graft sections was present 
in nano-scale encapsulated islet grafts but almost absent in non-encapsulated islet grafts. The 
presence of T cells identified by CD3 staining and macrophages indentified by CD68 staining 





Figure 22. Transplantation of allogeneic islets nano-scale encapsulated with 4 bilayers. 
A. Blood glucose of diabetic mice with allogeneic transplantations of 300 non-encapsulated 
islets (black circles, solid line, n=9) or nano-scale encapsulated islets with 4 bilayers (white 
circles, dotted line, n=7). Rejected nano-scale encapsulated graft recipients (white squares, 
dotted line, n=2) and nephrectomised nano-scale encapsulated recipients (white circles, 
dotted line, n=5) are shown as individual plots from the point of rejection or nephrectomy. 
Mice which were cured at 28 days were nephrectomised on or after day 28 as indicated by the 
arrows. B. Survival curve of diabetic mice transplanted with non-encapsulated islets (black 
circles, solid line) or nano-scale encapsulated islets (white circles, dotted line). P<0.001 
(Kaplan-Meier Survival Analysis (Log-Rank), n=7-9). C. Glucose tolerance test of non-diabetic, 
non-transplanted mice (black circles, solid line) and 4 bilayer nano-scale encapsulated islet 








































































6.4 Discussion  
 
We have described the nano-scale encapsulation of islets with a novel layer-by-layer polyion 
complex conformal coating to improve islet transplantation outcome in allogeneic diabetic 
mouse recipients. The polymers used are charged on each monosaccharide unit which 
provides hundreds of binding sites on each polysaccharide molecule. Negatively charged 
alginate or chondroitin-4-sulfate polymers therefore interact electrostatically with positively 
charged chitosan, and chitosan interacts with the negative charge on the cell membrane. We 
have demonstrated that using the nano-scale encapsulation the layer-by-layer technique 
effectively covers islets. A uniform fluorescence on the islet was observed when a fluorophore 
was incorporated into the nano-scale encapsulation and remained stable for at least 10 days in 
vitro. The modification of chitosan with PC increased the solubility of the polysaccharide so 
that it became soluble at physiological pH as opposed to the acidic conditions required for 
unmodified chitosan. Consequently the nano-scale encapsulation could be applied under mild 
physiological conditions, and was found not affect cell viability over a period of 4 weeks.  
 
The recruitment of activated cytokine producing macrophages to the site of immunoisolated 
islets has a detrimental effect on islet viability and function (de Vos et al., 2003). We have 
demonstrated the ability of the alginate in the nano-scale encapsulation to partially inhibit 
cytokine induced apoptosis which may confer an advantage in a transplantation setting. Upon 
transplantation rapid infiltration of complement components can occur leading to lysis of islet 
cells (Tjernberg et al., 2008). We have demonstrated the ability of chondroitin-4-sulfate-PC to 
partially inhibit complement induced apoptosis which may be of particular advantage for 
transplantations in the intraportal site. MHC class II molecules present self antigens which 
trigger the host immune response in allogeneic transplantations. Using an antibody exclusion 
assay we were able to demonstrate that an anti-MHC class II was prevented from binding 
when the islet was coated. Therefore the nano-scale encapsulation may prevent an adaptive 
immune response in allogeneic transplantation models.  
 
Nano-scale encapsulation of islets with 2 bilayers inhibited insulin secretion compared to non-
encapsulated islets. A greater inhibition of insulin secretion could be observed with nano-scale 
encapsulated islets with 4 bilayers. The significant differences observed in islets with a greater 
number of layers were mostly during the 20 mM stimulated glucose period of the perifusion. 
This suggests the encapsulation is permissive to diffusion of low concentrations of insulin but 




2 to 4 increases the diffusion limitation therefore it is probable that further increasing the 
number of layers would further lower the diffusion threshold. A similar finding was reported in 
the previous study in our lab coating pseudoislets in 3 bilayers (Zhi et al., 2010). In both studies 
no evidence was found to suggest that the nano-scale encapsulation has any impact on cell 
viability, which suggests that β cell death is not a contributing factor to the reduction in insulin 
secretion observed.        
 
Syngeneic transplantations were carried out to assess the impact of the nano-scale 
encapsulation on islet graft function in the absence of an allogeneic immune response. Islets 
coated with 2 bilayers had a similar impact to non-encapsulated islets on the recipients’ blood 
glucose kinetics, effectively reversing hyperglycaemia and maintaining normoglycaemia for up 
to 28 days. Insulin staining of graft sections were similar between non-encapsulated and nano-
scale encapsulated islet grafts suggesting the coating does not affect graft structure. No 
deleterious effects were observed in the recipients and no major inflammatory reaction was 
observed by eye in graft sections, which suggests that the nano-scale encapsulation is likely to 
be non-toxic and biocompatible. Removal of non-encapsulated or nano-scale encapsulated 
islet grafts resulted in reversion to the diabetic state thereby confirming the curative ability of 
the grafts. 
 
Allogeneic transplantations were carried out to assess the ability of the nano-scale 
encapsulation to protect the islets from the allogeneic immune response. Transplantation of 
islets coated with 2 bilayers resulted in a short delay in the onset of rejection whereas 
transplantation of islets coated in 4 bilayers resulted in graft success in 5/7 of recipients for 28 
days. This indicates that the thickness of the nano-scale encapsulation is critical to graft 
success. It is likely that increasing the number of bilayers reduces the permeability and 
provides a more substantial immunobarrier to protect the islets from an immune mediated 
attack, or from triggering an immune attack. Removal of nano-scale encapsulated islet grafts 
resulted in reversion to the diabetic state thereby confirming the curative ability of the grafts. 
 
To date the most successful islet conformal coating tested in immunocompetent allogeneic 
diabetic animal models without the use of any immunosuppression has been to coat the islets 
sequentially with 3 layers of reactive PEG (Lee et al., 2007). Using a single layer of reactive PEG 
7/7 grafts rejected whereas using a triple layer of reactive PEG 4/7 graft rejected. The layer-by-
layer coating allows sequential layers of reactive PEG deposits to form a more substantial and 
effective immunobarrier. The findings from the study are similar to the current study which 




prevent allorejection. Our nano-scale encapsulation was unable to protect all of the grafts 
from rejection which suggests that the addition of more bilayers may be necessary for full 
protection. However, as there is some limitation of insulin diffusion out of the coating, 
increasing the number of bilayers may ultimately be detrimental to graft function. The best 
solution may be a balance between improving immunoprotection at the cost of decreasing 
insulin diffusion. It has been demonstrated that microencapsulated islets recovered at 6 weeks 
from grafts implanted intraperitoneally can have as much as a 10 fold reduction in insulin 
secretion compared to pre-implantation levels and still maintain normoglycaemia in recipients 
(Figure 15). It is possible that maintaining islet viability by immunoprotection may be 
preferable to preserving maximal insulin diffusion.        
 
Recovered graft sections from cured mice with encapsulated islet grafts at 28 days revealed 
grafts with normal morphology and no infiltration of T cells or macrophages. Conversely graft 
sections from rejected grafts had little insulin staining and infiltration of T cells and 
macrophages indicating allorejection. Recruitment of lymphocytes around immunoisolated 
islet grafts has been reported. Microencapsulated islet grafts transplanted intraperitoneally 
are detrimentally affected by recruitment and overgrowth of macrophages and fibroblasts on 
the capsule surface (de Vos et al., 2003).  Although it has been shown that there is less 
overgrowth under the kidney capsule compared to the intraperitoneal site (Bakeine et al., 
2007). However, triple coated reactive PEG conformal coated islets transplanted under the 
kidney capsule do recruit lymphocytes (Lee et al., 2007). It is surprising that no recruited 
lymphocytes can be detected at all in the encapsulated graft sections. Chondroitin-4-sulfate 
can reduce the formation of pro-inflammatory cytokines (du Souich et al., 2009) and PC 
modification confers resistance to protein adsorption. It is possible that the properties of these 
biomaterials may play a role in inhibiting the recruitment of lymphocytes to the immediate 
graft area. The nano-scale encapsulation may also prevent the leakage of antigens out of the 
encapsulation thereby reducing immune recruitment and activation. 
 
The nano-scale encapsulation is held together by electrostatic forces and is weak in 
comparison to other immunoisolation methods such as cross-linked alginate hydrogel 
microcapsules. Consequently it is predicted that the nano-scale encapsulation would provide 
short term protection from the inflammatory and immune responses in the early post-
transplantation period. The negligible increase in graft volume of the nano-scale encapsulation 
confers suitability for intraportal transplantation. Intraportal allogeneic transplantation of 
reactive PEG coated islets has been reported (Wee et al., 2008) although 4 times as many islets 




al., 2006c, Yun Lee et al., 2007) using the subcapsular kidney site. If these studies are 
representative, the allogeneic intraportal site may present a significant challenge for 
conformally coated islet grafts. It is therefore likely that using the current nano-scale 
encapsulation design, intraportal transplantation may be need to be augmented with low 
levels of immunosuppressants or tolerance induction mechanisms for long term graft success. 
Alternatively, it may be necessary to alter the design of the nano-scale encapsulation so that it 
is tailored for the intraportal site. For example the immobilisation of heparin or 
thrombomodulin onto the outer surface may be necessary to combat the IBMIR.  
 
We have demonstrated that a conformal coating composed of a layer-by-layer polyion 
complex can improve graft outcome in an allogeneic mouse model of T1DM. The incorporation 
of polymers with functional properties and the ability to alter the number of layers make the 
nano-scale encapsulation a unique and flexible approach. Long term and intraportal 


















7 General Discussion 
 
Clinical islet transplantation is currently an experimental therapeutic strategy for T1DM 
patients. The necessity for immunosuppression limits islet transplantation as a suitable 
therapeutic option to a small subset of patients with recurrent severe hypoglycaemic episodes, 
or to those who are already using immunosuppressants for kidney grafts. The practical reality 
for islet alone graft recipients is swapping hypoglycaemic episodes with the risks associated 
with immunosuppression. Islet transplantation without immunosuppression would reduce the 
risks predominantly to the risks associated with the surgical procedure alone. As a 
consequence islet transplantation could become a realistic option for the majority of T1DM 
patients. This is the goal of immunoisolation approaches such as microencapsulation. Recent 
clinical microencapsulated islet transplantation studies report reduction in insulin 
requirements and eradication of hypoglycaemic episodes for up to 3 years (Basta et al., 2011). 
Compared to the breakthrough study using the Edmonton protocol (Shapiro et al., 2000) of 
insulin independence in 7/7 cases, the graft outcomes are modest. However, as current islet 
transplantation recipients are selected on the basis of severity of hypoglycaemic episodes, 
reduction in hypoglycaemic episodes should be the primary therapeutic goal. If 
microencapsulated grafts are able to treat hypoglycaemic episodes with minimal risk due to 
the absence of immunosuppression then this approach may be preferable to current clinical 
islet transplantation protocols. It is early in the development of clinical microencapsulated islet 
transplantation however the future looks promising.  
 
The studies in this thesis were designed to investigate novel strategies to improve 
immunoisolated islet transplantation. It has been demonstrated that islet viability and 
functionality are greatly diminished by microencapsulated transplantation into the peritoneal 
cavity after several weeks. Transplantation into the peritoneal cavity avoids the IBMIR, and 
therefore the acute loss of islets upon transplantation, as reported with intraportal 
transplantations. Indeed after 7 days the GSIS and insulin content of microencapsulated islets 
are not significantly reduced compared to cultured islets, although ATP content levels are 
reduced. At 6 weeks there is a 4 fold reduction in insulin content and at 6 or 8 weeks there is a 
10 fold reduction in GSIS. From these results it is apparent that a gradual reduction in islet 
viability and function occurs. However microencapsulated islets can cure diabetic rodents for 
several months despite the reduced viability and functionality of the islets (Bohman and King, 
2008). This suggests that the reduction in viability and functionality of islets reaches a plateau 
and the remaining β cells are able to maintain a sufficient degree of functionality to sustain 




double the number of islets compared to non-encapsulated islet transplantations under the 
kidney capsule. There is therefore a need to investigate new approaches for 
microencapsulated islet transplantation in order to improve the maintenance of graft viability 
and efficacy.   
 
A major factor influencing islet viability and functionality of microencapsulated grafts is the 
site of transplantation.  The intraperitoneal site is conventionally used for microencapsulated 
islet grafts predominantly due to the large capacity of the site. Implanted microcapsules are 
randomly dispersed throughout the peritoneal cavity which may locate them next to a 
vascularised tissue. However the distance to the nearest capillary is likely to be large enough 
that the islets predominantly rely on passive diffusion through the intraperitoneal fluid for 
acquisition of oxygen, nutrients and glucose, and the dissemination of insulin. This results in 
insufficient oxygen and nutrients getting to the islets and a lag in insulin entering the 
circulation. Consequently the subcutaneous site was investigated as an alternative to the 
intraperitoneal site. It was discovered that microencapsulated islet GSIS, insulin content, and 
ATP content were all lower after a week transplanted in the subcutaneous site compared to 
the intraperitoneal site. Accordingly, equivalent grafts were ineffective at the subcutaneous 
site but efficacious at the intraperitoneal site. Successful transplantation of islets to the 
subcutaneous site has been reported by inducing angiogenesis at the site (Pileggi et al., 2006) 
(Dufrane et al., 2010, Lacy et al., 1991, Golocheikine et al., 2010). Indeed it has been reported 
that microcapsules composed of high-M alginate were efficacious at the subcutaneous site 
(Veriter et al., 2010). Taken together this suggests that the passive diffusion at the 
subcutaneous site is worse than at the intraperitoneal site but can be improved by induction of 
angiogenesis by materials of specific composition. The high-G alginate capsule composition 
used for the study in this thesis was not appropriate for the specific demands of the site. With 
this work we were able to highlight the comparatively poor environment the unmodified 
subcutaneous site provides compared to the intraperitoneal site, and also the importance of 
optimising the composition of alginate microcapsules for the specific task. 
 
It was established that the conventional site in the intraperitoneal cavity is preferable for 
microencapsulated islet transplantation. We decided to investigate the use of helper cells to 
enhance intraperitoneal microencapsulated islet transplantation. Helper cells have several 
advantages to drug based enhancement of islet transplantation including the ability to localise 
helper cells with the islets, physiological responsiveness, adaptation to microenvironments, 
and the ability to secrete factors continuously for the lifetime of the graft. GLP-1R agonists 




β cell proliferation (Buteau et al., 2003) and neogenesis (Xu et al., 2006), and protect β cells 
against apoptosis (Li et al., 2003). The L cells of the intestine are the major endogenous source 
of GLP-1. A study was undertaken to demonstrate the impact of co-encapsulating L cells with 
islets to improve microencapsulated islet transplantation. Transformed L cell lines were used 
due to their convenience for this proof of principle study. It was found that the L cells secreted 
GLP-1 in a glucose responsive manner and but did not stimulate GSIS in islets when co-
cultured. However, when L cells were co-encapsulated with islets it was found that GSIS was 
increased in islets, although it was not determined if the increase was GLP-1-mediated. In a 
pilot study using a minimal mass of 250 microencapsulated islets, there was a trend 
improvement in graft outcome in L cell co-encapsulated islet grafts. However when the study 
was extended, the incorporation of L cells did not improve graft outcome. It was hypothesised 
that either L cells are not beneficial for microencapsulated islet grafts or the minimal mass 
model was too stringent to detect a positive effect. Overall, it is possible that L cells can offer 
an advantage in an islet transplantation setting, however the results from the study were 
inconclusive.  
 
The use of mesenchymal stem cells as helper cells in non-encapsulated islet transplantation 
has been shown to benefit islet viability, function, and revascularisation, and to protect islets 
from alloimmune rejection by immunomodulation (Figliuzzi et al., 2009, Ito et al., 2010, Sordi 
et al., 2010b, Rackham et al., 2011, Jacobson et al., 2008, Ding et al., 2009, Solari et al., 2009, 
Longoni et al., 2010, Berman et al., 2010). Co-encapsulation of islets with MSCs was 
hypothesised to improve graft outcome and also demonstrate the importance of MSC-
mediated enhancement of revascularisation. MSC co-encapsulated islets had improved GSIS 
and insulin content, and improved graft outcome in a minimal mass transplantation model of 
350 islets per graft. Recovered co-encapsulated islets had greater GSIS, insulin content, and 
islet area than recovered encapsulated islets alone. MSCs had a positive effect on islet function 
in pre-transplantation culture which is sustained after transplantation. The MSC co-
encapsulation study also demonstrated that MSC-mediated enhancement of revascularisation 
and preservation of morphology is not necessary to improve graft outcome in islet and MSC 
co-transplantation. Studies have reported enhanced islet revascularisation and preservation of 
morphology by co-transplanting with MSCs, however we have demonstrated that MSC-
mediated enhancement of GSIS and insulin content alone enhances graft outcome.  
 
The minimal mass model of 350 islets used for the MSC study was of appropriate stringency as 
the impact of the MSCs on graft outcome could be detected. If the model is not stringent 




not be detected. Conversely if the model were too stringent, the benefit of the treatment 
would have to be large in order to be detected. From the results of the L cell study it was 
suggested that the minimal mass model of 250 islets was too stringent. Comparing the control 
groups from all of the microencapsulated studies it was found that graft masses of 250, 350, 
and 700 islets resulted in average blood glucose measurements and graft failure proportions 
(Figure 23) which were significantly different from each other over 28 days. 350 islet grafts 
were only different to 700 islet grafts at individual time-points after 21 days. However 250 islet 
grafts were different from 700 islet grafts in the first 3 days post-transplantation and then 
from 14 days onward. This data indicates that the 250 islet minimal mass model is highly 
stringent and it may therefore be difficult to detect differences in treatments using this model.   
The 350 microencapsulated islet graft seems to act as an appropriate minimal mass model, 
with average blood concentrations at day 28 between 10 mM and 20 mM.     
 
Figure 23. The impact of graft mass on microencapsulated graft outcome. 
Microencapsulated islets were transplanted intraperitoneally in graft masses of 250 (black 
circles, solid line, n=7), 350 (white circles, dotted line, n=6) and 700 (white squares, solid line, 
n=5) syngeneic islets in separate studies. A. Blood glucose measurements. *P<0.05 vs. 700 islet 
grafts, #P<0.05 vs. 350 islet grafts (Two way repeated measures analysis of variance, multiple 
comparisons versus control group (Holm-Sidak method)) B. Percentage of failed grafts. P<0.05 
(Kaplan-Meier survival analysis (Log-rank).  
 
The MSC study demonstrated that intraperitoneal microencapsulated islet transplantation can 
be improved. However the reduction in islet GSIS and insulin content decreased from pre-
transplantation levels proportionally in both control islet alone and MSC co-encapsulated islets 
post-transplantation. It is therefore clear that although MSCs improve graft outcome they 
cannot completely protect islets from the course of functional decay. Consequently we sought 
to investigate the efficacy of a novel conformal coating immunoisolation approach. The 
concept of conformal coating is to create a minimal islet immunobarrier with maximal 
diffusion and minimal impact on islet volume. Conformally coated islet grafts may therefore 




















































sites such as under the kidney capsule or the intraportal site.   It was demonstrated that the 
layer-by-layer nano-scale encapsulated islets secreted insulin, although the coating did inhibit 
secretion to some degree which was dependent on the number of layers. However nano-scale 
encapsulated islets maintained curative potential as demonstrated by blood glucose 
normalisation in syngeneic transplantations. Subsequently it was found that nano-scale 
encapsulation with 4 bilayers but not 2 bilayers was able to protect islets from allorejection for 
1 month in 5/7 recipients.  This result represents a significant advance in the field of conformal 
coating for immunoisolation of islets grafts. The study demonstrated that the layer-by-layer 
method allows a balance between diffusion limitation and immunoprotection to be optimised. 
Immunosuppressants have been used in many islet conformal coating studies (Lee et al., 
2006b, Lee et al., 2006c, Lee et al., 2006a, Yun Lee et al., 2007, Wee et al., 2008, Jeong et al., 
2011), however no immunosuppressant was used in our study. Interestingly the only other 
study to successfully transplant conformally coated islets in a fully immunocompetent 
allogeneic setting also used a layer-by-layer approach (Lee et al., 2007). Consequently the 
layer-by-layer approach is an attractive option for the development of conformal coating 
strategies.   
 
In summary, the studies presented in this thesis have made some contribution to the 
advancement of immunoisolated islet transplantation. The use of MSCs to improve 
immunoisolated islet transplantation and a novel immunoisolation approach have been 
validated. These approaches show promise for development into the clinic. The use of MSCs 
for immunoisolated islet grafts has the potential to reduce the number of islets necessary for 
successful transplantation and may improve outcomes in higher animal studies. The use of 
nano-scale encapsulation has the potential to equalise the number of islets used in non-
immunoisolated and immunoisolated grafts. With improved graft efficacy a stronger case can 
be made for the development of immunoisolation approaches for islet transplantation into the 
clinic.  
 
7.1 Future Work 
 
The subcutaneous site was unable to support the viability of implanted microencapsulated 
islets. As safety is a priority in the development of novel therapeutic approaches the 
subcutaneous site is worth perusing for immunoisolated islet transplantation despite the 
challenges it presents. Strategies which may improve the outcome at the site are based around 




minimising the immunoisolation device by using nano-scale encapsulation for example. It is 
likely that this alone would be insufficient and would need to be coupled with angiogenic 
modification of the site. It is possible that the angiogenic properties of MSCs could be applied 
in subcutaneous islets grafts by co-transplantation or co-encapsulation of MSCs and islets. 
 
The positive effect of co-localising islets with L cells was not as reliable or pronounced in 
comparison to the effects observed using MSCs. As a result it is difficult to justify the 
continuation of the L cell work. However one important distinction between the two bodies of 
work is the derivation of the cells. It is possible that primary cells are better suited for 
application as helper cells and it would satisfy curiosity to try using primary L cells.   
 
As MSCs are already used therapeutically the development of co-encapsulation of islets with 
MSCs for clinical application is feasible. The MSC study demonstrated that MSCs can enhance 
microencapsulated islet graft function in a syngeneic transplantation model. As MSCs are 
immunomodulatory it is hypothesised that in addition to the enhancement of islet 
functionality MSCs mediated in a syngeneic setting, they may also attenuate immune 
responses such as overgrowth in an allogeneic setting. The immunomodulatory properties of 
MSCs may also be applicable to pig islet xenotransplantation. There is interest in pig islets as 
an alternate source of islets to fill the donor shortage gap. However due to the high 
immunological discordance, immunosuppression at efficacious doses cannot be safely used 
and therefore immunoisolation approaches are necessary. Therefore it would be of interest to 
investigate if MSCs are also able to improve microencapsulated pig islet xenotransplantation.  
 
By co-encapsulating islets with MSCs, the MSCs were located with the islet throughout the islet 
and MSC co-encapsulation transplantation study. The MSCs enhanced islet function in culture, 
however it was not determined if MSCs continue to have an impact on islet function post-
transplantation. Studies simulating the conditions in vivo such as using cytokines or hypoxic 
conditions could give an indication of whether it is beneficial to have MSCs co-encapsulated 
with the islets post-transplantation. Alternatively co-culture of MSCs with microencapsulated 
islets alone prior to transplantation may be sufficient, which would avoid transplanting the 
MSCs and therefore avoid increasing the risk of transplantation.  
 
The conformal coating study had an endpoint of 28 days as the initial objective was to 
determine if the nano-scale encapsulation could protect islets from early post-transplantation 
rejection. It would be interesting to determine if grafts stabilised at 28 days could continue to 




kidney capsule of mice as the model allows for ease of implantation and the possibility of 
retrieving the graft and confirming graft efficacy. However, there is interest in developing 
conformal coatings which can immunoprotect islets in the conventional clinical intraportal site. 
It is possible that the nano-scale encapsulation could provide an advantage at the site. 
However poor results from other studies suggest that the rapid inflammatory and immune 
responses in this lymphocyte rich site may present challenges not present to the same degree 
under the kidney capsule (Wilson et al., 2011, Wee et al., 2008). It may be necessary to modify 
the nano-scale encapsulation by functionalisation. For example anticoagulant molecules could 
be incorporated onto the outer layer of the coating to combat the IBMIR. Overall the nano-
scale encapsulation approach which was validated in an allogeneic transplantation model in 
this thesis represents a novel and potentially versatile approach for immunoisolation of islets.  
The use of MSCs and nano-scale encapsulation have both proved to enhance islet graft 
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Abstract
Aims/hypothesis The success of islet transplantation as a
treatment for type 1 diabetes is currently hampered by
post-transplantation loss of functional islets through adverse
immune and non-immune reactions. We aimed to test
whether early islet loss can be limited and transplant survival
improved by the application of conformal nano-coating layers
to islets.
Methods Our novel coating protocol used alternate layers of
phosphorylcholine-derived polysaccharides (chitosan or
chondroitin-4-sulphate) and alginate as coating materials,
with the binding based on electrostatic complexation. The
in vitro function of encapsulated mouse islets was studied
by analysing islet secretory function and cell viability. The
in vivo function was evaluated using syngeneic and allogeneic
transplantation in the streptozotocin-induced mouse model of
diabetes.
Results Nano-scale encapsulated islets retained appropriate
islet secretory function in vitro and were less susceptible to
complement- and cytokine-induced apoptosis than non-
encapsulated control islets. In in vivo experiments using a
syngeneic mouse transplantation model, no deleterious
responses to the coatings were observed in host animals,
and the encapsulated islet grafts were effective in reversing
hyperglycaemia. Allo-transplantation of the nano-coated
islets resulted in preserved islet function post-implantation
in five of seven mice throughout the 1 month monitoring
period.
Conclusions/interpretation Nano-scale encapsulation offers
localised immune protection for implanted islets, and may
be able to limit early allograft loss and extend survival of
transplanted islets. This versatile coating scheme has the po-
tential to be integrated with tolerance induction mechanisms,
thereby achieving long-term success in islet transplantation.
Keywords Allogeneic transplantation . Graft survival .
Immunoisolation . Islet transplantation . Nano-coating .
Nano-scale encapsulation . Type 1 diabetes
Abbreviations
HBSS Hanks’ buffered salt solution
PC Phosphorylcholine
PEG Polyethylene-glycol
TEM Transmission electron microscopy
Introduction
Islet transplantation is arguably one of the most important
conceptual advances in the treatment of type 1 diabetes and
has the potential to cure the disease [1]. A major barrier to
successful transplantation is early post-transplantation deple-
tion of functional islets in response to activated complement
and coagulation systems, and to a chronic inflammatory and
immunogenic environment [2–5]. This has obvious detrimen-
tal effects on the outcome of individual grafts and further
exacerbates the scarcity of donor tissue. Moreover, allogeneic
transplantation requires pharmacological suppression of the
host immune system to circumvent graft rejection, while
current immunosuppressive regimens are likely to contribute
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to the early loss of engrafted islets [6]. A strategy that conceals
implanted islets from the host immune system may help to
minimise or even prevent the post-transplantation loss of islet
mass and function by immune rejection. Thus physical isola-
tion of islets from the host environment by encapsulation,
while maintaining islet responsiveness to metabolic changes,
could be an effective means of improving islet survival and
function after transplantation.
Islet encapsulation strategies to date have mainly focused
on macrocapsules (encapsulation of the whole islet graft)
and microcapsules (encapsulation of individual islets) [7].
Previous studies in animal models [8, 9] and in human
participants [10, 11] have demonstrated that physical isola-
tion of islets from the host immune system by, for example,
alginate microencapsulation is effective in preventing beta
cell loss and in maintaining long-term secretory function in
transplanted allogeneic and xenogeneic islets without sys-
temic immunosuppression [12–16]. Although conferring the
immunological advantages predicted from graft/host isola-
tion, microcapsules have some significant drawbacks. Thus
the relatively large volume of a typical alginate capsule
(diameter ∼500–800 μm) compared with a typical islet
(∼150 μm) results in a greatly increased diffusion length,
which can lead to impaired diffusion of oxygen and
nutrients to the islet, with consequent hypoxic cell death or
malfunction. A more immediate consequence of the size of
microcapsules is the choice of anatomical location for the
graft material, with most experimental studies focussing on
intraperitoneal or subcutaneous compartments due to their
large capacity [17]. In contrast, intraportal infusion is the
current site of choice for clinical programmes [1], with the
transplanted islets lodging in the hepatic microcirculation.
An encapsulation technology designed for application to
current clinical transplantation of human islets must there-
fore be compatible with intraportal delivery to the hepatic
capillary bed, excluding microcapsules or macrocapsules on
the basis of their size.
Conformal nano-coating avoids these problems by gen-
erating a biocompatible nanometre-scale isolating layer
close to the cell surface, thus reducing barriers to diffusion,
while ensuring that the encapsulated islets can be implanted
into any site suitable for non-encapsulated islets [7]. The
challenge with conformal nano-coating is to nano-engineer
an efficient and lasting immune-protective layer that covers
islets completely or nearly completely, and is biocompatible
with the recipient.
Several methods of conformal coating have been devel-
oped recently, including covalent surface attachment of
polyethylene glycol (PEG), known as ‘PEGylation’ [18],
and layer-by-layer encapsulation [19–28]. Nano-layers with
different combinations of components, including streptavidin
and biotin–PEG derivatives [19, 24], complement receptor 1
and heparin [25], and PEG–lipid and poly(vinyl alcohol)
[26, 27], have been previously researched as islet surface
coatings. Most of these attempts at islet encapsulation have
focused on development of the method, with relatively little
emphasis on in vivo evaluation of the technology, and partic-
ularly on the maintenance of functional beta cells in an allo-
geneic environment. Teramura and Iwata demonstrated that
coating of islet surfaces with PEG-lipid and urokinase could
effectively protect against blood-mediated inflammatory reac-
tions in a syngeneic mouse model of transplantation [23].
However, a recent study using conformal coating to encapsu-
late islets via layer-by-layer deposition of poly(L-lysine)-g-
PEG-(biotin) and streptavidin failed to show any improve-
ment in the survival and function of the implanted allo-islets
[19]. Effective immunoprotection using nano-coating thus
remains a challenge in islet transplantation.
Layer-by-layer nanofilm deposition has been studied ex-
tensively in connection with the coating of biodevices such
as implants in biomedical applications [29, 30]. In the cur-
rent study, we aimed to adapt this technology to produce a
conformal nano-coating for islets, which covers individual
islets in nano-layers that possess anti-coagulation and anti-
inflammatory properties [31, 32], thus achieving effective
encapsulation without significantly increasing the size of the
islet. Charged linear polysaccharides carrying phosphoryl-
choline (PC) modification were used as coating materials
(Fig. 1), with the binding being based on electrostatic inter-
actions. As demonstrated previously [33], layer-by-layer
deposition of alginate–chitosan nano-layers provides a mild
process (near physiological conditions) that does not in-
volve covalent cross-linking, it is therefore able to leave
the cell surfaces and cell interior undisturbed. In this study,
we investigated the localised immune protective effects of
biopolymer nano-coating of islets and tested whether nano-
scale encapsulation improves early outcomes from syngeneic
and allogeneic islet transplantation in the commonly used
streptozotocin-induced mouse model of type 1 diabetes.
Methods
A more detailed description of research design and methods,
including regents and materials, is available in the electronic
supplementary material (ESM Methods).
Experimental animals For syngeneic transplantation, male
C57BL/6 mice aged 8 weeks and weighing 20–25 g
(Charles River, Margate, UK) were used as donors and
recipients of grafts. For allogeneic transplantation, male
C57BL/6 mice were used as islet graft recipients and Balb/
c mice as tissue donors. Recipient mice were made diabetic
by a single i.p. streptozotocin injection (180 mg/kg; Sigma-
Aldrich, Poole, UK) 5–6 days prior to transplantation and
those with a non-fasting blood glucose concentration of
Diabetologia
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≥20 mmol/l were used as recipients. All animal procedures
were approved by our institution’s Ethics Committee and
carried out under licence, in accordance with the UK Home
Office Animals (Scientific Procedures) Act 1986.
Islet isolation Islets were isolated from mice by injecting
collagenase (type XI, 1 mg/ml; Sigma-Aldrich) into the
pancreas via the common bile duct, followed by digestion
for 10 min at 37°C. The islets were purified by centrifugation
(3,500 rpm, 25 min; Universal 320R, Hettich Zentrifugen,
Tuttingen, Germany) in a density gradient (Histopaque-
1077; Sigma-Aldrich). Before being used for encapsulation,
the purified islets were incubated for 16 h in RPMI-1640
medium (Sigma-Aldrich) that was supplemented with 10%
fetal bovine serum, 100 U/ml penicillin and 0.1 mg/ml
streptomycin.
Nano-coating of islets The working solutions of the polysac-
charides, including PC-chitosan, alginate and PC-modified
chondroitin-4-sulphate (1 mg/ml; Fig. 1), were prepared by
dissolving the solids in Hanks’ buffered salt solution (HBSS;
PAA Laboratories, Pasching, Austria), which was pH-
adjusted to 6.9–7.0 and supplemented by 2 mmol/l CaCl2.
Positively charged chitosan-PC and negatively charged algi-
nate (unmodified) were alternately deposited into a multilayer
film on individual islets in suspension in a 1.5 ml Eppendorf
tube. Cationic chitosan-PC (400 μl) was added first to a
suspension of the islets (pre-washed with HBSS) to form a
seeding layer. After 5 min deposition time, two intermediate
washings with the buffer were made using gravity sedimen-
tation for 1 to 2 min to remove any excess, unadsorbed
chitosan-PC. Subsequently, anionic alginate (400 μl) was
adsorbed in the same manner. This process was repeated n
times per batch of islets according to the following layering
scheme: islets/(chitosan-PC–alginate layers)n, where n repre-
sents the number of bilayers. Finally, a PC-modified
chondroitin-4-sulphate (400 μl) layer was added as the outer-
most layer in the same manner as for alginate. Some loss of
islets was incurred, totalling <10% for a typical eight-layer
coating process. All encapsulation solutions were filtered
through a sterile 0.2 μm membrane filter cartridge. All
coating, washing and sample solutions were kept on ice dur-
ing the coating process.
Dynamic insulin secretion from the encapsulated islets En-
capsulated islets were incubated for 16 h (37°C) before
perifusion. The rate and patterns of in vitro insulin secretion
from encapsulated and control islets were assessed using a
temperature-controlled (37°C) multi-channel perifusion sys-
tem, as described previously [34]. Briefly, 40 islets were
loaded on to nylon filters in Swinnex filter holders (Millipore,
Cork, Ireland) and perifused with a bicarbonate-buffered
physiological salt solution (Gey& Gey buffer, made in house)
supplemented by 2 mmol/l CaCl2, 0.5 mg/ml bovine serum
albumin and a concentration of glucose as indicated below.
Fractions were collected every 2 min during (1) a 10 min
perifusion period with buffer containing 2 mmol/l glucose, (2)
a 20 min perifusion with 20 mmol/l glucose and (3) an
additional 20 min perifusion with 2 mmol/l glucose. Insulin
content was assessed by radioimmunoassay [34].
Transplantation of encapsulated islets in diabetic mice Mice
were anaesthetised by inhalation of isoflurane and trans-
planted with 300 islets under the kidney capsule, according
to a procedure reported previously [35]. Briefly, a lumbar
incision was made, the kidney exposed and an incision
made in the capsule. Encapsulated and control islets that
had been centrifuged into pellets in PE50 polyethylene
tubing (Becton Dickinson, Franklin Lakes, NJ, USA) were
placed underneath the kidney capsule using a Hamilton
syringe (Fisher, Two Rivers, WI, USA). All islets were trans-
planted with a delay of no more than 2 h after encapsulation.
In vivo function of islet graft The body weight and blood
glucose concentrations of recipient mice were monitored
every 1–2 days. Reversal of hyperglycaemia was defined
as non-fasting blood glucose concentrations ≤11.1 mmol/l on
at least two consecutive readings. In cured animals, we
assessed the in vivo function of the transplanted islets by an
intraperitoneal glucose tolerance test at 1 month after trans-
plantation. Weight-matched, non-diabetic, non-transplanted




































Fig. 1 Chemical structure of the PC moiety-functionalised polysaccharides used in the nano-scale encapsulation. (a) PC-modified (40% of the amine
groups) chitosan (protonated); (b) PC-modified (100% of the carboxylic group) chondroitin-4-sulphate (deprotonated); and (c) PC
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glucose concentrations weremeasured prior to an i.p. injection
of 2 g/kg of glucose dissolved in saline solution and then after
15, 30, 60, 90 and 120 min. The islet graft-bearing kidneys
were removed 1 or 2 days later to assess whether graft removal
would result in a reversion to hyperglycaemia. Other mice in
which the graft was rejected in less than 28 days were killed
and the graft-bearing kidney removed for histological
analysis.
Immunohistochemistry Detailed descriptions of histological
and immunohistological analysis of the graft-bearing
kidneys is available in the ESM Methods.
Statistical analysis Independent t tests were used to test for
significant difference between individual groups of the cy-
tokine assay results and glucose tolerance data. Values of p<
0.05 were considered significant.
Results
Deposition of coating layers on islets We used a nano-scale
encapsulation approach that uses spontaneous deposition
of alternate layers of charged linear polysaccharides (PC-
chitosan/alginate) as coating materials, with a final layer of
PC-modified chondroitin-4-sulphate, as illustrated in Fig. 2.
The nano-coated C57BL/6 mouse islets showed better phys-
ical strength than the uncoated ones, as evidenced by an
increase of 20–30% in packed tissue volume for the same
amounts of islets when loaded in PE50 polyethylene trans-
plantation tubing.
The deposition of eight layers was assessed by fluores-
cence microscopy following the incorporation of two layers
of PC-chitosan tagged with FITC in the fifth and seventh
layers. As shown in Fig. 3a, the addition of the FITC-tagged
layer to the islets resulted in strong fluorescence localised on
the surface of the islets, which is consistent with their
extracellular architecture and indicates uniform coverage.
A few bright spots found on the surfaces of islets may have
been due to the higher surface charges that can occur on cell
or extracellular surfaces. The above image (Fig. 3a) was
taken shortly after encapsulation; however, the coating was
found to be stable in culture throughout 10 days of monitoring
(ESM Fig. 1). Due to the instability of FITC under paraffin-
embedding conditions, we also generated fluorescence-
labelled islets by incorporating poly-L-lysine tagged with
Alexa Fluor 647 in the seventh layer as a fluorescent marker
(see ESMMethods) (Fig. 3b). The cross-section of the labelled
islet showed that the exterior islet surfaces were completely
covered and that the coating was localised extracellularly
(Fig. 3c). Note that the thickness of the fluorescent layer ring
could have been affected by the surface roughness of the islet
and the position of the section taken from the islet.
The deposition of the non-labelled polysaccharide multi-
layers on the individual islets was further confirmed by
high-resolution transmission electron microscopy (TEM)
imaging of the encapsulated islets (Fig. 3d; ESM Methods).
The ultrastructural image showed an intact coating consist-
ing of nano-layers of approximately 80 nm thickness that
covered the outer surface of cells on the islet periphery. The
nano-layer was not found in the extracellular space between
the islet cells. Insulin-secreting vesicles (dense-core gran-
ules) were seen by TEM to be aligned along the plasma
membrane ready for exocytosis, suggesting that beta cells





Fig. 2 Schematic representation of the nano-scale encapsulation of
pancreatic islets, with layer-by-layer deposition of charged polysac-
charide multilayers on individual islet surfaces. Blue lines with +
symbol, chitosan-PC; red lines with − symbol, alginate; green lines








Fig. 3 Confirmation of the nano-scale encapsulation of mouse islets.
a Deposition of eight layers with incorporation of two layers of PC-
chitosan tagged with FITC into the fifth and seventh layers. Scale bar
50 μm. b Fluorescence labelling of islets by incorporation of Alexa
Fluor 647-tagged poly-L-lysine into the seventh layer as a fluorescent
marker. Scale bar 100 μm. c Cross-section of a coated islet with an
incorporated layer of Alexa Fluor 647-tagged poly-L-lysine (formalin-
fixed and paraffin-embedded), showing that the nano-layer appears to
completely cover the islet surface. Scale bar 50 μm. d TEM micro-
graph of the cross-section of an islet encapsulated by an eight-layer
coating (consisting of PC-chitosan, alginate and condroitin-4-sulphate
as described in Methods, non-labelled). Islets were imaged shortly after
completion of coating. Scale bar 100 nm
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In vitro cytotoxicity exerted by the coating materials After
maintenance in culture for up to 4 weeks, the survival of
encapsulated mouse islet cells within eight layers was
assessed using a two-colour fluorescence live–dead cell
assay with the cell-permeable esterase substrate, fluorescein
diacetate, and the cell-impermeant nucleic acid stain, propi-
dium iodide (ESM Methods). Most of the cells in the islet
were viable after 1 and 4 weeks of culturing, indicating that
islets tolerated the multi-step nano-coating process with no
or little detectable loss in cell viability (Fig. 4a, b).
In addition, no elevated level of apoptosis in the nano-
coated islets was detected after 48 h in culture compared
with non-encapsulated islets, as shown in Fig. 4c (see ESM
Methods). The rate of islet cell apoptosis (determined as
caspase-3/7 activity) in control islets was increased by ap-
proximately 620% following exposure to combined cytokines
(IL-1β 1.7 ng/ml, TNF-α 1.7 ng/ml and IFN-γ 3 ng/ml), but
this was significantly less in the nano-coated islets. The neg-
ative coating layer with alginate was more potent in inhibiting
cytokine-induced cell damage than chondroitin-4-sulphate-
PC. Nano-coated islets were also protected against apoptosis
mediated by complement (50% rabbit serum; Fig. 4d).
Chondroitin-4-sulphate-PC, an anti-coagulatory molecule
[31, 32], was found to provide a better protective effect than
alginate. Based on the findings above, the coating scheme
adopted for our in vivo experiments used chitosan-PC and
alginate in repeated layers, with the last layer being
chondroitin-4-sulphate-PC.
Assessment of the in vitro function of nano-scale encapsulated
islets Dynamic insulin secretion of the encapsulated islets
was studied and compared with control using a perifusion
system that simulates physiological conditions. As shown in
Fig. 5, the four-layer encapsulated mouse islets retained
glucose-induced insulin secretory responses. Increasing the
glucose concentration from 2 to 20 mmol/l induced a rapid,
biphasic and reversible stimulation of insulin secretion from
islets encapsulated with four layers, with identical or similar
response patterns from control islets. Increasing the nano-
film thickness to eight layers caused a small reduction in the
kinetics and overall amount of insulin released, but the
pattern and reversibility of the glucose-induced response
were maintained.
In vivo assessment of nano-scale encapsulated islet function:
syngeneic transplantation Figure 6a shows the data from
islet transplantation under the kidney capsule from
C57BL/6 donor mice (300 islets/graft) to diabetic recipients
of the same strain. As expected, implantation of non-
encapsulated islets as a control reversed hyperglycaemia
and restored normoglycaemia for the duration of the study
(4 weeks). Nano-scale encapsulated islets with four layers





































































Fig. 4 Live–dead cell staining in coated islets. Nano-coated islets
within eight layers of PC-chitosan and alginate were stained with
fluorescein diacetate (green) and propidium iodide (red), and visualised
(a) after 1 week and (b) at 4 weeks post-encapsulation of maintenance
in culture. Green shows viable and red (dots) non-viable cells/islets.
Similar data on uncoated islets can be found in our previous paper [28].
c Activity of caspase-3 and -7 in the eight-layer-encapsulated and
control (non-encapsulated) islets, with (white bars) and without
(hatched bars) exposure to cytokine combination (IL-1β, TNF-α and
IFN-γ). Data were normalised against the value of control non-coated
islets without cytokines. Ch, PC-chitosan; Alg, alginate; CS,
chondroitin-4-sulphate. d Activity of caspase-3 and -7 in islets as
above (c) after 24 h in culture with 50% rabbit serum. Data were
normalised against the value of control non-coated islets exposed to
the serum. Values (c, d) are mean±SD; n03; *p<0.05 for PC-chitosan/
Alg or PC-chitosan/condroitin-4-sulphate-coated islets vs control islets
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time course similar to that of control islet grafts, in agree-
ment with the functionality displayed in in vitro analyses.
All mice reverted to the hyperglycaemic state on removal of
the graft-bearing kidney (Fig. 6a). Subsequent histological
assessment of graft material retrieved 28 days after implan-
tation showed the presence of insulin-positive islet cell mass
in the graft (Fig. 6b, c). There were no morphological differ-
ences between control and encapsulated islet grafts, with
normal patterns of immunostaining for insulin, and no de-
tectable major T cell (CD3 as the biomarker) and host
macrophage (CD68 as the biomarker) infiltration at the graft
sites (ESM Fig. 2).
In vivo assessment of nano-scale encapsulated islet function:
allogeneic transplantation To assess whether encapsulation
offers effective protection against immune rejection, we also
performed studies using an allogeneic islet transplantation
model, in which 300 Balb/c islets (H-2d) were transplanted
below the kidney capsule of streptozotocin-induced diabetic
C57BL/6 mice (H-2b). Transplanted islets reversed hypergly-
caemia within 2–4 days. Animals implanted with control islets
reverted to hyperglycaemia (blood glucose >11.1 mmol/l)
within 10 to 14 days (median survival time 12 days)
(Fig. 7a), consistent with graft rejection by the host im-
mune system. Subsequent histological analysis of the non-
encapsulated islet graft material revealed complete loss of the
islet mass with little or no immunoreactive insulin being de-
tectable (Fig. 7d). T lymphocytic and macrophage recruitment
at the subcapsular implantation site was observed (ESM
Fig. 3). Islets nano-encapsulated with four layers also reverted
to hyperglycaemia, albeit a few days later (median survival
time 15 days), suggesting that this level of encapsulation was
not sufficient to prevent immune rejection (ESM Fig. 4).
Protection from immune assault was more successful in a
further study, in which we implanted islets coated with eight
layers in the allogeneic model. In this study, the graft material
was retrieved after about 1 month for histological analysis.
Nano-scale encapsulated islets maintained normoglycaemia
for 28–37 days (Fig. 7b) in five of seven mice. Reversion to
hyperglycaemia for mice receiving encapsulated islet trans-
plants was caused by graft-bearing kidney removal. Two mice
receiving the encapsulated islets reverted to hyperglycaemia
in less than 28 days due to rejection.
To determine whether transplanted islets secrete insulin
and maintain glycaemic control in response to increases in
blood glucose levels, we carried out intraperitoneal glucose



































Fig. 5 Dynamic insulin production in vitro in control (non-encapsu-
lated) and encapsulated (PC-chitosan, alginate, condroitin-4-sulphate)
Balb/C mouse islets in response to changes in extracellular glucose.
Insulin secretion in response to the glucose challenge as a function of
time was studied in a temperature-controlled cell perifusion system.
Non-encapsulated islets (black squares) and encapsulated islets with
four (black circles) and eight layers (black triangles) are shown. Periods
of glucose stimulation and glucose concentration were as indicated.
Values are mean±SD; n04
























Fig. 6 Syngeneic transplantation of the encapsulated islets. a STZ-
induced hyperglycaemia was reversed by implantation of 300 islets of
either control (black circles) islets or islets encapsulated with four
layers (PC-chitosan, alginate, PC-chitosan, PC-condroitin-4-sulphate)
(black squares). Graft removal (upright arrow) caused reversion to
hyperglycaemia. Values are mean±SEM; n06. b Histological analysis
of recovered representative graft sections (5 μm) of encapsulated and
(c) non-encapsulated (control) islets using insulin immune-staining
(brown). Scale bars 50 μm
Diabetologia
Author's personal copy
had remained normoglycaemic. Figure 7c shows that the
change in glucose level was similar to that of non-diabetic
mice. Histological analysis of the recovered grafts showed
significant amounts of insulin-positive tissue (Fig. 7e) and
no evidence of infiltration of T cells into the islets, although
a few macrophages were detected (ESM Fig. 3).
Discussion
We describe here a new protocol for nano-scale encapsula-
tion of pancreatic islet cells and for the first time demon-
strate in an animal model improved post-transplant survival
of such coated islet cells in comparison with uncoated islets.
Alternate layers of PC-grafted polysaccharides (chitosan
and chondroitin-4-sulphate) were used with alginate as the
coating materials, with the binding being based on electro-
static complexation. Multilayer film formation is possible
because of charge reversal on the film surface after each
adsorption step. The polysaccharides we used contain at
least one charge in each monosaccharide unit, which serves
as the binding site, offering hundreds of binding sites for
each polysaccharide molecule, thus providing a strong affinity
to the charged cellular surfaces. The rationale for using
these polymers in the layer architecture was based on
our in vitro studies, which identified potential complement-
and inflammation-inhibitory activities of these polysacchar-
ides (Fig. 3c, d). Any success of islet encapsulation in extend-
ing graft survival in this study is likely to be dependent to a
large part on the ability of the nano-coating to control the local
transplant microenvironment and restrict immune cell infiltra-
tion, essentially blocking a variety of protein–protein interac-
tions involved in complement (molecular mass 500 kDa),
macrophage and T cell activation. In this regard, we intro-
duced the protein-repelling zwitterionic PC modification
(Fig. 1) in the coating constructs to minimise interactions
between islets and the environment. The PC moiety, which
is a component of plasma cell membranes, confers hydro-
philicity, haemocompatibility and resistance to non-specific
protein absorption, thus inhibiting the development of fibrosis,
supporting endothelial cell growth [36] and also carrying anti-
coagulatory properties [37, 38], all of which should enhance
islet survival in vivo and encourage host integration. In addi-





























































Fig. 7 Allogeneic transplantation of non-encapsulated (a) and eight-
layer-encapsulated ((PC-chitosan and alginate)3 + PC-chitosan + PC-
condroitin-4-sulphate) (b) Balb/c islets reversed STZ-induced hyper-
glycaemia in diabetic C57BL/6 mice. Blood glucose concentrations of
the individual animals (colour + symbol) are shown. Upright arrows
(b), day of nephrectomy. c Intraperitoneal glucose tolerance tests were
performed 4 weeks post-transplantation on mice with encapsulated
islets (black circles) and on non-diabetic, non-transplanted mice as
controls (black squares). Values (a–c) are mean±SEM; n05; (c) p>
0.05 for each data pair. d Histological analysis (insulin immune-
staining, brown) of recovered representative graft-bearing kidney capsu-
les in control non-encapsulated islets and (e) eight-layer-encapsulated
islets. Scale bars 50 μm
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chitosan increased the solubility of the polysaccharide up to
about 2 mg/ml under physiological pH conditions (pH∼7.0).
Using the layer-by-layer deposition technique, a defined
multilayer coating containing PCmodification could be immo-
bilised on the islet cell surfaces (ESM Fig. 5). The thickness
(80 nm) of a typical eight-layer coating, as measured by TEM,
is consistent with that previously reported with similar polymer
sizes (200 nm with 20 layers) [39]. The addition of a polymer,
chondroitin-4-sulphate, that carried a strongly ionic sulphate
group into the complexation pair confers anti-coagulatory
properties to the coating. It also contributes greatly to the
stability of the layered nanofilm [40], making it a very durable
coating even under harsh physiological conditions.
The nano-scale encapsulated mouse islets were found to
preserve appropriate islet secretory function and survival in
vitro. This indicates that the multilayers of the polysaccharides
were deposited non-covalently on to the cell surfaces without
perturbing cellular physiology or compromising cell survival.
Pro-inflammatory cytokines, including IFN-γ, TNF-α and IL-
1β, are major products of activated effective T cells and
macrophages, and are known to be damaging to pancreatic
islets via apoptosis induction [41]. In this study, we found that
the nano-coating also rendered the islets less susceptible to
cytokine- and complement-induced apoptosis (Fig. 4c, d). In
addition, we found that the PC-displayed nano-coating effec-
tively inhibited specific adsorption of large molecules of the
immune systems (IgG, 150 kDa) on to the islet cell surfaces
(ESM Fig. 6), indicating the effectiveness of the non-fouling
PC-modification of the coating materials.
We used the syngeneic transplantation model to assess the
in vivo secretory functionality of nano-scale encapsulated
mouse islets and their ability to reduce hyperglycaemia and
maintain normoglycaemia thereafter. These studies were used
to avoid any influences of graft-versus-host immune rejection
on islet function, while focusing on how the coating layers
could impact on the immediate inflammatory reaction. Our in
vivo tests using the syngeneic mouse transplantation model
showed no deleterious responses from host animals to the
coating materials, suggesting the materials used for encapsu-
lation are non-toxic. Allo-transplantation studies in present
work have shown that tailored encapsulating layers could
optimise islet function post-implantation, allowing a degree
of protection against inflammation and immune rejection in
the majority of the studies. In the current study, nano-scale
encapsulated islets were responsive to a hyperglycaemic en-
vironment, secreted appropriate amounts of insulin to restore
normoglycaemia and survived for an extended period in vivo.
The failure of encapsulation to prevent rejection in two of
the seven animals studied is of note and may indicate
incomplete coating before transplantation or degradation at
some time after transplantation. Future studies will need to
test whether the robustness or completeness of the coating
can be improved.
Since the purpose of our study was to prevent or reduce
early-stage islet loss, we considered that a 4–5 week post-
transplant observation period was appropriate. The rejection
in controls normally occurs at 10–14 days (Fig. 7a), so the
chosen study period showed that graft survival was twice as
long. We have to look at grafts when the animals are normo-
glycaemic to determine whether there are any signs of graft
destruction or whether the graft has a normal histological
appearance. A long-term study of the function and graft sur-
vival with this multilayer coating scheme has not yet been
performed. Nevertheless, unlike the arguably more expected
durability of alginate microcapsules [15, 42], the nano-layers
used in this study, while being non-biodegradable, are not
expected or intended to last for many months under in vivo
conditions. Rather, we propose that nano-scale encapsulation is
an alternative technology that may promote engraftment by
allowing intraportal administration and by limiting early islet
loss caused by exposure to an inflammatory environment. In
fact, our in vitro cytokine exposure study (Fig. 3c, d) confirmed
that the encapsulation layers were protective against the cyto-
toxic effects of cytokines and complement proteins, as assessed
by a reduction of apoptosis. Thus by the integration of graft
tolerance inductionmechanisms, the encapsulated environment
may promote the development of regulatory T cells, which
inhibit unintended host immune system activation, thereby
achieving permanent survival of the transplanted islets [43, 44].
Studies are now needed to test whether modifications of
the nano-layers will enhance engraftment and prevent rejec-
tion of islets in the longer term. This may involve: (1)
incorporating bioactive molecules such as complement and
coagulation inhibitors into the layers to prevent islet loss
caused by the instant blood-mediated inflammatory reac-
tion; (2) incorporating anti-inflammatory agents to reduce
localised inflammation and fibrosis; or (3) incorporating
natural and/or artificial extracellular matrices to provide
optimal cell functioning after engraftment. Since there is
little or no increase in size and volume of the islets after
encapsulation, we expect this protocol will be potentially
suitable for hepatic implantation via intraportal infusion.
Such an option now needs to undergo experimental testing.
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Electronic supplementary material  
Detailed Research Design and Methods  
Reagents and materials. Tissue culture reagents, including RPMI-1640 medium, 
penicillin, streptomycin,  fetal bovine serum, chitosan (low molecular weight, 50−190 
kDa, 75% deacetylation) and alginic acid sodium salt from crown algae, viscosity of 2% 
solution at 25 °C, 250 cps, molecular weight, 75−100 kDa, poly-L-lysine (40-60 kDa) 
and chondroitin-4-sulphate (20 kDa) were from Sigma-Aldrich (Poole, UK). Rabbit 
polyclonal antibody to insulin and rabbit polyclonal antibody to CD68 were purchased 
from Gene Tex (Irvine, CA, USA). Rabbit anti-human T cell CD3 (cross-reacted to 
mouse T cell CD3) were provided by Sigma. Goat anti-rabbit IgG (H+L)-HRP conjugate 
was provided by Alpha Diagnostic International (San Antonio, TX, USA). Dako Liquid 
DAB + substrate chromogen system was purchased from Dako (Glostrup, Denmark). 
Recombinant mouse IL-1, TNF- and IFN-(carrier-free) were purchased from 
Biolegend (San Diego, CA, USA). Alexa Fluor 647-labelled poly-L-lysine and PC-
modified chondroitin-4-sulphate was prepared using the previously reported procedures 
[Zhi ZL et al. Biomacromolecules 2010, 11, 610-616]. PC-chitosan conjugate was 
prepared by the procedure reported by Miyazawa and Winnik (Miyazawa, K., Winnik, F. 
M. Macromolecules 2002, 35, 9536– 9544).  
 
TEM analysis of the encapsulated islets. Encapsulated islet ultrastructure was studied 
with transmission electron microscopy (TEM). Briefly, the islets were fixed overnight in 
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2.5% (vol/vol) glutaraldehyde and 0.1 mol/l cacodylate buffer. The islets were post-fixed 
for 20 min in 1% (wt/vol) OsO4 dissolved in cacodylate buffer, and then dehydrated in 
graded series of ethanol. The islets were finally embedded in Agar 100 Resin (Agar 
Scientific, Stansted, UK). Sections were cut, contrasted, and examined in an Hitachi 
H7600 transmission electron microscope (Hitachi, Tokyo, Japan) at 75 kV.  
 
Fluorescence-labelling for confirmation of the nanocoating.  Eight layers were deposited 
to give an encapsulation with the incorporation of a layer of poly-L-lysine labelled with 
Alexa Fluor 647 into the 7th layer as a fluorescent marker. The islets were assessed by 
fluorescence microscopy. The islets were then fixed in 4% (vol/vol) neutral-buffered 
formalin, dehydrated in graded series of ethanol and xylene, and then paraffin-embedded 
(at 70 °C); the cooled specimen were sectioned at a thickness of m and observed by 
fluorescence microscopy. The deposition of the layers was also assessed by fluorescence 
microscopy following the incorporation of two layers of PC-chitosan-tagged with FITC 
into the 5th and 7th layers. However, the histological images can not be obtained due to 
poor photostability of the dye. 
 
The building-up of the multilayers on individual islets was also monitored by using  
FITC-labelled chitosan-PC. Eight layers (four bilayers) of FITC-chitosan-PC/alginate 
were deposited on islets. The fluorescence intensity increases with increasing the number 
of bilayers on the islets, as is shown in ESM Fig.1 & 5. The fluorescence intensity was 
obtained by reading the intensity of pixels in the histograms using Photoshop software. 
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Live-dead cell assay of the encapsulated islets in culture. The long-term cell survival in 
culture was tested by a two-colour fluorescence live/dead cell test involving the use of PI 
and FDA (Jones KH & Senft JA. J Histochem & Cytochem 1985, 33, 77-79). The 
staining process involved removing medium from cells, adding working solutions of 
PI/FDA to cells containing 2 pg of FDA plus 0.6 pg of P1 in 0.2 mL, resuspending the 
cells, and incubating for 3 min at room temperature. This was followed by removing the 
staining solution and washing cells with 0.5 mL of PBS three times. The cells were then 
viewed under a fluorescence microscope with 478−495 nm and 530−560 nm excitation 
filters and 510−555 nm and 573−648 nm emission filters, respectively. This allowed 
green (viable) and red (dead) fluorescing cells to be imaged separately. The cell survival 
experiments were carried out after one and four weeks of culturing. Note this method 
could not used to distinguish whether the dead or living cells are alpha or beta cells in an 
islet. 
 
Effect of exposure to the apoptosis-inducing cytokines and complement factors of the 
nanoencapsulated islets. Islets isolated from BALB/C mice were encapsulated with 8 
layers of PC-chitosan/alginate by layer-by-layer deposition. Following the encapsulation, 
the experimental cells (50 islets in 2 ml medium) were exposed to a mixture of IL-1 (1 
ng/ml), TNF- (5 ng/ml) and IFN- (5 ng/ml) in the culture medium or to 50% diluted 
rabbit serum at 37 °C for 48 h. The incidence of islet cell apoptosis (5 islets and 50 l 
medium in each well) was tested using the Apo-ONE® Homogeneous Caspase-3/7 Assay 
(Promega, Southampton, UK) and read using a Spectra Max Gemine EM microwell plate 
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reader (Molecular Devices, Wokingham, UK). Islet cell viability was also assessed 
separately by the CellTiter-Blue Cell Viability assay (Promega). 
 
Antibody Exclusion Assay. An antibody exclusion assay with FITC-labeled antimouse 
major histocompatibility antigens (MHC) Class II antibody (eBioscience, Hatfield, UK) 
was used to test the permeability of the nanocoating to large immunologically relevant 
molecules. Twenty of the naked and nanoencapsulated islets (live cells without fixing) 
were added to 100 l of the blocking buffer (2% BSA and HBSS buffer), and then 1 μl of 
antibody-FITC solution was added. The solution was then incubated at 37 °C for 30 min. 
The islets were then rinsed three times with HBSS-0.1% Tween (0.5 mL) to remove all 
unbound dye. The islets were then transferred to a coverslip for observation with a 
fluorescence microscope. As shown in ESM Fig. 6, a bare islet showed clear binding of 
the antibody-FITC probe to the surface of some individual cells on the islet face. The 
image of an 8-layer-coated islet shows exclusion of the antibody probe, indicating a 
complete nanolayer coating. Low levels of fluorescence were detected around the surface 
of the capsules surrounding the islet, suggesting some nonspecific antibody adsorption on 
the surfaces.  
 
Graft morphology, histology and immunohistochemistry. After unilateral nephrectomy at 
the end of the study, graft-bearing kidneys were fixed in 4% (vol/vol) neutral-buffered 
formalin and later paraffin-embedded, the specimen was sectioned at a thickness of 
m. The paraffin sections were re-hydrated by sequential 5 min incubations in xylene 
(twice), 100% ethanol, 95% ethanol and then 70% ethanol. The re-hydrated sections were 
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stained with haematoxylin or haematoxylin/eosin for routine morphology studies (ESM 
Fig 2 &3). The graft sections were further evaluated by immunohistchemical staining of 
the kidney sections with antibodies targeting insulin and two types of immune cells 
(CD3+ and CD68+). No further study is performed in the CD68+ staining to clarify 
whether the infiltrated macrophages (CD68+) belong to proinflammatory ‘M1’ 
phenotype that exacerbate islet cell damage, or to anti-inflammatory ‘M2c/suppressor’ 
one that promote epithelial and vascular repair (Anders HJ, Ryu M Kidney Intern 2011, 
80: 915-25). Haematoxylin/eosin staining was also shown. The de-waxed sections were 
microwave-heated in 10 mmol/l citrate buffer (pH 6.0) with 0.05% Tween at 100 °C for 
20 min to retrieve the antigen (the microwave was initially set at 700 Watts, after boiling, 
it was adjusted to 120 Watts to keep boiling minimal). The samples were then blocked 
using 1% BSA in PBS buffer for 10 min and incubated with primary antibody (diluted 
with the same blocking buffer) for 1 h followed by horseradish peroxidase-conjugated 
rabbit anti-rabbit IgG (H+L) secondary antibody. Bound peroxidase was colour-
developed with the liquid DAB and substrate chromogen system containing 3,3’-
diaminobenzidine. Sections were then counterstained with haematoxylin or 











ESM Fig 1.  Time course monitoring of the stability of chitosan/alginate multilayers 
deposited on islets in culture. Fluorescence was generated by incorporation of two 
layers of PC-chitosan-tagged with FITC into the 5th and 7th layers. Note the real 
fluorescence intensity may decrease with time. The exposure time of the camera thus 

















































ESM Fig. 2.  Immunohistochemical analysis of cross sections of the kidney capsules 
of C57BL/6 mice transplanted with the nanoencapsulated and bare syngeneic 
C57BL/6 islets. Kidney sections were stained for the presence of immune cells (CD3+ 
and CD68+ cells).  Haematoxylin/eosin staining was also shown.  
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ESM Fig. 3.  Histochemical and immunohistochemical analysis of the cross-sections 
of the kidney capsules of C57BL/6 mice allotransplanted with the nanoencapsulated 
(8 layers) and bare Balb/C islets. Kidney sections were stained for the presence of 


















































ESM Fig. 4 Allogeneic transplantation of non-encapsulated (control) and 4-layer-
encapsulated (PC-chitosan/alginate/PC-chitosan/PC-condroitin-4-sulphate) Balb/c 
islets reversed STZ-induced hyperglycaemia in diabetic C57BL/6 mice. Average 
















ESM Fig. 5 Monitoring of the stepwise build-up of the polysaccharide layers on 
mouse islets. Chitosan-PC (Ch-PC) conjugated with FITC was incorporated into the 
multilayers by alternative deposition with alginate (Alg) on the islet surfaces. Bright 
spots may due to the density difference of either cells or extracellular matrix. A, 
FITC-Ch-PC/Alg; B, (FITC-Ch-PC/Alg)2; C, (FITC-Ch-PC/Alg)3; D, (FITC-Ch-
PC/Alg)4; E. Fluorescence intensity measured on islet surfaces increases with the 















































































ESM Fig. 6 IgG recognition of the uncoated and coated islets (live cells). A: binding 
of anti-MHC II-FITC to the individual cells in an islet. B: exclusion of the antibody 
binding by the nanocoating. 
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